
<html lang="en"     class="pb-page"  data-request-id="2bae932b-256e-4cbb-bbf8-d7b4c0ae0eaf"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2015.58.issue-20;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.5b01073;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor" /></meta><meta name="dc.Creator" content="Qingbei  Zeng" /></meta><meta name="dc.Creator" content="Jiabing  Wang" /></meta><meta name="dc.Creator" content="Ziqiang  Cheng" /></meta><meta name="dc.Creator" content="Kan  Chen" /></meta><meta name="dc.Creator" content="Peter  Johnström" /></meta><meta name="dc.Creator" content="Katarina  Varnäs" /></meta><meta name="dc.Creator" content="David Yunzhi  Li" /></meta><meta name="dc.Creator" content="Zhen Fan  Yang" /></meta><meta name="dc.Creator" content="Xiaolin  Zhang" /></meta><meta name="dc.Description" content="Recent reports suggest that an increasing number of patients with lung cancer, especially those with activating mutations of the epidermal growth factor receptor (EGFR), also present with brain met..." /></meta><meta name="Description" content="Recent reports suggest that an increasing number of patients with lung cancer, especially those with activating mutations of the epidermal growth factor receptor (EGFR), also present with brain met..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 9, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01073" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01073" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01073" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01073" /></link>
        
    
    

<title>Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01073" /></meta><meta property="og:title" content="Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0017.jpeg" /></meta><meta property="og:description" content="Recent reports suggest that an increasing number of patients with lung cancer, especially those with activating mutations of the epidermal growth factor receptor (EGFR), also present with brain metastases and leptomeningeal metastases. These patients have poor prognosis as there are no approved drugs for these indications. Available agents have poor efficacy for these patients even at well above their standard dose. Herein, we report the discovery of (4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl (2R)-2,4-dimethylpiperazine-1-carboxylate 1m (AZD3759), an investigational drug currently in Phase 1 clinical trial, which has excellent central nervous system penetration and which induces profound regression of brain metastases in a mouse model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01073"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01073">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01073&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01073&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01073&amp;href=/doi/10.1021/acs.jmedchem.5b01073" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 8200-8215</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01072" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01101" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qingbei++Zeng">Qingbei Zeng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiabing++Wang">Jiabing Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ziqiang++Cheng">Ziqiang Cheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kan++Chen">Kan Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Johnstr%C3%B6m">Peter Johnström</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Katarina++Varn%C3%A4s">Katarina Varnäs</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+Yunzhi++Li">David Yunzhi Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhen+Fan++Yang">Zhen Fan Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaolin++Zhang">Xiaolin Zhang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Innovation Center China, Asia & Emerging Markets iMed, AstraZeneca Innovative Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">AstraZeneca Translational Centre, Personal Healthcare and Biomarkers iMed, AstraZeneca R&D, Karolinska Institutet, Department of Clinical Neuroscience, R5:U1 Karolinska University Hospital, SE-171 76 Stockholm, Sweden</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, R5:02 Karolinska University Hospital, SE-171 76 Stockholm, Sweden</span></div><div class="corresp-info"><strong>*</strong>Phone: +86 21 61097888. Fax: +86 21 61097711. E-mail: <a href="/cdn-cgi/l/email-protection#81f9e8e0eeede8efaffbe9e0efe6c1e0f2f5f3e0fbe4efe4e2e0afe2eeec"><span class="__cf_email__" data-cfemail="d2aabbb3bdbebbbcfca8bab3bcb592b3a1a6a0b3a8b7bcb7b1b3fcb1bdbf">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01073&amp;href=/doi/10.1021%2Facs.jmedchem.5b01073" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 8200–8215</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 27, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 July 2015</li><li><span class="item_label"><b>Published</b> online</span>9 October 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 October 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01073" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01073</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8200%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DQingbei%2BZeng%252C%2BJiabing%2BWang%252C%2BZiqiang%2BCheng%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D20%26contentID%3Dacs.jmedchem.5b01073%26title%3DDiscovery%2Band%2BEvaluation%2Bof%2BClinical%2BCandidate%2BAZD3759%252C%2Ba%2BPotent%252C%2BOral%2BActive%252C%2BCentral%2BNervous%2BSystem-Penetrant%252C%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BTyrosine%2BKinase%2BInhibitor%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8215%26publicationDate%3DOctober%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01073"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6285</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">64</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01073" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Qingbei&quot;,&quot;last_name&quot;:&quot;Zeng&quot;},{&quot;first_name&quot;:&quot;Jiabing&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Ziqiang&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Kan&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Johnström&quot;},{&quot;first_name&quot;:&quot;Katarina&quot;,&quot;last_name&quot;:&quot;Varnäs&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Yunzhi Li&quot;},{&quot;first_name&quot;:&quot;Zhen&quot;,&quot;last_name&quot;:&quot;Fan Yang&quot;},{&quot;first_name&quot;:&quot;Xiaolin&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;8200-8215&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01073&quot;},&quot;abstract&quot;:&quot;Recent reports suggest that an increasing number of patients with lung cancer, especially those with activating mutations of the epidermal growth factor receptor (EGFR), also present with brain metastases and leptomeningeal metastases. These patients have poor prognosis as there are no approved drugs for these indications. Available agents have poor efficacy for these patients even at well above their standard dose. Herein, we report the discovery of (4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl (2R)-2,4-dimethylpiperazine-1-carboxylate 1m (AZD3759), an investigational drug currently in Phase 1 clinical trial, which has excellent central nervous system penetration and which induces profound regression of brain metastases in a mouse model.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01073&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01073" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01073&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01073" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01073&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01073" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01073&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01073&amp;href=/doi/10.1021/acs.jmedchem.5b01073" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01073" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01073" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01073%26sid%3Dliteratum%253Aachs%26pmid%3D26313252%26genre%3Darticle%26aulast%3DZeng%26date%3D2015%26atitle%3DDiscovery%2Band%2BEvaluation%2Bof%2BClinical%2BCandidate%2BAZD3759%252C%2Ba%2BPotent%252C%2BOral%2BActive%252C%2BCentral%2BNervous%2BSystem-Penetrant%252C%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BTyrosine%2BKinase%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D20%26spage%3D8200%26epage%3D8215%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/jmcmar.2015.58.issue-20/20151022/jmcmar.2015.58.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0017.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Recent reports suggest that an increasing number of patients with lung cancer, especially those with activating mutations of the epidermal growth factor receptor (EGFR), also present with brain metastases and leptomeningeal metastases. These patients have poor prognosis as there are no approved drugs for these indications. Available agents have poor efficacy for these patients even at well above their standard dose. Herein, we report the discovery of (4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl (<i>2R</i>)-2,4-dimethylpiperazine-1-carboxylate <b>1m</b> (AZD3759), an investigational drug currently in Phase 1 clinical trial, which has excellent central nervous system penetration and which induces profound regression of brain metastases in a mouse model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46735" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46735" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancer cases and is one of the leading causes of cancer death worldwide.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It is estimated that in 2014 there were 224,210 new lung cancer cases and 159,260 NSCLC-related deaths in the United States alone.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Genetic aberrations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) have been identified as one of the key drivers of NSCLC progression.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> EGFR kinase inhibitors, such as gefitinib, erlotinib, and afatinib (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), deliver significant patient benefit and have been approved for the treatment of advanced NSCLC with EGFR activating mutations.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4-7)</a></div><div class="NLM_p">An increased incidence of CNS metastases has been reported as patients live longer with treatment and with the improvement of imaging technology and routine screening.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> Studies have suggested that around 40–50% of patients with lung cancer would develop CNS metastases, including brain and leptomeningeal metastases, in their life span.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> Currently approved drugs can neither effectively treat lung cancer CNS metastases nor prevent development of the metastases at standard dosing due to their limited blood-brain-barrier (BBB) penetration.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a> For patients with symptomatic brain metastases, selective use of radiation therapy and surgery are still the mainstays of treatment but provide limited benefit.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> Given the effectiveness of EGFR TKIs in treating tumors in the lung, there is a major unmet medical need for an agent that can effectively penetrate the CNS and treat tumors in this tissue.</div><figure id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Approved EGFR Kinase Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37407" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37407" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Discovery of Compound <b>1m</b></h3><div class="NLM_p">To achieve efficacy in the CNS and periphery, it is necessary to design biologically active agents with sufficient free drug exposure in both environments. Initially, we started with the clinically proven EGFR TKI gefitinib, developed by AstraZeneca, as the lead for the project with the objective of developing a CNS penetrable candidate with potency and selectivity equal to or better than gefitinib.</div><div class="NLM_p">It has been a challenging task to deliver a pharmaceutical agent that can enter the CNS.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Efflux transport is a major determinant of drug disposition to the CNS. ATP-binding cassette (ABC) export proteins such as P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) are localized in the luminal membrane of brain microvessel endothelial cells.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> Pgp and BCRP have been shown to play an important role in limiting distribution of various drugs into the CNS. We examined several key parameters related to BBB penetration for approved EGFR inhibitors (see the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01073/suppl_file/jm5b01073_si_001.pdf" class="ext-link">Supporting Information</a> for experimental protocols). <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> summarizes physicochemical properties, unbound brain to unbound blood ratios (<i>K</i><sub>puu,brain</sub>), cerebrospinal fluid (CSF) to unbound blood ratios (<i>K</i><sub>puu,CSF</sub>), and efflux ratios of these compounds in MDCKII-MDR1 and MDCKII-BCRP permeability experiments. All these agents are either Pgp (MDR1) or BCRP substrates such that their <i>K</i><sub>puu,brain</sub> or <i>K</i><sub>puu,CSF</sub> values are low. Unfavorable rotatable bonds in gefitinib (10 rotatable bonds) and erlotinib (11 rotatable bonds) and undesired hydrogen bond donors in afatinib (2 hydrogen bond donors) are likely responsible for the low CNS penetration of these agents. Recently published papers have highlighted that the correct balance of permeability, potential for active efflux, and physicochemical properties is needed to achieve good drug partitioning and distribution into CNS with CNS active drugs having lower molecular weight, fewer rotatable bonds, smaller polar surface area (PSA), and fewer hydrogen bond donors than non-CNS-penetrant drugs.<a onclick="showRef(event, 'ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22 ref23">(19-23)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Physicochemical Properties, Permeability, and CNS Penetration Properties of Approved EGFR Kinase Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="center"> </th><th class="colsep0 rowsep0" align="center">gefitinib</th><th class="colsep0 rowsep0" align="center">erlotinib</th><th class="colsep0 rowsep0" align="center">afatinib</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">molecular weight</td><td class="colsep0 rowsep0" align="left">446.7</td><td class="colsep0 rowsep0" align="left">393.4</td><td class="colsep0 rowsep0" align="left">485.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">tPSA (Å<sup>2</sup>)</td><td class="colsep0 rowsep0" align="left">62.6</td><td class="colsep0 rowsep0" align="left">70.3</td><td class="colsep0 rowsep0" align="left">86.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">rotatable bonds<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">hydrogen bond donor number</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">MDCKII-MDR1<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><i>P</i><sub>app,AtoB</sub> (10<sup>–6</sup> cm/s)</td><td class="colsep0 rowsep0" align="left">8.3</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">efflux ratio<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">MDCKII-BCRP<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"><i>P</i><sub>app,AtoB</sub> (10<sup>–6</sup> cm/s)</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">efflux ratio<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">5.4</td><td class="colsep0 rowsep0" align="left">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left"><i>f</i><sub>u,blood</sub> (%)<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left"><i>f</i><sub>u,brain</sub> (%)<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">2.9</td><td class="colsep0 rowsep0" align="left">0.54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left"><i>K</i><sub>puu,brain</sub><a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">0.021</td><td class="colsep0 rowsep0" align="left">0.11</td><td class="colsep0 rowsep0" align="left">0.0066</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left"><i>K</i><sub>puu,CSF</sub><a class="ref internalNav" href="#t1fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="left">0.088</td><td class="colsep0 rowsep0" align="left">0.29</td><td class="colsep0 rowsep0" align="left">0.27</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Rotatable bond number is calculated by the equation <i>N</i><sub>rot</sub> = <i>N</i><sub>rot,ac</sub> + Σ(size – 4 – <i>N</i><sub>ring,ac</sub> – <i>N</i><sub>fused</sub>), where <i>N</i><sub>rot</sub> is the rotatable bond number in the molecule, <i>N</i><sub>rot,ac</sub> is the number of rotatable acyclic bonds, size is the size of the nonaromatic ring, <i>N</i><sub>rig,cyc</sub> is the number of rigid bonds within the ring, and <i>N</i><sub>fused</sub> is the number of bonds that belong to more than one ring system.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Permeability was estimated using MDR1-transfected MDCKII cells seeded onto polyethylene membranes in 96-well BD insert systems with test compounds at 1 μM.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Efflux ratio = <i>P</i><sub>app,BtoA</sub>/<i>P</i><sub>app,AtoB</sub>.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Permeability was estimated using BCRP-transfected MDCKII cells seeded onto polyethylene membranes in 96-well BD insert systems with test compounds at 1 μM.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">Fraction of unbound drug in blood was obtained with the test compound at 5 μM by equilibrium dialysis.</p></div><div class="footnote" id="t1fn6"><sup>f</sup><p class="last">Fraction of unbound drug in brain homogenate was obtained with the test compound at 5 μM by equilibrium dialysis.</p></div><div class="footnote" id="t1fn7"><sup>g</sup><p class="last">Ratio of unbound AUC<sub>0–24h</sub> in rat brain to that in blood at the clinically relevant dose of EGFR TKIs.</p></div><div class="footnote" id="t1fn8"><sup>h</sup><p class="last">Ratio of AUC<sub>0–24h</sub> in rat CSF to unbound AUC<sub>0–24h</sub> in blood at the clinical relevant dose of EGFR TKIs (see the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01073/suppl_file/jm5b01073_si_001.pdf" class="ext-link">Supporting Information</a> for more details).</p></div></div></div><div class="NLM_p">Achieving these desirable physicochemical properties while retaining good EGFR TKI potency was the challenge. X-ray structure analysis of the gefitinib–EGFR complex indicated that the quinazoline positions a hydrogen bond acceptor to Met793 in the hinge region of EGFR and the anilino substituent extends into the hydrophobic pocket at the back of the ATP-binding cleft.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> These structural elements therefore are essential to EGFR inhibitor activity, and hence, we decided to retain this template but to re-engineer the quinazoline-based molecules to deliver the physicochemical properties needed for CNS penetration, initially by redirecting the fluoro moiety present in the phenyl group from the para to ortho position (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The previous SAR study at AstraZeneca indicated that repositioning the fluorine atom present in gefitinib from the para position to the ortho position maintained EGFR kinase inhibitory potency.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> It was believed that an <i>o</i>-fluorine atom could partially mask the hydrogen bond donating effect of the N–H by forming an intramolecular interaction.<a onclick="showRef(event, 'ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28">(26-28)</a> Additionally, the linear and rotatable side chain present in gefitinib was shortened to derive molecules with the general structure <b>1</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Design Strategy Starting from Gefitinib as an Initial Lead</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The brain and CSF penetration of the agents was estimated by <i>K</i><sub>puu,brain</sub> and <i>K</i><sub>puu,CSF</sub>, respectively.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29, 30)</a><i>K</i><sub>puu,brain</sub> is the ratio of unbound AUC in the brain to unbound AUC in blood, and <i>K</i><sub>puu,CSF</sub> is the ratio of AUC in CSF to unbound AUC in blood (see the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01073/suppl_file/jm5b01073_si_001.pdf" class="ext-link">Supporting Information</a> for more details). Compared to gefitinib, compound <b>1a</b> has a lower molecular weight and polar surface area (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) and is also a more rigid molecule (7 rotatable bonds) than gefitinib (10 rotatable bonds). As a result, CNS druglike properties, such as efflux ratio (0.33) and permeability (<i>P</i><sub>app,AtoB</sub> = 32 × 10<sup>–6</sup> cm/s) were achieved. Encouragingly, this compound exhibited an inhibitory potency (IC<sub>50</sub>) at 3.8 and 6.6 nM in PC-9 and H3255 cell line EGFR phosphorylation assays, respectively, which were comparable to those of gefitinib at 6.2 and 6.5 nM, respectively. Furthermore, compound <b>1a</b> demonstrated an acceptable human CYP450 inhibition profile (IC<sub>50</sub> > 10 μM for CYP2C9, CYP2D6, and CYP3A4) and low hERG inhibition liability (hERG IC<sub>50</sub> = 17 μM, patch clamp assay). More importantly, the preferred CNS druglike properties of the compound translated into much improved brain and CSF penetration (<i>K</i><sub>puu,brain</sub> and <i>K</i><sub>puu,CSF</sub> were 0.47 and 0.76, respectively) and reasonable exposures in both brain and blood (AUC<sub>0–7h</sub> values in brain and blood at 2 mg/kg were 1013 and 834 nM·h, respectively) were achieved. These excellent in vitro potency and promising CNS penetration results were achieved while maintaining reasonable pharmacokinetic (PK) properties in rat (oral bioavailability, 44%; elimination half-life, 1.1 h; clearance, 59 mL min<sup>–1</sup> kg<sup>–1</sup>; and volume of distribution at steady state, 2.8 L/kg). With these encouraging results, further reduction in the molecular weight and the number of rotatable bonds of <b>1a</b> led to <b>1b</b>. As expected, this compound benefits from increased <i>K</i><sub>puu,brain</sub> and <i>K</i><sub>puu,CSF</sub> (0.96 and 0.93, respectively). To examine the importance of the position of the fluorine atom, we prepared inhibitor <b>2</b> with a para substituent. Comparison of <b>1b</b> with <b>2</b> suggested that, indeed, the intramolecular interaction between the fluoro and N–H in <b>1b</b> is important for CNS penetration. However, agents <b>1b</b> and <b>2</b> also showed substantially lower levels of blood and brain AUCs compared with those of <b>1a</b>. As subsequent attempts to modify either <b>1b</b> or <b>2</b> did not lead to further improvement in PK properties, <b>1b</b> and <b>2</b> analogues were no longer pursued, and optimization of <b>1a</b> became the priority. To improve the PK properties of <b>1a</b>, we next put effort into modifying the potentially labile methylene group (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). An initial attempt was to change the methylene unit into a carbonyl moiety (<b>1c</b>), which could reduce potential oxidative liability and further decrease the bond rotation. Unfortunately, this compound (<b>1c</b>) was not a CNS penetrant and was much less potent in a cell-based phosphorylation assay (L858R pEGFR IC<sub>50</sub> = 166 nM). However, an extension of the amide present in <b>1c</b> by one atom to give the carbamate (<b>1d</b>) significantly improved potency (L858R pEGFR IC<sub>50</sub> = 4.1 nM), although the exposures of <b>1d</b> in the brain and plasma were very low (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). The poor equilibrium solubility (12 nM in pH 7.4 buffer) of the compound was identified as a potential limiting factor for oral exposure. Thus, further modifications were undertaken to replace the oxygen present in the morpholine ring at the terminal position with a basic nitrogen (<b>1e</b>). Indeed, the solubility of <b>1e</b> (free base) was increased substantially (202 mM in neutral buffer). With this increase in basicity (p<i>K</i><sub>a</sub> 8.4) and solubility, the exposure of <b>1e</b> in the brain and blood improved dramatically.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Results from Optimizing Physicochemical Properties</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0011.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0012.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Rotatable bond number is calculated by the equation <i>N</i><sub>rot</sub> = <i>N</i><sub>rot,ac</sub> + Σ(size – 4 – <i>N</i><sub>ring,ac</sub> – <i>N</i><sub>fused</sub>), where <i>N</i><sub>rot</sub> is the rotatable bond number in the molecule, <i>N</i><sub>rot,ac</sub> is the number of rotatable acyclic bonds, size is the size of the nonaromatic ring, <i>N</i><sub>rig,cyc</sub> is the number of rigid bonds within the ring, and <i>N</i><sub>fused</sub> is the number of bonds that belong to more than one ring system.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Cellular phosphorylation assay on H3255 (L858R) cell lines (<i>n</i> = 2).</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">MDR1-transfected MDCKII cells with test compound at 1 μM were used to estimate apical to basolateral permeability.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Efflux ratio = <i>P</i><sub>app,BtoA</sub>/<i>P</i><sub>app,AtoB</sub>.</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">Male Han Wistar rats (PO, 2 mg/kg; 1% MC).</p></div><div class="footnote" id="t2fn6"><sup>Table f</sup><p class="last">Clinically equivalent dose of 20 mg/kg was orally administrated for CNS penetration assessment of gefitinib, and exposure was measured between 0.5 and 24 h.</p></div><div class="footnote" id="t2fn7"><sup>Table g</sup><p class="last">Fraction of unbound drug in blood was obtained with the test compound at 5 μM by equilibrium dialysis.</p></div><div class="footnote" id="t2fn8"><sup>Table h</sup><p class="last">Fraction of unbound drug in brain homogenate was obtained with the test compound at 5 μM by equilibrium dialysis.</p></div><div class="footnote" id="t2fn9"><sup>Table i</sup><p class="last">Ratio of unbound brain AUC<sub>0–7h</sub> to unbound blood AUC<sub>0–7h</sub>.</p></div><div class="footnote" id="t2fn10"><sup>Table j</sup><p class="last">Ratio of unbound brain AUC<sub>0–24h</sub> to unbound blood AUC<sub>0–24h.</sub></p></div><div class="footnote" id="t2fn11"><sup>Table k</sup><p class="last">Ratio of CSF AUC<sub>0–7h</sub> to unbound blood AUC<sub>0–7h</sub>.</p></div><div class="footnote" id="t2fn12"><sup>Table l</sup><p class="last">Ratio of CSF AUC<sub>0–24h</sub> to unbound blood AUC<sub>0–24h</sub>.</p></div></div><div></div></div><div class="NLM_p">Given its promising in vitro potency and good brain penetration, a rat PK study was conducted for compound <b>1e</b>, and the results are summarized in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. Compared to <b>1a</b>, inhibitor <b>1e</b> significantly improved clearance (22 mL min<sup>–1</sup> kg<sup>–1</sup>) in rats. It was quickly absorbed. The oral bioavailability was 45%, and the elimination half-life was increased to 2.6 h. This improved half-life, however, did not meet our design criteria (>4 h in rats).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Rat PK Data for Compound <b>1e</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (route)</th><th class="colsep0 rowsep0" align="center">formulation</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–24h</sub> (nM·h)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> (h)<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (nM)<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">CL (mL min<sup>–1</sup> kg<sup>–1</sup>)<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a></th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L/kg)<a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5 mg/kg (PO)</td><td class="colsep0 rowsep0" align="left">1% methylcellulose</td><td class="colsep0 rowsep0" align="left">3905</td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">2020</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1 mg/kg (IV)</td><td class="colsep0 rowsep0" align="left">DMSO:10% captisol in saline =1:99</td><td class="colsep0 rowsep0" align="left">1713</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">1.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Male Han Wistar rats (nonfasted) were used in this study.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Area under concentration time curve from 0 to 24 h.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">Bioavailability (%).</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">Mean elimination half-life.</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last">Time to reach maximum concentration.</p></div><div class="footnote" id="t3fn6"><sup>f</sup><p class="last">Peak concentration.</p></div><div class="footnote" id="t3fn7"><sup>g</sup><p class="last">Clearance obtained from intravenous infusion.</p></div><div class="footnote" id="t3fn8"><sup>h</sup><p class="last">Volume of distribution at steady state. All pharmacokinetic parameters were calculated with Phoenix v6.3 (Certara, St. Louis, MO, USA).</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Properties of Compounds <b>1f</b>–<b>n</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0013.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0014.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Rotatable bond number is calculated by the equation <i>N</i><sub>rot</sub> = <i>N</i><sub>rot,ac</sub> + Σ(size – 4 – <i>N</i><sub>ring,ac</sub> – <i>N</i><sub>fused</sub>), where <i>N</i><sub>rot</sub> is the rotatable bond number in the molecule, <i>N</i><sub>rot,ac</sub> is the number of rotatable acyclic bonds, size is the size of the nonaromatic ring, <i>N</i><sub>rig,cyc</sub> is the number of rigid bonds within the ring, and <i>N</i><sub>fused</sub> is the number of bonds that belong to more than one ring system.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Cellular phosphorylation assay on H3255 (L858R) cell lines (<i>n</i> = 2).</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">MDR1-transfected MDCKII cells with the test compound at 1 μM were used to estimate apical to basolateral permeability.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">Efflux ratio = <i>P</i><sub>app,BtoA</sub>/<i>P</i><sub>app,AtoB</sub>.</p></div><div class="footnote" id="t4fn5"><sup>Table e</sup><p class="last">Male Han Wistar rats (PO, 2 mg/kg; 1% MC).</p></div><div class="footnote" id="t4fn6"><sup>Table f</sup><p class="last">AUC<sub>0–6.5h</sub>.</p></div><div class="footnote" id="t4fn7"><sup>Table g</sup><p class="last">Compound <b>1h</b> concentrations in CSF at predefined time points were below the quantification limit (1 ng/mL).</p></div><div class="footnote" id="t4fn8"><sup>Table h</sup><p class="last">Fraction of unbound drug in blood was obtained with test compound at 5 μM by equilibrium dialysis.</p></div><div class="footnote" id="t4fn9"><sup>Table i</sup><p class="last">Average value from 4 independent tests.</p></div><div class="footnote" id="t4fn10"><sup>Table j</sup><p class="last">Fraction of unbound drug in brain homogenate was obtained with the test compound at 5 μM by equilibrium dialysis.</p></div><div class="footnote" id="t4fn11"><sup>Table k</sup><p class="last">Ratio of unbound brain AUC<sub>0–7h</sub> to unbound blood AUC<sub>0–7h</sub>.</p></div><div class="footnote" id="t4fn12"><sup>Table l</sup><p class="last">Ratio of CSF AUC<sub>0–7h</sub> to unbound blood AUC<sub>0–7h</sub>.</p></div></div><div></div></div><div class="NLM_p">The subsequent <b>1e</b> metabolite identification in rat hepatocytes suggested that piperazine oxidation was the main metabolic pathway (see the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01073/suppl_file/jm5b01073_si_001.pdf" class="ext-link">Supporting Information</a> for more details). Thus, the introduction of substituent(s) to the piperazine ring or change of the piperazine to another moiety was examined (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Initially, we designed compounds <b>1f</b> and <b>1g</b> by replacing the piperazine with a dimethylaminopyrrolidine moiety. These pyrrolidine derivatives (<b>1f</b> and <b>1g</b>) displayed excellent potency (IC<sub>50</sub> = 1.1 nM and 2.7 nM, respectively) in cellular EGFR phosphorylation assays, but even though the blood AUC levels of these compounds were also increased, their levels of brain penetration were not acceptable (<i>K</i><sub>puu,brain</sub> < 0.3). The limited brain penetration is potentially due to the increased flexibility of the rotatable bond between the terminal dimethylamino and pyrrolidine ring. Hence subsequently, the piperazine was substituted by a much more rigid bridged bicyclic system. The constrained analogue <b>1h</b> (four rotatable bonds) showed further reduction of the CNS penetration (<i>K</i><sub>puu,brain</sub> and <i>K</i><sub>puu,CSF</sub> < 0.1), which led us to speculate that balanced molecular flexibility (rotatable bond number) is needed for favorable CNS penetration. Thus, compounds <b>1i</b>–<b>n</b> were designed and prepared. In these compounds, the rotatable bond numbers were retained at a range of 5–6, which is comparable to the number in <b>1e</b>, whereas the piperazine ring was substituted by a small group. Encouragingly, most compounds achieved <i>K</i><sub>puu,brain</sub> and <i>K</i><sub>puu,CSF</sub> values >0.5. In particular, the free brain and cerebrospinal fluid AUCs of <b>1m</b> were similar to that in blood, indicating its equivalent exposures in the brain, CSF, and blood.</div><div class="NLM_p">With the introduction of substituents to the piperazine moiety, several compounds achieved good CNS penetration (<i>K</i><sub>puu,brain</sub> and <i>K</i><sub>puu,CSF</sub> > 0.5) as well as in vitro potency. As the final selection of the compound for progression into preclinical testing would be the rat PK profile, potent inhibitors with <i>K</i><sub>puu,brain</sub> and <i>K</i><sub>puu,CSF</sub> > 0.5 were further evaluated in rats (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Overall, these compounds showed good oral bioavailability (>52%) except for compound <b>1k</b> (24%). Agent <b>1m</b> exhibited the best pharmacokinetic profile with moderate blood clearance at 17 mL min<sup>–1</sup> kg<sup>–1</sup> and volume of distribution of 5.2 L/kg. The intrinsic clearance (Cl<sub>int</sub>) of <b>1m</b> is 11.4 μL min<sup>–1</sup> 10<sup>–6</sup> cells in human hepatocytes, and the predicted clearance of the agent in humans is 7.7 mL min<sup>–1</sup> kg<sup>–1</sup> by in vitro–in vivo extrapolation (IVIVe).<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> Liver blood flow (LBF) method with blood protein binding correction was applied to generate individual estimates of unbound human hepatic clearance (CL<sub>hepatic</sub>) using available data from each preclinical species.<a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33-35)</a> The predicted human clearance by the LBF method from rat is 8.1 mL min<sup>–1</sup> kg<sup>–1</sup>, which is very similar to that derived from IVIVe. Following oral dosing in rats at 2 mg/kg, absorption of <b>1m</b> was rapid with blood <i>C</i><sub>max</sub> of 0.58 μM achieved at 1.0 h. Subsequently, blood concentrations of <b>1m</b> declined monoexponentially with a mean elimination half-life of 4.3 h, which was close to the same parameter obtained from intravenous dosing of 4.1 h. The bioavailability following an oral dose in rats was 91%. Given its promising PK properties, CNS penetration, and in vitro potency, <b>1m</b> was selected as the candidate for comprehensive biological profiling.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Rat PK Data of Compounds <b>1i</b>–<b>n</b> (PO: 2 mg/kg; IV: 1 mg/kg)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>1i</b></th><th class="colsep0 rowsep0" align="center"><b>1j</b></th><th class="colsep0 rowsep0" align="center"><b>1k</b></th><th class="colsep0 rowsep0" align="center"><b>1l</b></th><th class="colsep0 rowsep0" align="center"><b>1m</b></th><th class="colsep0 rowsep0" align="center"><b>1n</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">oral AUC<sub>0–24h</sub> (nM·h)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1570</td><td class="colsep0 rowsep0" align="left">2315</td><td class="colsep0 rowsep0" align="left">789</td><td class="colsep0 rowsep0" align="left">1037</td><td class="colsep0 rowsep0" align="left">3803</td><td class="colsep0 rowsep0" align="left">2948</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">84</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="left">83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">4.1</td><td class="colsep0 rowsep0" align="left">2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL min<sup>–1</sup> kg<sup>–1</sup><b>)</b><a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">5.2</td><td class="colsep0 rowsep0" align="left">2.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">In vivo PK was obtained via an intravenous infusion route (DMSO: 10% captisol in saline = 1:99) and oral gavage route (1% methylcellulose) in male Wistar Han rats (nonfasted).</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Area under concentration time curve from 0 to 24 h.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Bioavailability (%).</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Mean elimination half-life obtained from intravenous infusion.</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last">Clearance obtained from intravenous infusion.</p></div><div class="footnote" id="t5fn6"><sup>f</sup><p class="last">Volume of distribution at steady state. All pharmacokinetic parameters were calculated with Phoenix v6.3 (Certara, St. Louis, MO, USA).</p></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> In Vitro Profile of Candidate <b>1m</b></h3><div class="NLM_p">The inhibition of <b>1m</b> against EGFR tyrosine kinase (EGFR TK) wild type and mutant enzymes was tested at their corresponding <i>K</i><sub>m</sub> and 2 mM ATP concentrations (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). At <i>K</i><sub>m</sub> ATP concentrations, the inhibition IC<sub>50</sub> values were 0.3, 0.2, and 0.2 nM for EGFR TK wild-type, L858R mutant, and Exon 19Del enzymes, respectively. In cellular EGFR phosphorylation and proliferation studies, PC-9 (Exon 19Del), H3255 (L858R), and H838 (wild-type EGFR) cells were used (see details in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01073/suppl_file/jm5b01073_si_001.pdf" class="ext-link">Supporting Information</a>). The results are shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>. Compound <b>1m</b> was an equally potent inhibitor of cellular phosphorylation or proliferation in EGFR-activating mutant cell lines (PC-9 and H3255 cell lines) in the range of 7.0–7.7 nM, suggesting a high level of potency against all these clinically relevant EGFR mutations. In cellular phosphorylation studies, <b>1m</b> also demonstrated 9-fold inhibition selectivity in EGFR-activating mutant cell lines over EGFR wild-type cell lines (H838 cell line). This was consistent with the findings in biochemical assays when ATP concentration was increased from <i>K</i><sub>m</sub> to 2 mM (the hypothesized cellular ATP concentration), suggesting ATP competitive binding mode of <b>1m</b> with its possible differential binding affinities to mutant and wild-type EGFRs. Although <b>1m</b> showed some activity against pEGFR in H838 cells, as these cells do not rely on activation of the EGFR pathway for proliferation, we did not see activity of <b>1m</b> on cell proliferation of H838 cells. In contrast, <b>1m</b> demonstrated inhibitory effects on both the pEGFR pathway and cell proliferation of EGFR mutation-derived cells PC-9 and H3255, suggesting these cells rely on activation of the EGFR pathway for proliferation. To broadly evaluate the selectivity of the compound, we screened <b>1m</b> in a kinase panel and in a secondary pharmacology panel (see details in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01073/suppl_file/jm5b01073_si_001.pdf" class="ext-link">Supporting Information</a>). The kinase panel, screened at Millipore, was comprised of 124 recombinant protein kinases and lipid kinases. The percent inhibition of <b>1m</b> was tested at one single concentration (1 μM) across each of these kinases. At this concentration, <b>1m</b> displayed <50% inhibition against 115 kinases and >50% inhibition against the other nine kinases, including EGFR kinase in the panel. The inhibition of those eight off targets were 83% for EphB4, 57% for Flt, 58% for Fyn, 62% for KDR, 61% for activated Lck, 74% for Lyn, 69% for Src, and 87% for Yes. A secondary pharmacology panel, performed at Cerep, covered 150 distinct molecular targets. Assays were run in concentration–response mode. It was found that 147 molecular targets exhibited >1 μM and 3 targets <1 μM of IC<sub>50</sub>s. These active molecular targets with an IC<sub>50</sub> of <1 μM were KDR (156 nM), Src (622 nM), and D2 (797 nM). The results from these panel screenings indicated that <b>1m</b> was a highly selective compound. Furthermore, <b>1m</b> was neither a direct inhibitor (IC<sub>50</sub> > 50 μM) nor a time-dependent inhibitor for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4/5 isoforms. This agent exhibited <3-fold mRNA induction for CYP1A2, CYP2B6, and CYP3A4 at the predicted maximum total concentration (0.3 μM) of the compound, suggesting a low enzyme induction liability.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> Also, the candidate showed acceptable hERG inhibition activity with an IC<sub>50</sub> of 13.3 μM in a conventional manual whole-cell patch clamp study.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Compound <b>1m</b> Activity in Biochemical and Cellular Assays<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="6" align="center">biochemical assay</th><th class="rowsep1 colsep0" colspan="3" align="center">cellular phosphorylation</th><th class="rowsep1 colsep0" colspan="3" align="center">cellular proliferation</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">EGFR (exon 19Del) IC<sub>50</sub> at <i>K</i><sub>m</sub> of ATP (nM) (<i>n</i> = 14)</th><th class="colsep0 rowsep0" align="center">EGFR (exon 19Del) IC<sub>50</sub> at 2 mM of ATP (nM) (<i>n</i> = 5)</th><th class="colsep0 rowsep0" align="center">EGFR (L858R) IC<sub>50</sub> at <i>K</i><sub>m</sub> of ATP (nM) (<i>n</i> = 65)</th><th class="colsep0 rowsep0" align="center">EGFR (L858R) IC<sub>50</sub> at 2 mM of ATP (nM) (<i>n</i> = 10)</th><th class="colsep0 rowsep0" align="center">EGFR (wt) IC<sub>50</sub> at <i>K</i><sub>m</sub> of ATP (nM) (<i>n</i> = 65)</th><th class="colsep0 rowsep0" align="center">EGFR (wt) IC<sub>50</sub> at 2 mM of ATP (nM) (<i>n</i> = 10)</th><th class="colsep0 rowsep0" align="center">PC-9 (exon 19Del) pEGFR IC<sub>50</sub> (nM) (<i>n</i> = 12)</th><th class="colsep0 rowsep0" align="center">H3255 (L858R) pEGFR IC<sub>50</sub> (nM) (<i>n</i> = 12)</th><th class="colsep0 rowsep0" align="center">H838 (wt) pEGFR IC<sub>50</sub> (nM) (<i>n</i> = 13)</th><th class="colsep0 rowsep0" align="center">PC-9 (exon 19Del) GI<sub>50</sub> (nM) (<i>n</i> = 40)</th><th class="colsep0 rowsep0" align="center">H3255 (L858R) GI<sub>50</sub> (nM) (<i>n</i> = 40)</th><th class="colsep0 rowsep0" align="center">H838 (wt) GI<sub>50</sub> (nM) (<i>n</i> = 11)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">0.2 ± 0.02</td><td class="colsep0 rowsep0" align="center">2.4 ± 0.3</td><td class="colsep0 rowsep0" align="center">0.2 ± 0.06</td><td class="colsep0 rowsep0" align="center">7.6 ± 2.1</td><td class="colsep0 rowsep0" align="center">0.3 ± 0.04</td><td class="colsep0 rowsep0" align="center">102 ± 34</td><td class="colsep0 rowsep0" align="center">7.4 ± 1.3</td><td class="colsep0 rowsep0" align="center">7.2 ± 1.3</td><td class="colsep0 rowsep0" align="center">64.5 ± 8.7</td><td class="colsep0 rowsep0" align="center">7.7 ± 2.6</td><td class="colsep0 rowsep0" align="center">7.0 ± 1.5</td><td class="colsep0 rowsep0" align="center">21556 ± 4866</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Average value from <i>n</i> number of repeat tests.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Dog Pharmacokinetics</h3><div class="NLM_p">Blood pharmacokinetic parameters of <b>1m</b> in male dogs were determined following both a single dose intravenous infusion and oral administration. These data are summarized in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. Following the IV dose in dogs, <b>1m</b> blood clearance was determined as 14 mL min<sup>–1</sup> kg<sup>–1</sup>, and the volume of distribution was 6.4 L/kg. Its elimination half-life was 6.2 h. Absorption of <b>1m</b> was rapid with blood <i>C</i><sub>max</sub> (698 nM) occurring between 0.5 and 1.5 h. The oral bioavailability of <b>1m</b> was excellent at 90%.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Dog PK Data of <b>1m</b><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (route)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–24h</sub> (nM·h)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (nM)<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center" char=".">CL (mL min<sup>–1</sup> kg<sup>–1</sup>)<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)<a class="ref internalNav" href="#t7fn8" aria-label="h">h</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1 mg/kg (IV)</td><td class="colsep0 rowsep0" align="char" char=".">2560</td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">6.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2 mg/kg (PO)</td><td class="colsep0 rowsep0" align="char" char=".">4625</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="char" char=".">90.2</td><td class="colsep0 rowsep0" align="char" char=".">0.5–1.5</td><td class="colsep0 rowsep0" align="char" char=".">698</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">In vivo PK was obtained via intravenous infusion route (DMSO: 10% captisol in saline = 1:99) and oral gavage route (1% methylcellulose) in male Beagle dog (fed).</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Area under concentration time curve from 0 to 24 h.</p></div><div class="footnote" id="t7fn3"><sup>c</sup><p class="last">Mean elimination half-life.</p></div><div class="footnote" id="t7fn4"><sup>d</sup><p class="last">Bioavailability (%) calculated with AUC<sub>0–24h</sub> and nominal dose.</p></div><div class="footnote" id="t7fn5"><sup>e</sup><p class="last">Time to reach maximum concentration.</p></div><div class="footnote" id="t7fn6"><sup>f</sup><p class="last">Peak concentration.</p></div><div class="footnote" id="t7fn7"><sup>g</sup><p class="last">Clearance.</p></div><div class="footnote" id="t7fn8"><sup>h</sup><p class="last">Volume of distribution at steady state. All pharmacokinetic parameters were calculated with Phoenix v6.3 (Certara, St. Louis, MO, USA).</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Microdosing Positron Emission Tomography (PET) Studies</h3><div class="NLM_p">Brain distribution of <b>1m</b> in monkeys was investigated by microdosing PET to substantiate the PK data in rats.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Radiolabeled [<sup>11</sup>C]-<b>1m</b> (0.28 μg, 150 MBq and 0.35 μg, 155 MBq) was injected into two male cynomolgus monkeys (PET1 and PET2, respectively). The PET distribution volume (<i>V</i><sub>T</sub>) was estimated for the whole brain region using the 2-tissue compartment model.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The distribution volume and estimated free brain to plasma partition coefficient (<i>C</i><sub>u,brain</sub>/<i>C</i><sub>u,plasma</sub>) are summarized in <a class="ref internalNav" href="#tbl10" aria-label="Table 8">Table 8</a>. The partition coefficient values (0.50 and 0.53 for PET1 and PET2, respectively) indicated <b>1m</b> penetrated extensively into monkey brain. PET images (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) for both monkeys also suggested that the radiolabeled compound was well distributed throughout the brain.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Unbound Brain/Plasma Ratio for [<sup>11</sup>C]-<b>1m</b> in Cynomolgus Monkeys<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">injected mass and radioactivity</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>T</sub> (mL cm<sup>–3</sup>)</th><th class="colsep0 rowsep0" align="center" char="."><i>f</i><sub>u,plasma</sub><a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="."><i>f</i><sub>u,brain</sub><a class="ref internalNav" href="#t10fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>u,brain</sub>/<i>C</i><sub>u,plasma</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PET1</td><td class="colsep0 rowsep0" align="left">0.28 μg, 150 MBq</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PET2</td><td class="colsep0 rowsep0" align="left">0.35 μg, 155 MBq</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">0.14</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="char" char=".">0.53</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup>a</sup><p class="last">PET microdosing studies were performed after a single dose of [<sup>11</sup>C]-<b>1m</b> (phosphate buffered saline, pH 7.4) via an intravenous bolus route.</p></div><div class="footnote" id="t10fn2"><sup>b</sup><p class="last">The unbound fraction in plasma was determined in the PET experiment using ultrafiltration.</p></div><div class="footnote" id="t10fn3"><sup>c</sup><p class="last">Data obtained from in vitro equilibrium dialysis of rat brain homogenates were used as an estimate of the unbound fraction in monkey brain tissue.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></p></div></div></div><figure id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0001.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Color-coded PET images showing the distribution of radioactivity in the monkey brain following the administration of [<sup>11</sup>C]-<b>1m</b>. Horizontal (left panel), coronal (middle panel), and sagittal (right panel) projections for monkey PET1 (A) and Monkey PET2 (B). Images created from summation images from 5 to 123 min, and image intensity is normalized for injected radioactivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> In Vivo Antitumor Efficacy Study</h3><div class="NLM_p">A brain metastasis model was generated by intracerebral injection of luciferase transfected PC-9 (Exon19Del) cells. Tumor growth was monitored by an IVIS Xenogen imaging system. <b>1m</b> demonstrated significant dose-dependent antitumor efficacy (∼78% tumor growth inhibition at 7.5 mg/kg qd and tumor regression at 15 mg/kg qd, respectively, 4 weeks after treatment) with <20% body weight loss, whereas erlotinib had a limited effect in this model (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). At the end of the study, brain tissues were collected for histological assessment. Significantly decreased tumor area was observed by <b>1m</b> treatment at the doses of 7.5 and 15 mg/kg (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B). In addition, modulation of pEGFR was detected by a single dose of <b>1m</b> at 15 mg/kg 1h after dosing, which confirmed target engagement by <b>1m</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C).</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. A brain metastasis model was established by injection of luciferase transfected PC-9 cells into the brain parenchyma. Tumor growth was monitored by measuring bioluminescence signals. Approximately 2–3 weeks after cell injection, animals were treated with erlotinib at 15 mg/kg qd and <b>1m</b> at 7.5 and 15 mg/kg qd, respectively. (A) Significant tumor growth inhibition was observed by <b>1m</b> treatment in a dose-dependent manner compared with that of erlotinib. (B) Histological assessment showed a dose-dependent reduction of tumor area with <b>1m</b> treatment. (C) Modulation of pEGFR in tumor tissue was observed by a single dose of <b>1m</b> at 15 mg/kg 1 h after dosing (at 1× and 20× amplification).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Synthesis</h3><div class="NLM_p"><a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> illustrates the synthesis of key intermediates <b>6</b> and <b>8</b>. Starting material <b>3</b> was conveniently prepared according to literature procedures.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40, 41)</a> The reaction of <b>3</b> and commercially available <b>4</b> was carried out in acetonitrile without the addition of other reagents. The resulting HCl salt of acetate <b>5</b> was treated with potassium carbonate in methanol to provide <b>6</b>. Another building block, <b>8</b>, was readily obtained from commercially available <b>7</b> by the reaction with triphosgene in dichloromethane.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Crude <b>6</b> and <b>8</b> were used for the further reactions without purification. Other similar starting materials <b>18a</b>–<b>h</b> and <b>19</b> were prepared by the same procedure, and the crude materials were used directly.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Intermediates <b>6</b> and <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) acetonitrile, reflux, 4 h; (ii) potassium carbonate, methanol, 10–15 °C, 2 h; (iii) triphosgene, pyridine, dichloromethane, 0 °C to rt.</p></p></figure><div class="NLM_p"><a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> describes the synthesis of <b>1a</b> and <b>1c</b>. Triflate <b>9</b>, prepared from <b>6</b>, was conveniently converted to <b>1c</b> under conditions described in the literature.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Heck reaction of <b>9</b> with methyl acrylate delivered <b>10</b>, which was subjected to ozonolysis to give aldehyde <b>11</b>. This agent was then reacted with morpholine under reductive conditions to afford desired compound <b>1a</b>.</div><div class="NLM_p"><a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a> depicts the synthetic route of <b>1b</b> and <b>2</b>. Triflate <b>13</b>, prepared from commercially available <b>12</b> under typical conditions, reacted with morpholine to provide <b>14</b>. After reduction of <b>14</b>, the resulting <b>15</b> was converted into quinazoline derivative <b>16</b> by using formamidine acetate in ethanol. The preparation of reactive intermediate <b>17</b> from <b>16</b> was accomplished with oxalyl chloride in chloroform at an elevated temperature. With this key material, <b>1b</b> and <b>2</b> were synthesized by substitution reaction without addition of other basic reagents.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>1a</b> and <b>1c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Tf<sub>2</sub>O, pyridine, 5 °C to rt; (ii) CO, Pd(OAc)<sub>2</sub>, dppf, morpholine, 70 °C, overnight; (iii) methyl acrylate, Pd(OAc)<sub>2</sub>, Et<sub>3</sub>N, dppf, Bu<sub>4</sub>NBr, DMF, 80 °C, overnight; (iv) O<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C then (CH<sub>3</sub>)<sub>2</sub>S, −78 °C to rt; (v) morpholine, NaBH<sub>3</sub>CN, acetic acid, rt.</p></p></figure><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>1b</b> and <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Tf<sub>2</sub>O, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 16 h; (ii) morpholine, CH<sub>3</sub>CN, reflux, overnight; (iii) Fe, NH<sub>4</sub>Cl, CH<sub>3</sub>OH, H<sub>2</sub>O, 80 °C, 4 h; (iv) formamidine acetate salt, C<sub>2</sub>H<sub>5</sub>OH, reflux, overnight; (v) oxalyl chloride, CHCl<sub>3</sub>, DMF, 60 °C, 2 h; (vi) 3-chloro-2-fluoroaniline, CH<sub>3</sub>CN, reflux, 18 h; (vii) 3-chloro-4-fluoroaniline, CH<sub>3</sub>CN, reflux, 2 days.</p></p></figure><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0008.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. General Synthesis of Compounds <b>1d</b>–<b>h</b>, <b>1k-l</b>, and <b>1n</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) (C<sub>2</sub>H<sub>5</sub>)<sub>3</sub>N or K<sub>2</sub>CO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub> or DMF, rt.</p></p></figure><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0009.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of <b>1i</b> and <b>1j</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) K<sub>2</sub>CO<sub>3</sub>, DMF, rt, overnight; (ii) HCl, 1,4-dioxane, ethyl acetate, rt, 1 h; (iii) paraformaldehyde, NaBH<sub>3</sub>CN, CH<sub>3</sub>CO<sub>2</sub>H, methanol, rt, overnight; (iv) chiral SFC.</p></p></figure><figure id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0010.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of <b>1m</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions and reagents: (i) potassium carbonate, DMF, rt; (ii) HCl in dioxane, methanol, rt; (iii) paraformaldehyde, sodium cyanoborohydride, methanol, rt.</p></p></figure><div class="NLM_p last">The syntheses of compounds <b>1d</b>–<b>h</b>, <b>1k</b>–<b>l</b>, and <b>1n</b> are illustrated in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. The carbamate formation was carried out in basic media at room temperature. Carbamate <b>20</b> was prepared (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>) in a similar manner. The subsequent deprotection of <b>20</b> and reductive methylation of <b>21</b> provided a racemic mixture (<b>22</b>). The resolution of this mixture by chiral SFC technology delivered the two optically pure isomers <b>1i</b> and <b>1j</b>. The preparation of compound <b>1m</b> from a chiral starting material (<b>8</b>) by a similar synthetic route is outlined in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22883" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22883" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">By correctly balancing physicochemical properties, such as permeability, solubility, and efflux ratio, we were able to identify compound <b>1a</b>. This early lead has significantly improved CNS penetration without compromising the in vitro potency. Replacement of the methylene group present in <b>1a</b> by carbamate linker led to compound <b>1e</b>. This compound significantly improved metabolic stability. The terminal basic nitrogen in <b>1e</b> was found to be an essential element to achieve good exposures in both brain and blood. By incorporating a methyl group into the piperazine moiety, we further improved PK properties of <b>1e</b>, leading to successful discovery of clinical candidate <b>1m</b>. <b>1m</b> exhibited excellent free compound distribution in brain, CSF, and blood. The extensive in vitro evaluation, including biochemical, cellular, and panel screening, indicates that this agent is highly potent against EGFR-activating mutants and highly selective toward these targets. Importantly, <b>1m</b> showed tumor regression in the mouse model with brain metastasis. The promising data package for <b>1m</b> strongly supported its selection as a drug candidate for development. The results from additional in vivo studies are due to be published separately.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81815" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81815" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> In Vivo Animal Models</h3><div class="NLM_p">PC-9 cells (EGFR Exon19 deletion) were cultured with RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) at 37 °C. To monitor tumor growth in the brain, we stably transfected PC-9 cells with pGL4.50[luc2/CMV/Hygro] vector containing luciferase, and the bioluminescence signals were measured by a Xenogen imaging system.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> A brain metastasis model was established by intracerebral (ICB) injection of PC-9_Luc cells using the method by Lal with modifications.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> In brief, after a sagittal incision over the parieto-occipital bone, a hole was punctured on the skull at 2.5 mm to the right of the bregma and 1 mm anterior to the coronal suture. Then, the syringe was placed perpendicular to the skull through the hole and placed 3 mm deep below the skull surface, and the PC-9_Luc cell suspension was slowly injected. After injection, a sterile bone gel was applied to the hole, the scalp was pulled back to cover the skull, and the wound was closed. The mouse was gently put on a heating pad to recover, and closely monitored after surgery. All in vivo studies were approved by the Institutional Animal Care and Use Committee (IACUC) before the experiments were started.</div><div class="NLM_p last">Xenograft tissues were obtained from the PC-9 model after treatment with <b>1m</b> for assessment of histology and pEGFR modulation. Samples were harvested following formalin fixation and paraffin embedding (FFPE) for further study. pEGFR(Tyr1068) (DAKO X9003) IHC was performed on 3 μm FFPE sections using a Ventana automation (Roche) for staining.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Chemistry, Materials, and General Methods</h3><div class="NLM_p">Unless otherwise noted, all reagents and solvents were obtained from commercial suppliers, such as Aldrich, Sigma, Fluka, Acros, EMD Sciences, and so forth, and used without further purification. Dry organic solvents (dichloromethane, acetonitrile, DMF, etc.) were purchased from Aldrich packaged under nitrogen in Sure/Seal bottles. All reactions involving air or moisture-sensitive reagents were performed under a nitrogen or argon atmosphere. Silica gel chromatography was performed using prepacked silica gel cartridges (Biotage or RediSep). <sup>1</sup>H NMR spectra were recorded on a Bruker AV 400 MHz, Bruker AV II 400 MHz, Bruker AV III 400 MHz, or a Varian 400 MHz spectrometer at ambient temperature. Chemical shifts are reported in parts per million (ppm, δ units). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constants, and number of protons. Reactions were monitored using LCMS (Shimadzu 20A) with UV detection at 220 and 254 nm and a low resonance electrospray mode (ESI). All final compounds were purified to >95% purity as determined by LCMS (4 min). LCMS (4 min) methods used the following: Shimadzu 20A spectrometer, Xtimate C18 2.1 × 30 mm, 3 μm at 50 °C with a 0.8 mL/min flow rate; solvent A of 1.5 mL TFA in 4 L of water, solvent B of 0.75 mL of TFA in 4 L of acetonitrile; 0.0–3.0 min, 10% B; 3.0–3.5 min, 80% B; 3.51–4.0 min, 10% B. Flow from the UV detector was split (1:2) to the MS detector, which was configured with ESI as the ionizable source. All high resolution mass spectrometry (HRMS) data were acquired on an Agilent 1100 Series (LC/MSD TOF G3251) operated in positive electrospray ionization mode. The mobile phase: 0.1% TFA in water (solvent A) and 0.1% TFA in acetonitrile (solvent B) using the elution gradient 10–80% (solvent B) over 2 min, holding at 80% for 1 min, then back to 10%, and holding at 10% for 1 min at a flow rate of 1 mL/min. Nebulization gas, nitrogen; time of flight mass spectrometer with ESI source; positive ion mode; drying gas (N<sub>2</sub>) flow, 12 l/min; nebulizer pressure, 20 psi, 350 centigrade; capillary voltage, 3000 V; and fragmentor voltage, 50 V.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl Acetate (<b>5</b>)</h4><div class="NLM_p last">To a suspension of 4-chloro-7-methoxyquinazolin-6-yl acetate (<b>3</b>) (100 g, 396 mmol) in acetonitrile (4 L) was added 3-chloro-2-fluoroaniline (<b>4</b>) (57.8 g, 396.8 mmol). The reaction mixture was heated to reflux for 4 h with stirring before being cooled to room temperature. After filtration, the cake was washed with acetonitrile (1 L) and dried in vacuo to afford the HCl salt of <b>5</b> (143.3 g, 91%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.64 (s, 1H), 8.87 (s, 1H), 8.68 (s, 1H), 7.67–7.62 (m, 1H), 7.52 (s, 2H), 7.39–7.33 (m, 1H), 4.01 (s, 3H), 2.39 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>17</sub>H<sub>13</sub>ClFN<sub>3</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 362.1. Found: 361.8.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-ol (<b>6</b>)</h4><div class="NLM_p last">Potassium carbonate (114.0 g, 826 mmol) was added to a solution of HCl salt of <b>5</b> (150.0 g, 377 mmol) in methanol (800 mL). The reaction mixture was stirred at 10–15 °C for 2 h. After filtration, the solid was rinsed with methanol (120 mL). The filtrate was concentrated in vacuo to a residue (∼300 g) and treated with methyl <i>tert</i>-butyl ether (800 mL). The resulting mixture was filtered. The solid was dried at 40–45 °C to afford a potassium salt of compound <b>6</b> (132.0 g, 98%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.97 (s, 1H), 7.61–7.57 (m,1H), 7.24–7.11 (m, 2H), 7.29–7.25 (m,1H), 6.89 (s,1H), 6.79 (s, 1H), 3.77 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>15</sub>H<sub>11</sub>ClFN<sub>3</sub>O<sub>2</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 320.1. Found: 319.9.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>R</i>)-<i>tert</i>-Butyl 4-(chlorocarbonyl)-3-methylpiperazine-1-carboxylate (<b>8</b>)</h4><div class="NLM_p last">Pyridine (18 g, 225 mmol) was added dropwise to a mixture of triphosgene (23 g, 75 mmol) in dry dichloromethane (250 mL) followed by (<i>R</i>)-4-boc-2-methylpiperazine (<b>7</b>) (15 g, 75 mmol) at 0 °C under nitrogen. The reaction mixture was stirred overnight at room temperature and concentrated to afford <b>8</b> as a yellow solid, which was used without further purification.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl Trifluoromethanesulfonate (<b>9</b>)</h4><div class="NLM_p last">Pyridine (5 g, 62.4 mmol) was added to a solution of <b>6</b> (5 g, 15.6 mmol) in dichloromethane (60 mL) followed by the addition of trifluoromethanesulfonic anhydride (13.2 g, 46.8 mmol) dropwise at 5 °C. The reaction mixture was warmed to room temperature and stirred at that temperature overnight. The mixture was treated with water and separated. The organic layer was dried over sodium sulfate and concentrated. The residue was purified by chromatography using a silica gel column and eluted with ethyl acetate in petroleum (1:3) to afford <b>9</b> (5.2 g, 11.53 mmol, 74%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.81 (s, 1H), 8.42–8.39 (m, 1H), 7.76 (s, 1H), 7.46 (s, 1H), 7.39 (s, 1H), 7.24–7.18 (m, 2H), 4.10 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>16</sub>H<sub>10</sub>ClF<sub>4</sub>N<sub>3</sub>O<sub>4</sub>S + H<sup>+</sup> [M + H<sup>+</sup>]: 452.0. Found: 451.8.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>E</i>)-Methyl 3-(4-(3-chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)acrylate (<b>10</b>)</h4><div class="NLM_p last">Methyl acrylate (2.21 g, 25.7 mmol), Pd(OAc)<sub>2</sub> (287 mg, 1.28 mmol), 1,1′-bis(diphenylphosphino)ferrocene (710 mg, 1.28 mmol), Bu<sub>4</sub>NBr (4.13 g, 12.8 mmol), and Et<sub>3</sub>N (2.6 g, 25.7 mmol) were added to a solution of <b>9</b> (5.8 g, 12.8 mmol) in DMF (200 mL). The reaction mixture was degassed and refilled with nitrogen three times. The mixture was stirred at 80 °C overnight, cooled to room temperature, and treated with ethyl acetate (500 mL) and water (600 mL). After separation, the aqueous layer was extracted with ethyl acetate three times. The combined extracts were washed with brine, dried over sodium sulfate, and concentrated. The residue was purified by flash chromatography eluting with ethyl acetate in petroleum (1:2) to afford <b>10</b> (4 g, 10.3 mmol, 80%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.76 (s, 1H), 8.48–8.44 (m, 1H), 8.07–7.03 (m, 2H), 7.72 (s, 1H), 7.30 (s, 1H), 7.23–7.16 (m, 2H), 6.74 (d, <i>J</i> = 16.4 Hz, 1H), 4.06 (s, 3H), 3.86 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>19</sub>H<sub>15</sub>ClFN<sub>3</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 388.1. Found: 387.9.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazoline-6-carbaldehyde (<b>11</b>)</h4><div class="NLM_p last">A solution of <b>10</b> (4 g, 10.3 mmol) in dichloromethane (100 mL) was cooled with a dry ice bath, and ozone gas was bubbled into the solution for 15 min. The nitrogen was bubbled into the mixture to remove O<sub>3</sub>. After addition of methyl sulfide (3.2 g, 51.9 mmol), the mixture was warmed to room temperature and stirred at that temperature for 30 min. The solvent was removed in vacuo, and the residue was purified by flash chromatography eluting with petroleum in ethyl acetate (2:1) to afford <b>11</b> (1.3 g, 38% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.58 (s, 1H), 8.79 (s, 1H), 8.54 (s, 1H), 8.34 (t, <i>J</i> = 7.2 Hz, 1H), 7.50 (s, 1H), 7.25–7.18 (m, 2H), 4.12 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>16</sub>H<sub>11</sub>ClFN<sub>3</sub>O<sub>2</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 332.1. Found: 332.1.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-(3-Chloro-2-fluorophenyl)-7-methoxy-6-(morpholinomethyl)quinazolin-4-amine (<b>1a</b>)</h4><div class="NLM_p last">Morpholine (420 mg, 4.82 mmol) and acetic acid (289 mg, 4.82 mmol) were added to a solution of <b>11</b> (800 mg, 2.41 mmol) in methanol (10 mL). The reaction mixture was stirred at room temperature for 30 min, and NaBH<sub>3</sub>CN (227 mg, 3.61 mmol) was added. The resulting mixture was stirred at room temperature for an additional 1 h and concentrated. The residue was purified by reverse phase preparative HPLC using Agella Venusil ASB C18 150 × 21 mm, 5 μm column, and eluted with a gradient of 5–35% acetonitrile in water containing 0.05% HCl to afford HCl salt of <b>1a</b> (575.2 mg, 1.31 mmol, 54%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.87 (s, 1H), 8.81 (s, 1H), 7.59–7.53 (m, 2H), 7.39 (s, 1H), 7.35–3.31 (m, 1H), 4.62 (s, 2H), 4.19 (s, 3H), 4.07 (d, <i>J</i> = 12.8 Hz, 2H), 3.91 (t, <i>J</i> = 12.0 Hz, 2H), 3.54 (d, <i>J</i> = 12.0 Hz, 2H), 3.43–3.37 (m, 2H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 166.1, 162.4, 153.5, 153.0, 143.6, 132.2, 131.6,, 128.3, 126.9, 126.3, 123.1, 122.6, 108.2, 100.9, 65.0, 58.2, 56.4, 53.6. HRMS(ESI) <i>m</i>/<i>z</i> calculated for C<sub>20</sub>H<sub>20</sub>ClFN<sub>4</sub>O<sub>2</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 403.1337. Found 403.1302</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Methyl 4-Methoxy-2-nitro-5-(trifluoromethylsulfonyloxy)benzoate (<b>13</b>)</h4><div class="NLM_p last">Pyridine (8.7 g, 110 mmol) was added to a solution of methyl 5-hydroxy-4-methoxy-2-nitrobenzoate (5 g, 22 mmol) in dichloromethane (50 mL). The reaction mixture was cooled to 0 °C with ice-water, and then trifluoromethanesulfonic anhydride (12.4 g, 44 mmol) was added slowly to maintain the internal temperature below 10 °C. The reaction mixture was slowly warmed to room temperature and stirred at that temperature for 16 h. Water (100 mL) was then added, and the organic layer was separated. The aqueous layer was extracted with dichloromethane (3 × 100 mL). The combined organic layers were washed with citric acid solution (2 × 100 mL) and brine. The organic solution was dried over sodium sulfate and concentrated to afford <b>13</b> (5.9 g, 75%) as a yellow solid. This material was used for the next reaction without purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.71 (s, 1H), 7.41 (s, 1H), 4.05 (s, 3H), 3.91 (s, 3H).</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Methyl 4-Methoxy-5-morpholino-2-nitrobenzoate (<b>14</b>)</h4><div class="NLM_p last">Morpholine (0.73 g, 7.35 mmol) was added to a solution of <b>13</b> (1 g, 2.78 mmol) in acetonitrile (20 mL). The reaction mixture was refluxed overnight prior to the addition of a second batch of morpholine (0.5 g, 5.73 mmol). The reaction mixture was refluxed for an additional 3 h and cooled to room temperature. The solvent was evaporated in vacuo, and the residue was purified by flash chromatography eluting with ethyl acetate in petroleum (1:3) to afford <b>14</b> (800 mg, 2.7 mmol, 97%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.48 (s, 1H), 7.02 (s, 1H), 3.96 (s, 3H), 3.90 (s, 3H), 3.87 (t, <i>J</i> = 4.8 Hz, 4H), 3.21 (t, <i>J</i> = 4.8 Hz, 4H).</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Methyl 2-Amino-4-methoxy-5-morpholinobenzoate (<b>15</b>)</h4><div class="NLM_p last">Water (5 mL), ammonium chloride (1.44 g, 27 mmol), and iron powder (753 mg, 13.5 mmol) were added to a solution of <b>14</b> (800 mg, 2.7 mmol) in methanol (15 mL). The suspension was heated to 60 °C for 4 h and cooled to room temperature. The mixture was filtered. The filtration cake was rinsed with dichloromethane. After separation of the filtrate, the aqueous layer was extracted with dichloromethane (2 × 50 mL). The combined extracts were dried over sodium sulfate and concentrated to afford <b>15</b> (720 mg, 2.7 mmol, 100%) as a yellow solid. This product was used for the next step without purification.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 7-Methoxy-6-morpholinoquinazolin-4-ol (<b>16</b>)</h4><div class="NLM_p last">Formamidine acetate salt (563 mg, 5.4 mmol) was added to a solution of <b>15</b> (720 mg, 2.7 mmol) in ethanol (20 mL). The reaction mixture was refluxed overnight and cooled to room temperature. The solvent was evaporated in vacuo, and the residue was suspended with water (10 mL). The solid was collected by filtration and dried in vacuo to afford <b>16</b> (400 mg, 1.53 mmol, 57%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.10 (br, 1H), 7.97 (s, 1H), 7.44 (s, 1H), 7.12 (s, 1H), 3.93 (s, 3H), 3.76 (t, <i>J</i> = 4.4 Hz, 4H), 3.03 (t, <i>J</i> = 4.4 Hz, 4H). LCMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>13</sub>H<sub>15</sub>N<sub>3</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 262.1. Found: 262.1.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-(4-Chloro-7-methoxyquinazolin-6-yl)morpholine (<b>17</b>)</h4><div class="NLM_p last">Three drops of DMF were added to a suspension of <b>16</b> (600 mg, 2.3 mmol) in chloroform (10 mL) followed by the dropwise addition of oxalyl chloride (870 mg, 6.9 mmol). The reaction mixture was stirred at 80 °C for 2 h and cooled to room temperature. The solvent was evaporated in vacuo to afford <b>17</b> (644 mg, 100%) as a brown solid, which was used directly for the next step. LCMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>13</sub>H<sub>14</sub>ClN<sub>3</sub>O<sub>2</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 280.1. Found: 279.8.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-(3-Chloro-2-fluorophenyl)-7-methoxy-6-morpholinoquinazolin-4-amine (<b>1b</b>)</h4><div class="NLM_p last">3-Chloro-2-fluoroaniline (670 mg, 4.6 mmol) was added to a suspension of <b>17</b> (644 mg, 2.3 mmol) in acetonitrile (10 mL). The reaction mixture was refluxed for 18 h and cooled to room temperature. The solvent was evaporated in vacuo, and the residue was purified by reverse phase preparative HPLC using YMC-pack ODS-AQ 150 × 30 mm, 5 μm column, and eluted with a gradient of 35–65% acetonitrile (containing 0.05% ammonia) in water to afford <b>1b</b> (446.6 mg, 1.15 mmol, 50%) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.36 (s, 1H), 7.72 (s, 1H), 7.58–7.54 (m, 1H), 7.44–7.41 (m, 1H), 7.25 (d, <i>J</i> = 9.6 Hz, 1H), 7.22 (s, 1H), 4.05 (s, 3H), 3.93–3.90 (m, 4H), 3.23–3.21 (m, 4H). HRMS(ESI) <i>m</i>/<i>z</i> calculated for C<sub>19</sub>H<sub>18</sub>ClFN<sub>4</sub>O<sub>2</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 389.1181. Found: 389.1186.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-(3-Chloro-4-fluorophenyl)-7-methoxy-6-morpholinoquinazolin-4-amine (<b>2</b>)</h4><div class="NLM_p last">3-Chloro-4-fluoroaniline (166 mg, 1.14 mmol) was added to a suspension of <b>17</b> (160 mg, 0.57 mmol) in acetonitrile (3 mL). The reaction mixture was refluxed for 2 days and cooled to room temperature. The mixture was treated with water, neutralized with sodium carbonate solution, and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were dried over sodium sulfate and concentrated. The residue was purified by reverse phase preparative HPLC using Agella Venusil ASB C18 150 × 25 mm, 5 μm column, and eluted with a gradient of 9–79% acetonitrile (containing 0.05% HCl) in water to afford HCl salt of <b>2</b> (110.8 mg, 0.26 mmol, 49%) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.72 (s, 1H), 7.96–7.94 (m, 2H), 7.69–7.66 (m, 1H), 7.39 (t, <i>J</i> = 8.8 Hz, 1H), 7.26 (s, 1H), 4.13 (s, 3H), 3.93–3.91 (m, 4H), 3.23–3.28 (m, 4H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 162.0, 160.4, 156.6, 149.8, 145.7, 138.0, 135.2, 128.4, 126.4, 121.9, 118.1, 112.0, 109.2, 100.6, 68.0, 57.5, 52.5. HRMS(ESI) <i>m</i>/<i>z</i> calculated for C<sub>19</sub>H<sub>18</sub>ClFN<sub>4</sub>O<sub>2</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 389.1181. Found: 389.1205.</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)(morpholino)methanone (<b>1c</b>)</h4><div class="NLM_p last">Pd(OAc)<sub>2</sub> (10 mg, 0.044 mmol) and 1,1′-bis(diphenylphosphino)ferrocene (24 mg, 0.044 mmol) were added to a solution of <b>9</b> (200 mg, 0.44 mmol) in morpholine (10 mL). The reaction mixture was stirred at 70 °C under a carbon monoxide atmosphere (45 psi) overnight. After being cooled to room temperature, the solvent was evaporated in vacuo. The residue was purified by reverse phase preparative HPLC using Phenomenex Gemini C18 200 × 25 mm, 10 μm column, and eluted with a gradient of 30–50% acetonitrile in water to afford <b>1c</b> (70.6 mg, 0.17 mmol, 39%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.48 (s, 1H), 8.30 (s, 1H), 7.59—7.55 (m, 1H), 7.45–7.42 (m, 1H), 7.31 (s, 1H), 7.27–7.23 (m, 1H), 4.06 (s, 3H), 3.84–3.77 (m, 4H), 3.69–3.64 (m, 2H), 3.37–3.34 (m, 2H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 168.6, 161.1, 160.5, 157.1, 155.8, 153.5, 129.4, 128.4, 127.9, 125.9, 124.4, 122.8, 122.7, 110.7, 107.3, 68.1, 67.8, 57.0, 43.8. HRMS(ESI) <i>m</i>/<i>z</i> calculated for C<sub>20</sub>H<sub>18</sub>ClFN<sub>4</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 417.1130. Found: 417.1144.</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl Morpholine-4-carboxylate (<b>1d</b>)</h4><div class="NLM_p last">Morpholine-4-carbonyl chloride (<b>18a</b>) (250 mg, ∼1.7 mmol) was added to a solution of <b>6</b> (500 mg, 1.4 mmol) and Et<sub>3</sub>N (285 mg, 2.8 mmol) in anhydrous dichloromethane (20 mL). The reaction mixture was stirred at 25 °C overnight and concentrated under reduced pressure. The residue was purified by reverse phase preparative HPLC using Synergi C18 200 × 25 mm, 10 μm column, and eluted with 0–41% acetonitrile in water to give <b>1d</b> (272 mg, 0.63 mmol, 45%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.46 (s, 1H), 8.11 (s, 1H), 7.62–7.58 (m, 1H), 7.43–7.40 (m, 1H), 7.31 (s, 1H), 7.26–7.22 (m, 1H), 4.03 (s, 3H), 3.78 (br, 6H), 3.58 (br, 2H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 160.1, 158.5, 156.0, 155.1, 151.0, 142.2, 129.2, 129.0, 127.8, 125.9, 122.8, 122.6, 117.4, 110.2, 108.4, 67.7, 57.1, 46.7. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>20</sub>H<sub>18</sub>ClFN<sub>4</sub>O<sub>4</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 433.1079. Found: 433.1106.</div></div><div id="sec4_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl 4-Methylpiperazine-1-carboxylate (<b>1e</b>)</h4><div class="NLM_p last">4-Methylpiperazine-1-carbonyl chloride (<b>18b</b>) (19.9 g, ∼122.3 mmol) and potassium carbonate (27.5 g, 196 mmol) were added to a solution of <b>6</b> (15.64 g, 48.9 mmol) in DMF (270 mL). The reaction mixture was stirred at room temperature for 60 h before being treated with water (100 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 500 mL). The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The residue was purified by column chromatography on silica gel eluting with methanol in ethyl acetate (1:10) to afford <b>1e</b> (3.586 g, 8.06 mmol, 16%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.45 (s, 1H), 8.10 (s, 1H), 7.61–7.58 (m, 1H), 7.43–7.40 (m, 1H), 7.30 (s, 1H), 7.26–7.23 (m, 1H), 4.03 (s, 3H), 3.80 (br, 2H), 3.61 (br, 2H), 2.55 (br, 4H), 2.39 (s, 3H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 160.0, 158.5, 156.0, 155.0, 153.2, 151.0, 142.2, 129.1, 127.7, 125.9, 125.8, 122.8, 117.4, 110.2, 108.3, 57.1, 55.8, 46.3, 45.7. HRMS(ESI) <i>m</i>/<i>z</i> calculated for C<sub>21</sub>H<sub>21</sub>ClFN<sub>5</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 446.1395. Found: 446.1421.</div></div><div id="sec4_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>R</i>)-4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl 3-(Dimethylamino)pyrrolidine-1-carboxylate (<b>1f</b>)</h4><div class="NLM_p last">Quinazolin-6-ol derivative <b>6</b> (4 g, 11 mmol) and potassium carbonate (4.5 g, 33 mmol) were added to a solution of (<i>R</i>)-3-(dimethylamino)pyrrolidine-1-carbonyl chloride (<b>18c</b>) (5 g, ∼22 mmol) in DMF (100 mL). The resulting solution was stirred at room temperature overnight and poured into water (500 mL). After extraction with dichloromethane (3 × 300 mL), the combined organic layers were dried and concentrated. The residue was purified by reverse phase preparative HPLC using Phenomenex Gemini C18 200 × 25 mm, 10 μm column, and eluted with a gradient of 25–55% acetonitrile (containing 0.05% ammonia) in water to afford <b>1f</b> (2100 mg). The free base was treated with 1 N HCl (5 mL) solution and lyophilized to afford HCl salt of <b>1f</b> (2231 mg, 4.50 mmol, 20%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.58 (s, 1H), 8.24 (d, <i>J</i> = 5.2 Hz, 1H), 7.60–7.56 (m, 1H), 7.50–7.46 (m, 1H), 7.35 (s, 1H), 7.30–7.25 (m, 1H), 4.27–4.22 (m, 1H), 4.14–3.91 (m, 2H), 4.05 (s, 3H), 3.89–3.55 (m, 2H), 3.02 (s, 3H), 3.01 (s, 3H), 2.64–2.55 (m, 1H), 2.42–2.27 (m, 1H). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>23</sub>ClFN<sub>5</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 460.1552. Found: 460.1576.</div></div><div id="sec4_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>S</i>)-4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl 3-(Dimethylamino)pyrrolidine-1-carboxylate (<b>1g</b>)</h4><div class="NLM_p last">Quinazolin-6-ol analogue <b>6</b> (1.8 g, 5 mmol) and potassium carbonate (2 g, 15 mmol) were added to a solution of (<i>S</i>)-3-(dimethylamino)pyrrolidine-1-carbonyl chloride (<b>18d</b>) (crude, ∼10 mmol) in DMF (100 mL). The reaction mixture was stirred at room temperature overnight and poured into water (500 mL). After extraction with dichloromethane (3 × 300 mL), the combined organic layers were dried and concentrated. The residure was purified by reverse phase preparative HPLC using Phenomenex Gemini C18 200 × 25 mm, 10 μm column, and eluted with a gradient of 20–50% acetonitrile (containing 0.05% ammonia) in water to afford <b>1g</b> (530 mg). The free base was treated with 1 N HCl (1.3 mL) solution and lyophilized to give HCl salt (558.7 mg, 1.12 mmol, 22%) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.54 (s, 1H), 8.22 (d, <i>J</i> = 5.6 Hz, 1H), 7.58–7.56 (m, 1H), 7.46–7.30 (m, 1H), 7.34 (s, 1H), 7.28–7.26 (m, 1H), 4.26–3.90 (m, 3H), 4.04 (s, 3H), 3.85–3.54 (m, 2H), 3.01 (s, 3H), 3.00 (s, 3H), 2.66–2.52 (m, 1H), 2.40–2.31 (m, 1H). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>23</sub>ClFN<sub>5</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 460.1552. Found: 460.1549.</div></div><div id="sec4_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (1<i>S</i>,4<i>S</i>)-4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl 5-Methyl-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (<b>1h</b>)</h4><div class="NLM_p last">A mixture of <b>6</b> (1.5 g, 4.69 mmol), (1<i>S</i>,4<i>S</i>)-5-methyl-2,5-diazabicyclo[2.2.1]heptane-2-carbonyl chloride (<b>18e</b>) (crude, ∼13.37 mmol), and triethylamine (950 mg, 9.38 mmol) in dichloromethane (20 mL) was stirred at room temperature overnight. After filtration, the filtrate was concentrated, and the residue was purified by reverse phase preparative HPLC using Synergi 250 × 77 mm, 10 μm column, and eluted with a gradient of 5–40% acetonitrile (containing 0.05% HCl) in water to afford HCl salt of <b>1h</b> as a white solid (836.5 mg, 1.69 mmol, 36%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.75 (s, 1H), 8.51–8.46 (m, 1H), 7.68 (s, 1H), 7.50 (s, 1H), 7.33 (s, 1H), 7.18–7.16 (m, 2H), 4.63–4.50 (m, 1H), 3.99 (s, 3H), 3.93–3.75 (m, 1H), 3.56–3.35 (m, 2H), 3.08–2.85 (m, 2H), 2.55–2.53 (m, 3H), 2.03–1.87 (m, 2H). HRMS(ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>21</sub>ClFN<sub>5</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 458.1395. Found: 458.1370.</div></div><div id="sec4_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 2-<i>tert</i>-Butyl 5-(4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl)-2,5-diazabicyclo[4.1.0]heptane-2,5-dicarboxylate (<b>20</b>)</h4><div class="NLM_p last">A mixture of <i>tert</i>-butyl 5-(chlorocarbonyl)-2,5-diazabicyclo[4.1.0]heptane-2-carboxylate (<b>19</b>) (5.2 g, crude, ∼15.1 mmol), <b>6</b> (3.4 g, 10.6 mmol), and potassium carbonate (3.1 g, 22.7 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (50 mL) was stirred at room temperature overnight. After the reaction was completed, the solvent was evaporated under reduced pressure. The residue was treated with water (100 mL). The solid was collected by filtration and dried in vacuo to afford <b>20</b> (5.85 g, crude). LCMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>26</sub>H<sub>27</sub>ClFN<sub>5</sub>O<sub>5</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 544.2. Found: 544.1.</div></div><div id="sec4_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl 2,5-Diazabicyclo[4.1.0]heptane-2-carboxylate (<b>21</b>)</h4><div class="NLM_p last">To a solution of <b>20</b> (5.85 g, crude) in ethyl acetate (20 mL) was added a solution of HCl in 1,4-dioxane (50 mL, 4.0 M). The reaction mixture was stirred at room temperature for 1 h, concentrated, and dried under vacumn to afford crude <b>21</b> (5.61 g), which was used directly for the next step.</div></div><div id="sec4_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl 5-Methyl-2,5-diazabicyclo[4.1.0]heptane-2-carboxylate (<b>22</b>)</h4><div class="NLM_p last">To a solution of <b>21</b> (5.61 g, ∼ 10 mmol) in methanol (50 mL) were added triethylamine (1.07 g, 10.6 mmol), paraformaldehyde (645 mg, 21.5 mmol), and acetic acid (1.29 g, 21.5 mmol). The resulting mixture was stirred at room temperature overnight. Then, NaBH<sub>3</sub>CN (1.35 g, 21.5 mmol) was added, and the reaction mixture was stirred at room temperature for an additional 24 h. The solvent was evaporated, and the residue was purified by reverse phase preparative HPLC using a Gemini 250 × 50 mm column with 10 μm particle size and eluted with a gradient of 25–50% acetonitrile (containing 0.05% ammonia) in water to provide <b>22</b> (2.0 g, 4.38 mmol, 41% for two steps) as a racemic mixture. LCMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>21</sub>ClFN<sub>5</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 458.1. Found: 458.0.</div></div><div id="sec4_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl 5-Methyl-2,5-diazabicyclo[4.1.0]heptane-2-carboxylate Isomer 1 (<b>1i</b>) and Isomer 2 (<b>1j</b>)</h4><div class="NLM_p last">Racemic mixture <b>22</b> (0.99 g, 2.17 mmol) was separated by chiral supercritical fluid chromatography using an AD 300 × 50 mm column and eluted with 40% methanol in ammonia to afford <b>1i</b> (isomer 1, 445 mg) and <b>1j</b> (isomer 2, 440 mg). Compounds <b>1i</b> and <b>1j</b> were separately treated with HCl aqueous solution (1.0 M, 1 mL) and lyophilized to provide HCl salt of <b>1i</b> (471.8 mg, 0.95 mmol, 44%) and HCl salt of <b>1j</b> (465.5 mg, 0.94 mmol, 43% yield). Analytical method: column Chiralpak AD-3 50 × 4.6 mm with 3 μm particle size; mobile phase, methanol containing 0.05% diethylamine in CO<sub>2</sub> from 5 to 40%; flow rate, 4 mL/min; wavelength, 220 nm. HCl salt of <b>1i</b> (peak 1): <i>t</i><sub>R</sub> = 1.30 min in 4 min chromatography (<i>t</i><sub>R</sub> = 1.90 min in chiral SFC). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.59 (s, 1H), 8.28 (s, 1H), 7.60–7.57 (m, 1H), 7.51–7.47 (m, 1H), 7.36 (s, 1H), 7.30–7.26 (m, 1H), 4.18–4.00 (m, 1H), 4.08 (s, 3H), 3.53–3.46 (m, 1H), 3.37–3.10 (m, 3H), 3.01–2.93 (m, 1H), 2.95 (s, 3H), 1.41–1.14 (m, 2H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 160.6, 159.2, 156.4, 154.7, 153.3, 147.8, 142.6, 142.4, 129.8, 127.9, 126.0, 122.9, 118.1, 109.6, 106.4, 57.4, 51.0, 43.9, 41.5, 38.5, 30.4, 9.7. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>21</sub>ClFN<sub>5</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 458.1395. Found: 458.1401. HCl of <b>1j</b> (peak 2): <i>t</i><sub>R</sub> = 1.33 min in 4 min chromatography (<i>t</i><sub>R</sub> = 2.11 min in chiral SFC). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.64 (s, 1H), 8.35 (s, 1H), 7.60–7.56 (m, 1H), 7.52–7.49 (m, 1H), 7.38 (s, 1H), 7.31–7.27 (m, 1H), 4.22–4.00 (m, 1H), 4.10 (s, 3H), 3.58–3.45 (m, 2H), 3.36–3.25 (m, 2H), 3.17–3.09 (m, 1H), 3.04 (s, 3H), 1.52–1.24 (m, 2H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 160.9, 159.5, 155.8, 155.4, 154.3, 153.3, 146.6, 142.7, 130.1, 128.1, 126.0, 122.9, 118.4, 109.4, 105.7, 57.5, 51.1, 43.9, 41.1, 38.4, 30.6, 9.9. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>21</sub>ClFN<sub>5</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 458.1395. Found: 458.1386.</div></div><div id="sec4_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (<i>S</i>)-4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl 3,4-Dimethylpiperazine-1-carboxylate (<b>1k</b>)</h4><div class="NLM_p last">A mixture of (<i>S</i>)-3,4-dimethylpiperazine-1-carbonyl chloride (<b>18f</b>) (5.8 g, ∼10.15 mmol), <b>6</b> (2.6 g, 8.12 mmol), and potassium carbonate (4.2 g, 30.45 mmol) in DMF (120 mL) was stirred at room temperature for 16 h. After evaporation of the solvent under vacuum, the residue was treated with water. The mixture was extracted with ethyl acetate (4 × 500 mL). The combined organic layers were dried over sodium sulfate and concentrated. The residue was purified by reverse phase preparative HPLC using a Phenomenex Synergi 250 × 50 mm column with 10 μm particle size and eluted with a gradient of 5–25% acetonitrile (containing 0.2% formic acid) in water. The fractions containing the desired product were neutralized with potassium carbonate, and the precipitate was collected by filtration and dried in vacuo to provide <b>1k</b> (2460 mg). This compound was dissolved in CH<sub>3</sub>CN (5 mL), treated with 1 N HCl (5.5 mL), and lyophilized to afford the HCl salt of <b>1k</b> (2647.1 mg, 5.34 mmol, 66%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.79 (s, 1H), 8.50 (s, 1H), 7.60–7.53 (m, 2H), 7.43 (s, 1H), 7.34–7.30 (m, 1H), 4.53 (br, 1H), 4.32 (br, 1H), 4.14 (s, 3H), 3.84–3.22 (m, 5H), 3.04 (s, 3H), 1.52 (br, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>23</sub>ClFN<sub>5</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 460.1552. Found: 460.1538.</div></div><div id="sec4_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (<i>R</i>)-4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl 3,4-dimethylpiperazine-1-carboxylate (<b>1l</b>)</h4><div class="NLM_p last">A mixture of (<i>R</i>)-3,4-dimethylpiperazine-1-carbonyl chloride (<b>18g</b>) (6.2 g, ∼13.4 mmol), <b>6</b> (3.56 g, 11.12 mmol) and potassium carbonate (5.76 g, 41.7 mmol) in DMF (100 mL) was stirred at room temperature for 16 h. The mixture was concentrated in vacuo and treated with water. The mixture was then extracted with ethyl acetate (4 × 500 mL). The combined organic layers were dried over sodium sulfate and concentrated. The residue was purified by reverse phase preparative HPLC using a Synergi Phenomenex Synergi 250 × 50 mm column with 10 μm particle size and eluted with a gradient of 2–40% acetonitrile (containing 0.2% formic acid) in water. The fractions containing the desired product were neutralized with potassium carbonate; the precipitate was collected by filtration and dried in vacuo to provide <b>1l</b> (2500 mg). Compound <b>1l</b> was dissolved in CH<sub>3</sub>CN (5 mL), treated with 1 N HCl (5.5 mL), and lyophilized to afford HCl salt of <b>1l</b> (2663.6 mg, 5.37 mmol, 48%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O): δ 8.38 (s, 1H), 7.84 (s, 1H), 7.51–7.44 (m, 2H), 7.27–7.23 (m, 1H), 7.06 (s, 1H), 4.34 (br, 1H), 4.23 (br, 1H), 3.92 (s, 3H), 3.68–3.48 (m, 2H), 3.45–3.15 (m, 3H), 2.99 (s, 3H), 1.41 (d, <i>J</i> = 4.8 Hz, 3H). HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>23</sub>ClFN<sub>5</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 460.1552. Found: 460.1539.</div></div><div id="sec4_2_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (<i>R</i>)-4-<i>tert</i>-Butyl 1-(4-(2-Fluorophenylamino)-7-methoxyquinazolin-6-yl)-2-methylpiperazine-1,4-dicarboxylate (<b>23</b>)</h4><div class="NLM_p last">A mixture of <b>8</b> (15.8 g, ∼ 60 mmol), <b>6</b> (19.2 g, 60 mmol), and potassium carbonate (16.6 g, 120 mmol) in dry <i>N</i>,<i>N</i>-dimethylformamide (300 mL) was stirred overnight at room temperature. The reaction mixture was poured into water (250 mL) and filtered. The filtration cake was dried under vacuum to afford crude <b>23</b> (25 g) as yellow solid, which was used without further purification. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>26</sub>H<sub>29</sub>ClFN<sub>5</sub>O<sub>5</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 546.1914. Found: 546.1901.</div></div><div id="sec4_2_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (<i>R</i>)-4-(3-Chloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl 2-Methylpiperazine-1-carboxylate (<b>24</b>)</h4><div class="NLM_p last">HCl in dioxane (4M, 1 L) was added to a solution of <b>23</b> (750 g, crude) in methanol (1.0 L). The mixture was stirred at room temperature for 1 h and concentrated. The residue was diluted with water (3 L) and neutralized to pH 7 with saturated sodium bicarbonate solution. After filtration, the collected solid was treated with toluene (300 mL), and the toluene was evaporated under reduced pressure. This process was repeated twice, and crude compound <b>24</b> (495 g, yellow solid) was used without further purification. HRMS (ESI) calculated for C<sub>21</sub>H<sub>21</sub>ClFN<sub>5</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 446.1390. Found: 446.1393.</div></div><div id="sec4_2_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl (2<i>R</i>)-2,4-Dimethylpiperazine-1-carboxylate (<b>1m</b>)</h4><div class="NLM_p last">Sodium cyanoborohydride (2.0 g, 32 mmol) was added to a mixture of <b>24</b> (8 g, ∼15 mmol) and paraformaldehyde (1.0 g, 32 mmol) in methanol (100 mL). The reaction mixture was stirred at room temperature overnight and then concentrated in vacuo. The residue was treated with water and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude product was purified by reverse phase preparative HPLC using a Synergi 250 × 77 mm column with 10 μm particle size and eluted with a gradient of 5–35% acetonitrile (containing 0.05% formic acid) in water. The combined desired fractions were neutralized with saturated potassium carbonate and concentrated under reduced pressure. The residue was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were concentrated in vacuo and freeze-dried to afford <b>1m</b> (4.0 g, 8.71 mmol, 58%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.76 (s, 1H), 8.53–8.48 (m, 1H), 7.65 (s, 1H), 7.44 (br, 1H), 7.34 (s, 1H), 7.19–7.15 (m, 2H), 4.51–4.50 (br, 1H), 4.20–4.05 (br, 1H), 3.99 (s, 3H), 3.50–3.30 (br, 1H), 2.87 (d, <i>J</i> = 10.8 Hz, 1H), 2.73 (d, <i>J</i> = 11.2 Hz, 1H), 2.35 (s, 3H), 2.35–2.25 (m, 1H), 2.13–2.11 (m, 1H), 1.47 (br, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 158.1, 156.7, 155.2, 154.2, 153.0, 151.7, 150.4, 140.4, 128.6, 127.8, 127.4, 125.4, 120.7, 116.9, 108.8, 59.5, 56.8, 55.0, 48.3, 46.4, 16.6. HRMS (ESI) calculated for C<sub>22</sub>H<sub>23</sub>ClFN<sub>5</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 460.1546. Found: 460.1540.</div></div><div id="sec4_2_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl (2<i>S</i>)-2,4-Dimethylpiperazine-1-carboxylate (<b>1n</b>)</h4><div class="NLM_p last">A mixture of <b>6</b> (150 mg, 0.47 mmol), (<i>S</i>)-2,4-dimethylpiperazine-1-carbonyl chloride (<b>18h</b>) (1 g, crude), and K<sub>2</sub>CO<sub>3</sub> (130 mg, 0.94 mmol) in DMF (10 mL) was stirred at 30 °C overnight. The mixture was cooled to room temperature, treated with water, and filtered. The filtration cake was purified by reverse phase preparative HPLC using an ASB 150 × 25 mm column with 5 μm particle size and eluted with a gradient of 3–28% acetonitrile (containing 0.05% HCl) in water to give HCl salt of <b>1n</b> (21.0 mg, 0.042 mmol, 9%). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.77 (s, 1H), 8.43 (s, 1H), 7.57–7.50 (m, 2H), 7.38 (s, 1H), 7.32–7.28 (m, 1H), 4.51–4.21 (m, 1H), 4.10 (s, 3H), 3.77–3.35 (m, 5H), 3.27–3.17 (m, 1H), 2.99 (s, 3H), 1.58–1.49 (m, 3H). LCMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>23</sub>ClFN<sub>5</sub>O<sub>3</sub> + H<sup>+</sup> [M + H<sup>+</sup>]: 460.1. Found: 460.1.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i60"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01073">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33381" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33381" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01073" class="ext-link">10.1021/acs.jmedchem.5b01073</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">EGFR inhibition activity of compounds <b>1a</b>–<b>n</b> and <b>2</b> in biochemical assay; cellular assay data of compounds <b>1a</b>–<b>n</b> and <b>2</b>; biochemical assay protocols; cellular phosphorylation and proliferation assay procedures; permeability and efflux transport in MDCKII-MDR1 and MDCKII-BCRP cell lines; unbound brain to unbound blood (<i>K</i><sub>puu,brain</sub>) and CSF to unbound blood (<i>K</i><sub>puu,CSF</sub>) ratios; compound <b>1e</b> hepatocyte metabolite ID; Millipore kinase panel screening results; secondary pharmacology panel screening results; PET microdosing study; summary of in vitro DMPK of <b>1m</b>; metabolites identified in rat, dog, monkey, and human hepatocytes; physical properties of <b>1m</b>; procedures for assessing pEGFR expression in tumor tissue by using immunohistochemistry; tumor growth curve of individual animals (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01073/suppl_file/jm5b01073_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">L858R pEGFR IC<sub>50</sub> values for gefitinib, compounds <b>1a</b>−<b>n</b>, and <b>2</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01073/suppl_file/jm5b01073_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01073/suppl_file/jm5b01073_si_001.pdf">jm5b01073_si_001.pdf (752.19 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01073/suppl_file/jm5b01073_si_002.csv">jm5b01073_si_002.csv (1.0 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01073" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12264" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12264" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaolin Zhang</span> - <span class="hlFld-Affiliation affiliation">Innovation
Center China, Asia & Emerging Markets iMed, AstraZeneca Innovative Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#512938303e3d383f7f2b39303f361130222523302b343f3432307f323e3c"><span class="__cf_email__" data-cfemail="f58d9c949a999c9bdb8f9d949b92b594868187948f909b909694db969a98">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingbei Zeng</span> - <span class="hlFld-Affiliation affiliation">Innovation
Center China, Asia & Emerging Markets iMed, AstraZeneca Innovative Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiabing Wang</span> - <span class="hlFld-Affiliation affiliation">Innovation
Center China, Asia & Emerging Markets iMed, AstraZeneca Innovative Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ziqiang Cheng</span> - <span class="hlFld-Affiliation affiliation">Innovation
Center China, Asia & Emerging Markets iMed, AstraZeneca Innovative Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kan Chen</span> - <span class="hlFld-Affiliation affiliation">Innovation
Center China, Asia & Emerging Markets iMed, AstraZeneca Innovative Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Johnström</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca Translational Centre,
Personal Healthcare
and Biomarkers iMed, AstraZeneca R&D, Karolinska Institutet, Department
of Clinical Neuroscience, R5:U1 Karolinska University Hospital, SE-171 76 Stockholm, Sweden</span>; 
    <span class="hlFld-Affiliation affiliation">Karolinska
Institutet, Department of Clinical Neuroscience,
Centre for Psychiatry Research, R5:02 Karolinska University Hospital, SE-171 76 Stockholm, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katarina Varnäs</span> - <span class="hlFld-Affiliation affiliation">Karolinska
Institutet, Department of Clinical Neuroscience,
Centre for Psychiatry Research, R5:02 Karolinska University Hospital, SE-171 76 Stockholm, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Yunzhi Li</span> - <span class="hlFld-Affiliation affiliation">Innovation
Center China, Asia & Emerging Markets iMed, AstraZeneca Innovative Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhen Fan Yang</span> - <span class="hlFld-Affiliation affiliation">Innovation
Center China, Asia & Emerging Markets iMed, AstraZeneca Innovative Medicines and Early Development, 199 Liangjing Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1660e4708-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55863" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55863" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the chemistry team at WuXi AppTec for collaboration and biology, the DMPK groups at the Innovation Center China (ICC), AstraZeneca, for generating data to support the project, Drs. Les Hughes, David Wilson, Honchung Tsui, and Anne Galer at AstraZeneca for proof reading of this manuscript, and Ms. Nanyan Zhou for data management.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i62" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i62"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i63" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i63"> <b>Abbreviations</b></h2><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EGFR TKI</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood-brain-barrier</p></td></tr><tr><td class="NLM_term">BM</td><td class="NLM_def"><p class="first last">brain metastasis</p></td></tr><tr><td class="NLM_term">LM</td><td class="NLM_def"><p class="first last">leptomeningeal metastasis</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney</p></td></tr><tr><td class="NLM_term">MDR1</td><td class="NLM_def"><p class="first last">multidrug resistance protein 1</p></td></tr><tr><td class="NLM_term">BCRP</td><td class="NLM_def"><p class="first last">breast cancer resistance protein</p></td></tr><tr><td class="NLM_term">Pgp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">CSF</td><td class="NLM_def"><p class="first last">cerebrospinal fluid</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">wt</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">OATP</td><td class="NLM_def"><p class="first last">organic anion-transporting polypeptide</p></td></tr><tr><td class="NLM_term">DDI</td><td class="NLM_def"><p class="first last">drug–drug interaction</p></td></tr><tr><td class="NLM_term">EGFR TK</td><td class="NLM_def"><p class="first last">EGFR tyrosine kinase</p></td></tr><tr><td class="NLM_term">Cl<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">CL<sub>hepatic</sub></td><td class="NLM_def"><p class="first last">hepatic clearance</p></td></tr><tr><td class="NLM_term">IVIVe</td><td class="NLM_def"><p class="first last">in vitro–in vivo extrapolation</p></td></tr><tr><td class="NLM_term">LBF</td><td class="NLM_def"><p class="first last">liver blood flow</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission tomography</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometry</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">hour(s)</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>R</sub></td><td class="NLM_def"><p class="first last">retention time</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07266" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07266" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 45 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Molina, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassivi, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schild, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alex, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Non–small cell lung cancer: epidemiology, risk factors, treatment, and survivorship</span> <span class="citation_source-journal">Mayo Clin. Proc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">584</span><span class="NLM_x">–</span> <span class="NLM_lpage">594</span><span class="refDoi"> DOI: 10.1016/S0025-6196(11)60735-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2FS0025-6196%2811%2960735-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=18452692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BD1c3ovFyhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2008&pages=584-594&author=J.+R.+Molinaauthor=P.+Yangauthor=S.+D.+Cassiviauthor=S.+E.+Schildauthor=A.+Alexauthor=A.+A.+Adjei&title=Non%E2%80%93small+cell+lung+cancer%3A+epidemiology%2C+risk+factors%2C+treatment%2C+and+survivorship&doi=10.1016%2FS0025-6196%2811%2960735-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship</span></div><div class="casAuthors">Molina Julian R; Yang Ping; Cassivi Stephen D; Schild Steven E; Adjei Alex A</div><div class="citationInfo"><span class="NLM_cas:title">Mayo Clinic proceedings</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">584-94</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung cancer is the leading cause of cancer-related mortality not only in the United States but also around the world.  In North America, lung cancer has become more predominant among former than current smokers.  Yet in some countries, such as China, which has experienced a dramatic increase in the cigarette smoking rate during the past 2 decades, a peak in lung cancer incidence is still expected.  Approximately two-thirds of adult Chinese men are smokers, representing one-third of all smokers worldwide.  Non-small cell lung cancer accounts for 85% of all lung cancer cases in the United States.  After the initial diagnosis, accurate staging of non-small cell lung cancer using computed tomography or positron emission tomography is crucial for determining appropriate therapy.  When feasible, surgical resection remains the single most consistent and successful option for cure.  However, close to 70% of patients with lung cancer present with locally advanced or metastatic disease at the time of diagnosis.  Chemotherapy is beneficial for patients with metastatic disease, and the administration of concurrent chemotherapy and radiation is indicated for stage III lung cancer.  The introduction of angiogenesis, epidermal growth factor receptor inhibitors, and other new anti-cancer agents is changing the present and future of this disease and will certainly increase the number of lung cancer survivors.  We identified studies for this review by searching the MEDLINE and PubMed databases for English-language articles published from January 1, 1980, through January 31, 2008.  Key terms used for this search included non-small cell lung cancer, adenocarcinoma, squamous cell carcinoma, bronchioalveolar cell carcinoma, large cell carcinoma, lung cancer epidemiology, genetics, survivorship, surgery, radiation therapy, chemotherapy, targeted therapy, bevacizumab, erlotinib, and epidermal growth factor receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmyOu2OSFHeW52AMpI4GK2fW6udTcc2ea9ZEZFNsO_Ybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3ovFyhtQ%253D%253D&md5=7d7f1147c10a3c6b0fd344757694b4aa</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0025-6196%2811%2960735-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0025-6196%252811%252960735-0%26sid%3Dliteratum%253Aachs%26aulast%3DMolina%26aufirst%3DJ.%2BR.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DCassivi%26aufirst%3DS.%2BD.%26aulast%3DSchild%26aufirst%3DS.%2BE.%26aulast%3DAlex%26aufirst%3DA.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DNon%25E2%2580%2593small%2520cell%2520lung%2520cancer%253A%2520epidemiology%252C%2520risk%2520factors%252C%2520treatment%252C%2520and%2520survivorship%26jtitle%3DMayo%2520Clin.%2520Proc.%26date%3D2008%26volume%3D83%26spage%3D584%26epage%3D594%26doi%3D10.1016%2FS0025-6196%2811%2960735-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Cancer Statistics, 2014</span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.3322/caac.21208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.3322%2Fcaac.21208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=24399786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BC2czjtVOlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2014&pages=9-22&author=R.+Siegelauthor=J.+Maauthor=Z.+Zouauthor=A.+Jemal&title=Cancer+Statistics%2C+2014&doi=10.3322%2Fcaac.21208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2014</span></div><div class="casAuthors">Siegel Rebecca; Ma Jiemin; Zou Zhaohui; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data were collected by the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data were collected by the National Center for Health Statistics.  A total of 1,665,540 new cancer cases and 585,720 cancer deaths are projected to occur in the United States in 2014.  During the most recent 5 years for which there are data (2006-2010), delay-adjusted cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.4% per year in women.  The combined cancer death rate (deaths per 100,000 population) has been continuously declining for 2 decades, from a peak of 215.1 in 1991 to 171.8 in 2010.  This 20% decline translates to the avoidance of approximately 1,340,400 cancer deaths (952,700 among men and 387,700 among women) during this time period.  The magnitude of the decline in cancer death rates from 1991 to 2010 varies substantially by age, race, and sex, ranging from no decline among white women aged 80 years and older to a 55% decline among black men aged 40 years to 49 years.  Notably, black men experienced the largest drop within every 10-year age group.  Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-53QNNisGn5agfuraLLzSfW6udTcc2ea9ZEZFNsO_Ybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czjtVOlsw%253D%253D&md5=2aa85d07bbfc7838e1d0e6bf94ce6c46</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21208%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DZ.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520Statistics%252C%25202014%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2014%26volume%3D64%26spage%3D9%26epage%3D22%26doi%3D10.3322%2Fcaac.21208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lhRcedOCcBz-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Mok, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, D.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunpaweravong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margono, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiwaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chewaskulyong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffield, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuoka, M.</span><span> </span><span class="NLM_article-title">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">947</span><span class="NLM_x">–</span> <span class="NLM_lpage">957</span><span class="refDoi"> DOI: 10.1056/NEJMoa0810699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1056%2FNEJMoa0810699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=19692680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=947-957&author=T.+S.+Mokauthor=Y.-L.+Wuauthor=S.+Thongprasertauthor=C.-H.+Yangauthor=D.-T.+Chuauthor=N.+Saijoauthor=P.+Sunpaweravongauthor=B.+Hanauthor=B.+Margonoauthor=Y.+Ichinoseauthor=Y.+Nishiwakiauthor=Y.+Oheauthor=J.-J.+Yangauthor=B.+Chewaskulyongauthor=H.+Jiangauthor=E.+L.+Duffieldauthor=C.+L.+Watkinsauthor=A.+A.+Armourauthor=M.+Fukuoka&title=Gefitinib+or+carboplatin-paclitaxel+in+pulmonary+adenocarcinoma&doi=10.1056%2FNEJMoa0810699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span></div><div class="casAuthors">Mok, Tony S.; Wu, Yi-Long; Thongprasert, Sumitra; Yang, Chih-Hsin; Chu, Da-Tong; Saijo, Nagahiro; Sunpaweravong, Patrapim; Han, Baohui; Margono, Benjamin; Ichinose, Yukito; Nishiwaki, Yutaka; Ohe, Yuichiro; Yang, Jin-Ji; Chewaskulyong, Busyamas; Jiang, Haiyi; Duffield, Emma L.; Watkins, Claire L.; Armour, Alison A.; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-957</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer.  METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calcd. to produce an area under the curve of 5 or 6 mg per mL per min) plus paclitaxel (200 mg per square meter of body-surface area) (608 patients).  The primary end point was progression-free survival.  RESULTS: The 12-mo rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel.  The study met its primary objective of showing the noninferiority of gefitinib and also showed its superiority, as compared with carboplatin-paclitaxel, with respect to progression-free survival in the intention-to-treat population (hazard ratio for progression or death, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P < 0.001).  In the subgroup of 261 patients who were pos. for the epidermal growth factor receptor gene (EGFR) mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin-paclitaxel (hazard ratio for progression or death, 0.48; 95% CI, 0.36 to 0.64; P < 0.001), whereas in the subgroup of 176 patients who were neg. for the mutation, progression-free survival was significantly longer among those who received carboplatin-paclitaxel (hazard ratio for progression or death with gefitinib, 2.85; 95% CI, 2.05 to 3.98; P < 0.001).  The most common adverse events were rash or acne (in 66.2% of patients) and diarrhea (46.6%) in the gefitinib group and neurotoxic effects (69.9%), neutropenia (67.1%), and alopecia (58.4%) in the carboplatin-paclitaxel group.  CONCLUSIONS: Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia.  The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKhpFOiEQu7Vg90H21EOLACvtfcHk0lhRcedOCcBz-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK&md5=31ce0983eedb9f248dcf0726adf18b88</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0810699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0810699%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%2BS.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.-H.%26aulast%3DChu%26aufirst%3DD.-T.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DSunpaweravong%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DMargono%26aufirst%3DB.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.-J.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DDuffield%26aufirst%3DE.%2BL.%26aulast%3DWatkins%26aufirst%3DC.%2BL.%26aulast%3DArmour%26aufirst%3DA.%2BA.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520or%2520carboplatin-paclitaxel%2520in%2520pulmonary%2520adenocarcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D947%26epage%3D957%26doi%3D10.1056%2FNEJMoa0810699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Shepherd, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciuleanu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maoleekoonpiroj, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smylie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kooten, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dediu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findlay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezjak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santabarbara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, L.</span><span> </span><span class="NLM_article-title">Erlotinib in previously treated non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1056/NEJMoa050753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1056%2FNEJMoa050753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=16014882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=123-132&author=F.+A.+Shepherdauthor=J.+R.+Pereiraauthor=T.+Ciuleanuauthor=E.+H.+Tanauthor=V.+Hirshauthor=S.+Thongprasertauthor=D.+Camposauthor=S.+Maoleekoonpirojauthor=M.+Smylieauthor=R.+Martinsauthor=M.+V.+Kootenauthor=M.+Dediuauthor=B.+Findlayauthor=D.+Tuauthor=D.+Johnstonauthor=A.+Bezjakauthor=G.+Clarkauthor=P.+Santabarbaraauthor=L.+Seymour&title=Erlotinib+in+previously+treated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa050753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib in previously treated non-small-cell lung cancer</span></div><div class="casAuthors">Shepherd, Frances A.; Pereira, Jose Rodrigues; Ciuleanu, Tudor; Tan, Eng Huat; Hirsh, Vera; Thongprasert, Sumitra; Campos, Daniel; Maoleekoonpiroj, Savitree; Smylie, Michael; Martins, Renato; van Kooten, Maximiliano; Dediu, Mircea; Findlay, Brian; Tu, Dongsheng; Johnston, Dianne; Bezjk, Andrea; Clark, Gary; Santabarbara, Pedro; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a randomized, placebo-controlled, double-blind trial to det. whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy.  Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens.  The patients were stratified according to center, performance status, response to prior chemotherapy, no. of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo.  The median age of the 731 patients who underwent randomization was 61.4 yeas; 49 % had received two prior chemotherapy regimens, and 93 % had received platinum-based chemotherapy.  The response rate was 8.9 % in the erlotinib group and less than 1 % in the placebo group (P < 0.001); the median duration of the response wa 7.9 mo and 3.7 mo, resp.  Progression-free survival was 2.2 mo and 1.8 mo, resp. (hazard ratio, 0.61, adjusted for stratification categories; P < 0.001).  Overall survival was 6.7 mo and 4.7 mo, resp. (hazard ratio, 0.70; P < 0.001), in favor of erlotinib.  Five percent of patients discontinued erlotinib because of toxic effects.  Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr8tjSBsYtbVg90H21EOLACvtfcHk0lhRcedOCcBz-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D&md5=1633999cf09b8387ad88f40f75a5bb93</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050753%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DPereira%26aufirst%3DJ.%2BR.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DCampos%26aufirst%3DD.%26aulast%3DMaoleekoonpiroj%26aufirst%3DS.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3DKooten%26aufirst%3DM.%2BV.%26aulast%3DDediu%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DB.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DD.%26aulast%3DBezjak%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DSantabarbara%26aufirst%3DP.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DErlotinib%2520in%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D123%26epage%3D132%26doi%3D10.1056%2FNEJMoa050753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Cataldo, V. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Soler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintás-Cardama, A.</span><span> </span><span class="NLM_article-title">Treatment of non–small-cell lung cancer with erlotinib or gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">947</span><span class="NLM_x">–</span> <span class="NLM_lpage">955</span><span class="refDoi"> DOI: 10.1056/NEJMct0807960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1056%2FNEJMct0807960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=21388312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFentbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=947-955&author=V.+D.+Cataldoauthor=D.+L.+Gibbonsauthor=R.+P%C3%A9rez-Solerauthor=A.+Quint%C3%A1s-Cardama&title=Treatment+of+non%E2%80%93small-cell+lung+cancer+with+erlotinib+or+gefitinib&doi=10.1056%2FNEJMct0807960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of non-small-cell lung cancer with erlotinib or gefitinib</span></div><div class="casAuthors">Cataldo, Vince D.; Gibbons, Don L.; Perez-Soler, Roman; Quintas-Cardama, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-955</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraDIxHbNbHr7Vg90H21EOLACvtfcHk0liB20rwoa85TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFentbg%253D&md5=5030feb97e5b6b09e3e11d6946cde577</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMct0807960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMct0807960%26sid%3Dliteratum%253Aachs%26aulast%3DCataldo%26aufirst%3DV.%2BD.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DP%25C3%25A9rez-Soler%26aufirst%3DR.%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26atitle%3DTreatment%2520of%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%2520with%2520erlotinib%2520or%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D947%26epage%3D955%26doi%3D10.1056%2FNEJMct0807960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Wu, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geater, S. L.</span><span> </span><span class="NLM_article-title">Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span><span class="refDoi"> DOI: 10.1016/S1470-2045(13)70604-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2FS1470-2045%2813%2970604-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=24439929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtF2gu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=213-222&author=Y.-L.+Wuauthor=C.+Zhouauthor=C.-P.+Huauthor=J.+Fengauthor=S.+Luauthor=Y.+Huangauthor=W.+Liauthor=M.+Houauthor=J.+H.+Shiauthor=K.-Y.+Leeauthor=C.+R.+Xuauthor=D.+Masseyauthor=M.+Kimauthor=Y.+Shiauthor=S.+L.+Geater&title=Afatinib+versus+cisplatin+plus+gemcitabine+for+first-line+treatment+of+Asian+patients+with+advanced+non-small-cell+lung+cancer+harbouring+EGFR+mutations+%28LUX-Lung+6%29%3A+an+open-label%2C+randomised+phase+3+trial&doi=10.1016%2FS1470-2045%2813%2970604-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial</span></div><div class="casAuthors">Wu, Yi-Long; Zhou, Caicun; Hu, Cheng-Ping; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Li, Wei; Hou, Mei; Shi, Jian Hua; Lee, Kye Young; Xu, Chong-Rui; Massey, Dan; Kim, Miyoung; Shi, Yang; Geater, Sarayut L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-222</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Afatinib-an oral irreversible ErbB family blocker-improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  We compared afatinib with gemcitabine and cisplatin-a chemotherapy regimen widely used in Asia-for first-line treatment of Asian patients with EGFR mutation-pos. advanced NSCLC.This open-label, randomised phase 3 trial was done at 36 centers in China, Thailand, and South Korea.  After central testing for EGFR mutations, treatment-naive patients (stage IIIB or IV cancer [American Joint Committee on Cancer version 6], performance status 0-1) were randomly assigned (2:1) to receive either oral afatinib (40 mg per day) or i.v. gemcitabine 1000 mg/m2 on day 1 and day 8 plus cisplatin 75 mg/m2 on day 1 of a 3-wk schedule for up to six cycles.  Randomisation was done centrally with a random no.-generating system and an interactive internet and voice-response system.  Randomisation was stratified by EGFR mutation (Leu858Arg, exon 19 deletions, or other; block size three).  Clinicians and patients were not masked to treatment assignment, but the independent central imaging review group were.  Treatment continued until disease progression, intolerable toxic effects, or withdrawal of consent.  The primary endpoint was progression-free survival assessed by independent central review (intention-to-treat population).  This study is registered with ClinicalTrials.gov, NCT01121393.910 patients were screened and 364 were randomly assigned (242 to afatinib, 122 to gemcitabine and cisplatin).  Median progression-free survival was significantly longer in the afatinib group (11·0 mo, 95% CI 9·7-13·7) than in the gemcitabine and cisplatin group (5·6 mo, 5·1-6·7; hazard ratio 0·28, 95% CI 0·20-0·39; p<0·0001).  The most common treatment-related grade 3 or 4 adverse events in the afatinib group were rash or acne (35 [14·6%] of 239 patients), diarrhoea (13 [5·4%]), and stomatitis or mucositis (13 [5·4%]), compared with neutropenia (30 [26·5%] of 113 patients), vomiting (22 [19·5%]), and leucopenia (17 [15·0%]) in the gemcitabine and cisplatin group.  Treatment-related serious adverse events occurred in 15 (6·3%) patients in the afatinib group and nine (8·0%) patients in the gemcitabine and cisplatin group.First-line afatinib significantly improves progression-free survival with a tolerable and manageable safety profile in Asian patients with EGFR mutation-pos. advanced lung NSCLC.  Afatinib should be considered as a first-line treatment option for this patient population.Boehringer Ingelheim.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOB23gvDAjnbVg90H21EOLACvtfcHk0liB20rwoa85TA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtF2gu78%253D&md5=9c496689c6b40e1682e7d3786d9ae1b9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970604-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970604-1%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DC.-P.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DHou%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DK.-Y.%26aulast%3DXu%26aufirst%3DC.%2BR.%26aulast%3DMassey%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DGeater%26aufirst%3DS.%2BL.%26atitle%3DAfatinib%2520versus%2520cisplatin%2520plus%2520gemcitabine%2520for%2520first-line%2520treatment%2520of%2520Asian%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520harbouring%2520EGFR%2520mutations%2520%2528LUX-Lung%25206%2529%253A%2520an%2520open-label%252C%2520randomised%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D213%26epage%3D222%26doi%3D10.1016%2FS1470-2045%2813%2970604-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Barajas, R. F.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cha, S.</span><span> </span><span class="NLM_article-title">Imaging diagnosis of brain metastasis</span> <span class="citation_source-journal">Prog. Neurol. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span><span class="refDoi"> DOI: 10.1159/000331174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1159%2F000331174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=22236668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BC387jslKqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=55-73&author=R.+F.+Barajasauthor=S.+Cha&title=Imaging+diagnosis+of+brain+metastasis&doi=10.1159%2F000331174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging diagnosis of brain metastasis</span></div><div class="casAuthors">Barajas Ramon Francisco Jr; Cha Soonmee</div><div class="citationInfo"><span class="NLM_cas:title">Progress in neurological surgery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hematogeneous spread of primary neoplasm can result in central nervous system (CNS) disease burden in various anatomically distinct regions; calvarial, pachymeningeal, leptomeningeal, and intraparenchymal.  The choice of imaging modality is dependent on the individual clinical situation, but, largely depends on the patients overall clinical status and the information needed to make treatment decisions.  Contrast-enhanced magnetic resonance (MR) imaging is the preferred imaging modality of choice; however, computed tomography (CT) is often utilized as the first-pass screening modality for CNS disease.  Despite the superior soft tissue resolution, multiplanar capability, and noninvasive nature of MR imaging, T(1)- and T(2)-weighted sequences are limited to delineating morphologic anatomical deraignment of tissues by tumor.  Several physiology based MR imaging sequences have been developed which compliment anatomic MR imaging.  Proton magnetic resonance spectroscopic and dynamic susceptibility contrast-enhanced perfusion-weighted imaging are two physiologic sequences which add additional diagnostic information allowing for improved tumor characterization.  Common pitfalls in evaluating for metastatic disease burden include the misidentification of non-neoplastic hematomas, remote microvascular ischemia, and acute onset of ischemic stroke.  In the pediatric population, CNS metastases are rare; however, the onset of acute neurological symptoms in a child with known primary tumor should prompt imaging of the neuroaxis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTand0BT_8r3ynGiHuhFGv8fW6udTcc2eaIInEuiG165rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387jslKqug%253D%253D&md5=0e6759877f00cf541284824dabe2c7e1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1159%2F000331174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000331174%26sid%3Dliteratum%253Aachs%26aulast%3DBarajas%26aufirst%3DR.%2BF.%26aulast%3DCha%26aufirst%3DS.%26atitle%3DImaging%2520diagnosis%2520of%2520brain%2520metastasis%26jtitle%3DProg.%2520Neurol.%2520Surg.%26date%3D2012%26volume%3D25%26spage%3D55%26epage%3D73%26doi%3D10.1159%2F000331174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Nguyen, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemanski, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinh-Hung, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altdorfer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ampil, F.</span><span> </span><span class="NLM_article-title">Potential applications of imaging and image-guided radiotherapy for brain metastases and glioblastoma to improve patient quality of life</span> <span class="citation_source-journal">Front. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="refDoi"> DOI: 10.3389/fonc.2013.00284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.3389%2Ffonc.2013.00284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=24312897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BC2cflsVamtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=284&author=N.+P.+Nguyenauthor=M.+L.+Nguyenauthor=J.+Vockauthor=C.+Lemanskiauthor=C.+Kerrauthor=V.+Vinh-Hungauthor=A.+Chiauthor=R.+Khanauthor=W.+Woodsauthor=G.+Altdorferauthor=M.+D%E2%80%99Andreaauthor=U.+Karlssonauthor=R.+Hamiltonauthor=F.+Ampil&title=Potential+applications+of+imaging+and+image-guided+radiotherapy+for+brain+metastases+and+glioblastoma+to+improve+patient+quality+of+life&doi=10.3389%2Ffonc.2013.00284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Potential applications of imaging and image-guided radiotherapy for brain metastases and glioblastoma to improve patient quality of life</span></div><div class="casAuthors">Nguyen Nam P; Nguyen Mai L; Vock Jacqueline; Lemanski Claire; Kerr Christine; Vinh-Hung Vincent; Chi Alexander; Khan Rihan; Woods William; Altdorfer Gabor; D'Andrea Mark; Karlsson Ulf; Hamilton Russ; Ampil Fred</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">284</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of glioblastoma multiforme (GBM) and brain metastasis remains a challenge because of the poor survival and the potential for brain damage following radiation.  Despite concurrent chemotherapy and radiation dose escalation, local recurrence remains the predominant pattern of failure in GBM most likely secondary to repopulation of cancer stem cells.  Even though radiotherapy is highly effective for local control of radio-resistant tumors such as melanoma and renal cell cancer, systemic disease progression is the cause of death in most patients with brain metastasis.  Preservation of quality of life (QOL) of cancer survivors is the main issue for patients with brain metastasis.  Image-guided radiotherapy (IGRT) by virtue of precise radiation dose delivery may reduce treatment time of patients with GBM without excessive toxicity and potentially improve neurocognitive function with preservation of local control in patients with brain metastasis.  Future prospective trials for primary brain tumors or brain metastasis should include IGRT to assess its efficacy to improve patient QOL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJvBOhVCPyOCEJCPKhJPuqfW6udTcc2ebxVlz1HjiV5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflsVamtQ%253D%253D&md5=28575349bc8b2b0ce41ec15433ec2e86</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2013.00284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2013.00284%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DN.%2BP.%26aulast%3DNguyen%26aufirst%3DM.%2BL.%26aulast%3DVock%26aufirst%3DJ.%26aulast%3DLemanski%26aufirst%3DC.%26aulast%3DKerr%26aufirst%3DC.%26aulast%3DVinh-Hung%26aufirst%3DV.%26aulast%3DChi%26aufirst%3DA.%26aulast%3DKhan%26aufirst%3DR.%26aulast%3DWoods%26aufirst%3DW.%26aulast%3DAltdorfer%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DM.%26aulast%3DKarlsson%26aufirst%3DU.%26aulast%3DHamilton%26aufirst%3DR.%26aulast%3DAmpil%26aufirst%3DF.%26atitle%3DPotential%2520applications%2520of%2520imaging%2520and%2520image-guided%2520radiotherapy%2520for%2520brain%2520metastases%2520and%2520glioblastoma%2520to%2520improve%2520patient%2520quality%2520of%2520life%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D3%26spage%3D284%26doi%3D10.3389%2Ffonc.2013.00284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Nayak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, P. Y.</span><span> </span><span class="NLM_article-title">Epidemiology of brain metastases</span> <span class="citation_source-journal">Curr. Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span><span class="refDoi"> DOI: 10.1007/s11912-011-0203-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1007%2Fs11912-011-0203-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=22012633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BC387nsVymtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=48-54&author=L.+Nayakauthor=E.+Q.+Leeauthor=P.+Y.+Wen&title=Epidemiology+of+brain+metastases&doi=10.1007%2Fs11912-011-0203-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of brain metastases</span></div><div class="casAuthors">Nayak Lakshmi; Lee Eudocia Quant; Wen Patrick Y</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology reports</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Brain metastases are one of the most common neurologic complications of cancer.  The incidence is 9%-17% based on various studies, although the exact incidence is thought to be higher.  The incidence is increasing with the availability of improved imaging techniques which aid early diagnosis, and effective systemic treatment regimens which prolong life, thus allowing cancer to disseminate to the brain.  Lung cancer, breast cancer, and melanoma are the most frequent to develop brain metastases, and account for 67%-80% of all cancers.  Most patients with brain metastases have synchronous extracerebral metastases.  Some patients present with no known primary cancer diagnosis.  In children, brain metastases are rare; germ cell tumors, sarcomas, and neuroblastoma are the common offenders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSXIJRn58ZYAfIW7hznt0zpfW6udTcc2ebxVlz1HjiV5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387nsVymtw%253D%253D&md5=441177f538efd8fb60f13df12602117e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs11912-011-0203-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-011-0203-y%26sid%3Dliteratum%253Aachs%26aulast%3DNayak%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DE.%2BQ.%26aulast%3DWen%26aufirst%3DP.%2BY.%26atitle%3DEpidemiology%2520of%2520brain%2520metastases%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2012%26volume%3D14%26spage%3D48%26epage%3D54%26doi%3D10.1007%2Fs11912-011-0203-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Gril, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeg, P. S.</span><span> </span><span class="NLM_article-title">Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1204</span><span class="NLM_x">–</span> <span class="NLM_lpage">1210</span><span class="refDoi"> DOI: 10.1016/j.ejca.2010.02.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2Fj.ejca.2010.02.033" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=1204-1210&author=B.+Grilauthor=L.+Evansauthor=D.+Palmieriauthor=P.+S.+Steeg&title=Translational+research+in+brain+metastasis+is+identifying+molecular+pathways+that+may+lead+to+the+development+of+new+therapeutic+strategies&doi=10.1016%2Fj.ejca.2010.02.033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2010.02.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2010.02.033%26sid%3Dliteratum%253Aachs%26aulast%3DGril%26aufirst%3DB.%26aulast%3DEvans%26aufirst%3DL.%26aulast%3DPalmieri%26aufirst%3DD.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26atitle%3DTranslational%2520research%2520in%2520brain%2520metastasis%2520is%2520identifying%2520molecular%2520pathways%2520that%2520may%2520lead%2520to%2520the%2520development%2520of%2520new%2520therapeutic%2520strategies%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2010%26volume%3D46%26spage%3D1204%26epage%3D1210%26doi%3D10.1016%2Fj.ejca.2010.02.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Grommes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holodny, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassman, A. B.</span><span> </span><span class="NLM_article-title">Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer</span> <span class="citation_source-journal">Neuro-Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1364</span><span class="NLM_x">–</span> <span class="NLM_lpage">1369</span><span class="refDoi"> DOI: 10.1093/neuonc/nor121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1093%2Fneuonc%2Fnor121" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=1364-1369&author=C.+Grommesauthor=G.+R.+Oxnardauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=W.+Paoauthor=A.+I.+Holodnyauthor=J.+L.+Clarkeauthor=A.+B.+Lassman&title=Pulsatile%E2%80%9D+high-dose+weekly+erlotinib+for+CNS+metastases+from+EGFR+mutant+non-small+cell+lung+cancer&doi=10.1093%2Fneuonc%2Fnor121"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnor121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnor121%26sid%3Dliteratum%253Aachs%26aulast%3DGrommes%26aufirst%3DC.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DHolodny%26aufirst%3DA.%2BI.%26aulast%3DClarke%26aufirst%3DJ.%2BL.%26aulast%3DLassman%26aufirst%3DA.%2BB.%26atitle%3DPulsatile%25E2%2580%259D%2520high-dose%2520weekly%2520erlotinib%2520for%2520CNS%2520metastases%2520from%2520EGFR%2520mutant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DNeuro-Oncology%26date%3D2011%26volume%3D13%26spage%3D1364%26epage%3D1369%26doi%3D10.1093%2Fneuonc%2Fnor121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Jackman, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borras, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jong, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span> </span><span class="NLM_article-title">Response and resistance in a non–small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4517</span><span class="NLM_x">–</span> <span class="NLM_lpage">4520</span><span class="refDoi"> DOI: 10.1200/JCO.2006.06.6126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1200%2FJCO.2006.06.6126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=16983123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BD28rlslemtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=4517-4520&author=D.+M.+Jackmanauthor=A.+J.+Holmesauthor=N.+Lindemanauthor=P.+Y.+Wenauthor=S.+Kesariauthor=A.+M.+Borrasauthor=C.+Baileyauthor=F.+D.+Jongauthor=P.+A.+J%C3%A4nneauthor=B.+E.+Johnson&title=Response+and+resistance+in+a+non%E2%80%93small-cell+lung+cancer+patient+with+an+epidermal+growth+factor+receptor+mutation+and+leptomeningeal+metastases+treated+with+high-dose+gefitinib&doi=10.1200%2FJCO.2006.06.6126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib</span></div><div class="casAuthors">Jackman David M; Holmes Alison J; Lindeman Neal; Wen Patrick Y; Kesari Santosh; Borras Ana M; Bailey Christopher; de Jong Francisca; Janne Pasi A; Johnson Bruce E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">4517-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQqXLAoggZ9OCO2kE7krGOBfW6udTcc2ebHSJ8tTory4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rlslemtA%253D%253D&md5=391e78d72a39626276f7ffcbee76d1a1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.06.6126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.06.6126%26sid%3Dliteratum%253Aachs%26aulast%3DJackman%26aufirst%3DD.%2BM.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DKesari%26aufirst%3DS.%26aulast%3DBorras%26aufirst%3DA.%2BM.%26aulast%3DBailey%26aufirst%3DC.%26aulast%3DJong%26aufirst%3DF.%2BD.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26atitle%3DResponse%2520and%2520resistance%2520in%2520a%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%2520patient%2520with%2520an%2520epidermal%2520growth%2520factor%2520receptor%2520mutation%2520and%2520leptomeningeal%2520metastases%2520treated%2520with%2520high-dose%2520gefitinib%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D4517%26epage%3D4520%26doi%3D10.1200%2FJCO.2006.06.6126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Owonikoko, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbiser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zelnak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, H.-K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalkanis, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitsett, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salhia, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryken, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, J. J.</span><span> </span><span class="NLM_article-title">Current approaches to the treatment of metastatic brain tumours</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2014.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1038%2Fnrclinonc.2014.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=24569448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsVChsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=203-222&author=T.+K.+Owonikokoauthor=J.+Arbiserauthor=A.+Zelnakauthor=H.-K.+G.+Shuauthor=H.+Shimauthor=A.+M.+Robinauthor=S.+N.+Kalkanisauthor=T.+G.+Whitsettauthor=B.+Salhiaauthor=N.+L.+Tranauthor=T.+Rykenauthor=M.+K.+Mooreauthor=K.+M.+Eganauthor=J.+Jeffreyauthor=J.+J.+Olson&title=Current+approaches+to+the+treatment+of+metastatic+brain+tumours&doi=10.1038%2Fnrclinonc.2014.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Current approaches to the treatment of metastatic brain tumours</span></div><div class="casAuthors">Owonikoko, Taofeek K.; Arbiser, Jack; Zelnak, Amelia; Shu, Hui-Kuo G.; Shim, Hyunsuk; Robin, Adam M.; Kalkanis, Steven N.; Whitsett, Timothy G.; Salhia, Bodour; Tran, Nhan L.; Ryken, Timothy; Moore, Michael K.; Egan, Kathleen M.; Olson, Jeffrey J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">203-222</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Metastatic tumors involving the brain overshadow primary brain neoplasms in frequency and are an important complication in the overall management of many cancers.  Importantly, advances are being made in understanding the mol. biol. underlying the initial development and eventual proliferation of brain metastases.  Surgery and radiation remain the cornerstones of the therapy for symptomatic lesions; however, image-based guidance is improving surgical technique to maximize the preservation of normal tissue, while more sophisticated approaches to radiation therapy are being used to minimize the long-standing concerns over the toxicity of whole-brain radiation protocols used in the past.  Furthermore, the burgeoning knowledge of tumor biol. has facilitated the entry of systemically administered therapies into the clinic.  Responses to these targeted interventions have ranged from substantial toxicity with no control of disease to periods of useful tumor control with no decrement in performance status of the treated individual.  This experience enables recognition of the limits of targeted therapy, but has also informed methods to optimize this approach.  This Review focuses on the clin. relevant mol. biol. of brain metastases, and summarizes the current applications of these data to imaging, surgery, radiation therapy, cytotoxic chemotherapy and targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMkDee2-upYrVg90H21EOLACvtfcHk0lh6CW60vjFsFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsVChsrY%253D&md5=499d772b17c0f7a323ddbdb7cfd88341</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2014.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2014.25%26sid%3Dliteratum%253Aachs%26aulast%3DOwonikoko%26aufirst%3DT.%2BK.%26aulast%3DArbiser%26aufirst%3DJ.%26aulast%3DZelnak%26aufirst%3DA.%26aulast%3DShu%26aufirst%3DH.-K.%2BG.%26aulast%3DShim%26aufirst%3DH.%26aulast%3DRobin%26aufirst%3DA.%2BM.%26aulast%3DKalkanis%26aufirst%3DS.%2BN.%26aulast%3DWhitsett%26aufirst%3DT.%2BG.%26aulast%3DSalhia%26aufirst%3DB.%26aulast%3DTran%26aufirst%3DN.%2BL.%26aulast%3DRyken%26aufirst%3DT.%26aulast%3DMoore%26aufirst%3DM.%2BK.%26aulast%3DEgan%26aufirst%3DK.%2BM.%26aulast%3DJeffrey%26aufirst%3DJ.%26aulast%3DOlson%26aufirst%3DJ.%2BJ.%26atitle%3DCurrent%2520approaches%2520to%2520the%2520treatment%2520of%2520metastatic%2520brain%2520tumours%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D11%26spage%3D203%26epage%3D222%26doi%3D10.1038%2Fnrclinonc.2014.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Gow, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, C.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P.-C.</span><span> </span><span class="NLM_article-title">Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">162</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-1468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1158%2F1078-0432.CCR-07-1468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=18172267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslGj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=162-168&author=C.-H.+Gowauthor=C.-R.+Chienauthor=Y.-L.+Changauthor=Y.-H.+Chiuauthor=S.-H.+Kuoauthor=J.-Y.+Shihauthor=Y.-C.+Changauthor=C.-J.+Yuauthor=C.-H.+Yangauthor=P.-C.+Yang&title=Radiotherapy+in+lung+adenocarcinoma+with+brain+metastases%3A+effects+of+activating+epidermal+growth+factor+receptor+mutations+on+clinical+response&doi=10.1158%2F1078-0432.CCR-07-1468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response</span></div><div class="casAuthors">Gow, Chien-Hung; Chien, Chun-Ru; Chang, Yih-Leong; Chiu, Yueh-Hsia; Kuo, Sung-Hsin; Shih, Jin-Yuan; Chang, Yeun-Chung; Yu, Chong-Jen; Yang, Chih-Hsin; Yang, Pan-Chyr</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">162-168</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Whole-brain radiation therapy (WBRT) has been applied to inoperable brain metastases in lung adenocarcinoma.  Recently, an in vitro study showed reduced clonogenic survival of mutant epidermal growth factor receptor (EGFR) lung cancer cell lines in response to ionizing radiation compared with that of the wild type.  To elucidate the role of EGFR mutations in radiation treatment, we evaluated the clin. response to WBRT and survival of lung adenocarcinoma patients with brain metastases.  Exptl. Design: This was a retrospective anal. of 63 patients with brain metastases from lung adenocarcinoma who were treated with WBRT.  Demog. data, EGFR mutation status, response to WBRT, and survival data were collected.  Clin. response was assessed 1 mo after the start of WBRT.  Univariate and logistic regression models were used to test potential predictive factors assocd. with clin. response.  Log-rank test and Cox regression were analyzed to identify factors that affected survival.  RESULTS: Clin. response to WBRT was obsd. in 29 patients (46%), with 34 nonresponder patients (54%).  Patients with EGFR mutations had higher response rates to WBRT compared with those with the wild-type (54% vs. 24%; P = 0.045).  Both the administration of EGFR tyrosine kinase inhibitor (P = 0.034) and EGFR mutation (P = 0.029) were independently assocd. with response to WBRT.  In Cox regression anal., WBRT responder (P = 0.010) and absence of extracranial metastases (P = 0.002) were assocd. with better survival.  CONCLUSIONS: Both the EGFR mutations and the administration of EGFR TKI during WBRT were independent predictors of response to WBRT in brain metastases of lung adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriObBEhxHr1rVg90H21EOLACvtfcHk0lh6CW60vjFsFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslGj&md5=b2228545dd1001b614a66817770ca85b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1468%26sid%3Dliteratum%253Aachs%26aulast%3DGow%26aufirst%3DC.-H.%26aulast%3DChien%26aufirst%3DC.-R.%26aulast%3DChang%26aufirst%3DY.-L.%26aulast%3DChiu%26aufirst%3DY.-H.%26aulast%3DKuo%26aufirst%3DS.-H.%26aulast%3DShih%26aufirst%3DJ.-Y.%26aulast%3DChang%26aufirst%3DY.-C.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DYang%26aufirst%3DC.-H.%26aulast%3DYang%26aufirst%3DP.-C.%26atitle%3DRadiotherapy%2520in%2520lung%2520adenocarcinoma%2520with%2520brain%2520metastases%253A%2520effects%2520of%2520activating%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%2520on%2520clinical%2520response%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D162%26epage%3D168%26doi%3D10.1158%2F1078-0432.CCR-07-1468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Pardridge, W. M.</span><span> </span><span class="NLM_article-title">The blood-brain barrier: bottleneck in brain drug development</span> <span class="citation_source-journal">NeuroRx</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1602/neurorx.2.1.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1602%2Fneurorx.2.1.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=15717053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BD2MzntVaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=3-14&author=W.+M.+Pardridge&title=The+blood-brain+barrier%3A+bottleneck+in+brain+drug+development&doi=10.1602%2Fneurorx.2.1.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The blood-brain barrier: bottleneck in brain drug development</span></div><div class="casAuthors">Pardridge William M</div><div class="citationInfo"><span class="NLM_cas:title">NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-14</span>
        ISSN:<span class="NLM_cas:issn">1545-5343</span>.
    </div><div class="casAbstract">The blood-brain barrier (BBB) is formed by the brain capillary endothelium and excludes from the brain approximately 100% of large-molecule neurotherapeutics and more than 98% of all small-molecule drugs.  Despite the importance of the BBB to the neurotherapeutics mission, the BBB receives insufficient attention in either academic neuroscience or industry programs.  The combination of so little effort in developing solutions to the BBB problem, and the minimal BBB transport of the majority of all potential CNS drugs, leads predictably to the present situation in neurotherapeutics, which is that there are few effective treatments for the majority of CNS disorders.  This situation can be reversed by an accelerated effort to develop a knowledge base in the fundamental transport properties of the BBB, and the molecular and cellular biology of the brain capillary endothelium.  This provides the platform for CNS drug delivery programs, which should be developed in parallel with traditional CNS drug discovery efforts in the molecular neurosciences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8zmuJRBq_D9y3lHz94U-GfW6udTcc2eZhXqeoMDjeF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzntVaqtw%253D%253D&md5=88e326d840c4ab0f4e55da8a2ffd513c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1602%2Fneurorx.2.1.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1602%252Fneurorx.2.1.3%26sid%3Dliteratum%253Aachs%26aulast%3DPardridge%26aufirst%3DW.%2BM.%26atitle%3DThe%2520blood-brain%2520barrier%253A%2520bottleneck%2520in%2520brain%2520drug%2520development%26jtitle%3DNeuroRx%26date%3D2005%26volume%3D2%26spage%3D3%26epage%3D14%26doi%3D10.1602%2Fneurorx.2.1.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Löscher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potschka, H.</span><span> </span><span class="NLM_article-title">Blood-brain barrier active efflux transporters: ATP-binding cassette gene family</span> <span class="citation_source-journal">NeuroRx</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span><span class="refDoi"> DOI: 10.1602/neurorx.2.1.86</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1602%2Fneurorx.2.1.86" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=15717060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BD2MzntVejsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=86-98&author=W.+L%C3%B6scherauthor=H.+Potschka&title=Blood-brain+barrier+active+efflux+transporters%3A+ATP-binding+cassette+gene+family&doi=10.1602%2Fneurorx.2.1.86"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Blood-brain barrier active efflux transporters: ATP-binding cassette gene family</span></div><div class="casAuthors">Loscher Wolfgang; Potschka Heidrun</div><div class="citationInfo"><span class="NLM_cas:title">NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-98</span>
        ISSN:<span class="NLM_cas:issn">1545-5343</span>.
    </div><div class="casAbstract">The blood-brain barrier (BBB) contributes to brain homeostasis by protecting the brain from potentially harmful endogenous and exogenous substances.  BBB active drug efflux transporters of the ATP-binding cassette (ABC) gene family are increasingly recognized as important determinants of drug distribution to, and elimination from, the CNS.  The ABC efflux transporter P-glycoprotein (Pgp) has been demonstrated as a key element of the BBB that can actively transport a huge variety of lipophilic drugs out of the brain capillary endothelial cells that form the BBB.  In addition to Pgp, other ABC efflux transporters such as members of the multidrug resistance protein (MRP) family and breast cancer resistance protein (BCRP) seem to contribute to BBB function.  Consequences of ABC efflux transporters in the BBB include minimizing or avoiding neurotoxic adverse effects of drugs that otherwise would penetrate into the brain.  However, ABC efflux transporters may also limit the central distribution of drugs that are beneficial to treat CNS diseases.  Furthermore, neurological disorders such as epilepsy may be associated with overexpression of ABC efflux transporters at the BBB, resulting in pharmacoresistance to therapeutic medication.  Therefore, modulation of ABC efflux transporters at the BBB forms a novel strategy to enhance the penetration of drugs into the brain and may yield new therapeutic options for drug-resistant CNS diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8zmuJRBq_DwvupmecNw_lfW6udTcc2eZhXqeoMDjeF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzntVejsA%253D%253D&md5=4de8b6e417fdc59a41aef2629475da8d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1602%2Fneurorx.2.1.86&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1602%252Fneurorx.2.1.86%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26aulast%3DPotschka%26aufirst%3DH.%26atitle%3DBlood-brain%2520barrier%2520active%2520efflux%2520transporters%253A%2520ATP-binding%2520cassette%2520gene%2520family%26jtitle%3DNeuroRx%26date%3D2005%26volume%3D2%26spage%3D86%26epage%3D98%26doi%3D10.1602%2Fneurorx.2.1.86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Mahringer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reimold, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fricker, G.</span><span> </span><span class="NLM_article-title">The ABC of the blood-brain barrier-regulation of drug efflux pumps</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2762</span><span class="NLM_x">–</span> <span class="NLM_lpage">2770</span><span class="refDoi"> DOI: 10.2174/138161211797440221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.2174%2F138161211797440221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=21827407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSis7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2762-2770&author=A.+Mahringerauthor=M.+Ottauthor=I.+Reimoldauthor=V.+Reichelauthor=G.+Fricker&title=The+ABC+of+the+blood-brain+barrier-regulation+of+drug+efflux+pumps&doi=10.2174%2F138161211797440221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The ABC of the blood-brain barrier - regulation of drug efflux pumps</span></div><div class="casAuthors">Mahringer, Anne; Ott, Melanie; Reimold, Isolde; Reichel, Valeska; Fricker, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2762-2770</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  According to the World Health Organization Central nervous system disorders are the major medical challenge of the 21st Century, yet treatments for many CNS disorders are either inadequate or absent.  One reason is the existence of the blood-brain barrier, which strictly limits the access of substances to the brain.  A key element of the barrier function is the expression of ABC export proteins in the luminal membrane of brain microvessel endothelial cells.  Understanding the signaling cascades, which lead to altered expression or function of the transporters, and the response to endogenous and exogenous stimuli as well as subsequent modulation of the transporters may offer novel strategies to overcome the barrier and to improve drug delivery to the brain.  This review gives a short overview about structure of the key elements of the blood-brain barrier with emphasis on ABC transporters.  An insight into regulation of function and expression of these transport proteins is given and the involvement of these transporters in CNS diseases is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOs9iG4klPaLVg90H21EOLACvtfcHk0lguAwJigV62gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSis7vL&md5=bb59f862120c3812d19088d30103d57b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F138161211797440221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161211797440221%26sid%3Dliteratum%253Aachs%26aulast%3DMahringer%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DReimold%26aufirst%3DI.%26aulast%3DReichel%26aufirst%3DV.%26aulast%3DFricker%26aufirst%3DG.%26atitle%3DThe%2520ABC%2520of%2520the%2520blood-brain%2520barrier-regulation%2520of%2520drug%2520efflux%2520pumps%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2011%26volume%3D17%26spage%3D2762%26epage%3D2770%26doi%3D10.2174%2F138161211797440221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Mahar Doan, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wring, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shampine, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serabjit-Singh, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adkison, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, J. W.</span><span> </span><span class="NLM_article-title">Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">303</span><span class="NLM_x">, </span> <span class="NLM_fpage">1029</span><span class="NLM_x">–</span> <span class="NLM_lpage">1037</span><span class="refDoi"> DOI: 10.1124/jpet.102.039255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1124%2Fjpet.102.039255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=12438524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BD38nptVKmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=1029-1037&author=K.+M.+Mahar+Doanauthor=J.+E.+Humphreysauthor=L.+O.+Websterauthor=S.+A.+Wringauthor=L.+J.+Shampineauthor=C.+J.+Serabjit-Singhauthor=K.+K.+Adkisonauthor=J.+W.+Polli&title=Passive+permeability+and+P-glycoprotein-mediated+efflux+differentiate+central+nervous+system+%28CNS%29+and+non-CNS+marketed+drugs&doi=10.1124%2Fjpet.102.039255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs</span></div><div class="casAuthors">Mahar Doan Kelly M; Humphreys Joan E; Webster Lindsey O; Wring Stephen A; Shampine Larry J; Serabjit-Singh Cosette J; Adkison Kimberly K; Polli Joseph W</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1029-37</span>
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Membrane permeability and P-glycoprotein (Pgp) can be limiting factors for blood-brain barrier penetration.  The objectives of this study were to determine whether there are differences in the in vitro permeability, Pgp substrate profiles, and physicochemical properties of drugs for central nervous system (CNS) and non-CNS indications, and whether these differences are useful criteria in selecting compounds for drug development.  Apparent permeability (P(app)) and Pgp substrate profiles for 93 CNS (n = 48) and non-CNS (n = 45) drugs were determined by monolayer efflux.  Calcein-AM inhibition assays were used to supplement the efflux results.  The CNS set (2 of 48, 4.2%) had a 7-fold lower incidence of passive permeability values <150 nm/s compared with the non-CNS set (13 of 45, 28.9%).  The majority of drugs (72.0%, 67 of 93) were not Pgp substrates; however, 49.5% (46 of 93) were positive in the calcein-AM assay when tested at 100 microM.  The CNS drug set (n = 7 of 48, 14.6%) had a 3-fold lower incidence of Pgp-mediated efflux than the non-CNS drug set (n = 19 of 45, 42.2%).  Analysis of 18 physicochemical properties revealed that the CNS drug set had fewer hydrogen bond donors, fewer positive charges, greater lipophilicity, lower polar surface area, and reduced flexibility compared with the non-CNS group (p < 0.05), properties that enhance membrane permeability.  This study on a large, diverse set of marketed compounds clearly demonstrates that permeability, Pgp-mediated efflux, and certain physicochemical properties are factors that differentiate CNS and non-CNS drugs.  For CNS delivery, a drug should ideally have an in vitro passive permeability >150 nm/s and not be a good (B --> A/A --> B ratio <2.5) Pgp substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_HiV1Xqt18Vf1XRtfYM0dfW6udTcc2eZn7EvL3KxOA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38nptVKmsw%253D%253D&md5=b841902aa8502de47c1e1603c80e09fb</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.039255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.039255%26sid%3Dliteratum%253Aachs%26aulast%3DMahar%2BDoan%26aufirst%3DK.%2BM.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DWebster%26aufirst%3DL.%2BO.%26aulast%3DWring%26aufirst%3DS.%2BA.%26aulast%3DShampine%26aufirst%3DL.%2BJ.%26aulast%3DSerabjit-Singh%26aufirst%3DC.%2BJ.%26aulast%3DAdkison%26aufirst%3DK.%2BK.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26atitle%3DPassive%2520permeability%2520and%2520P-glycoprotein-mediated%2520efflux%2520differentiate%2520central%2520nervous%2520system%2520%2528CNS%2529%2520and%2520non-CNS%2520marketed%2520drugs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26spage%3D1029%26epage%3D1037%26doi%3D10.1124%2Fjpet.102.039255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Wager, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villalobos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span> </span><span class="NLM_article-title">Strategies to optimize the brain availability of central nervous system drug candidates</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">371</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span><span class="refDoi"> DOI: 10.1517/17460441.2011.564158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1517%2F17460441.2011.564158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=22646015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVKmsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=371-381&author=T.+T.+Wagerauthor=A.+Villalobosauthor=P.+R.+Verhoestauthor=X.+Houauthor=C.+L.+Shaffer&title=Strategies+to+optimize+the+brain+availability+of+central+nervous+system+drug+candidates&doi=10.1517%2F17460441.2011.564158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to optimize the brain availability of central nervous system drug candidates</span></div><div class="casAuthors">Wager, Travis T.; Villalobos, Anabella; Verhoest, Patrick R.; Hou, Xinjun; Shaffer, Christopher L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-381</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Access to the CNS is essential for most neurotherapeutics to elicit their effects.  Leveraging design strategies incorporating physicochem. properties, in vitro and in vivo assays to predict and measure brain penetration, and brain delivery approaches may enable the drug discovery community to improve access of drug candidates into the CNS compartment.Areas covered: This article reviews aspects of the most recent mol. design, in vitro and in vivo strategies, and delivery technologies to optimize the unbound brain concns. (C b,u) of CNS mols.  Through this, the article provides insight into recent ideas and concepts in CNS drug mol. design, methods for evaluating CNS drug exposures and alternative approaches to maximize drug access to neurocompartments.Expert opinion: The most pharmacol. relevant measure in assessing a compd.'s pharmacodynamic response in the CNS is its C b,u.  The utilization of emerging design strategies, together with in vitro and in vivo assays, may enable the design of mols. with optimal C b,u:C p,u (C p,u, unbound plasma concn.) and appropriate C b,u, to elicit a biol. response from the neurotherapeutic target.  Where drug properties intrinsically render a compd. CNS impaired, using novel CNS delivery approaches may result in sufficient C b,u to furnish a biol. response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs2ijS8dIydLVg90H21EOLACvtfcHk0ljWJYqeuSA5cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVKmsbw%253D&md5=09a2b8b06bdbdc63db728416cb01081f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1517%2F17460441.2011.564158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2011.564158%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DVillalobos%26aufirst%3DA.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26atitle%3DStrategies%2520to%2520optimize%2520the%2520brain%2520availability%2520of%2520central%2520nervous%2520system%2520drug%2520candidates%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2011%26volume%3D6%26spage%3D371%26epage%3D381%26doi%3D10.1517%2F17460441.2011.564158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Hitchcock, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennington, L. D.</span><span> </span><span class="NLM_article-title">Structure-brain exposure relationships</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">7559</span><span class="NLM_x">–</span> <span class="NLM_lpage">7583</span><span class="refDoi"> DOI: 10.1021/jm060642i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060642i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yrtrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7559-7583&author=S.+A.+Hitchcockauthor=L.+D.+Pennington&title=Structure-brain+exposure+relationships&doi=10.1021%2Fjm060642i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-brain exposure relationships</span></div><div class="casAuthors">Hitchcock, Stephen A.; Pennington, Lewis D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7559-7583</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the use of structure modification to influence blood-brain barrier penetration by modulating either passive diffusion or active transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3V-TERRGy07Vg90H21EOLACvtfcHk0ljWJYqeuSA5cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yrtrnK&md5=97dff583ffae6d0ef66512ffbee38c34</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm060642i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060642i%26sid%3Dliteratum%253Aachs%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26atitle%3DStructure-brain%2520exposure%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7559%26epage%3D7583%26doi%3D10.1021%2Fjm060642i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbertz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">50</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1021/cn200100h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn200100h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=50-68&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=R.+L.+Hudkinsauthor=B.+D.+Dorseyauthor=J.+P.+Mallamo&title=Knowledge-based%2C+central+nervous+system+%28CNS%29+lead+selection+and+lead+optimization+for+CNS+drug+discovery&doi=10.1021%2Fcn200100h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery</span></div><div class="casAuthors">Ghose, Arup K.; Herbertz, Torsten; Hudkins, Robert L.; Dorsey, Bruce D.; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-68</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The central nervous system (CNS) is the major area that is affected by aging.  Alzheimer's disease (AD), Parkinson's disease (PD), brain cancer, and stroke are the CNS diseases that will cost trillions of dollars for their treatment.  Achievement of appropriate blood-brain barrier (BBB) penetration is often considered a significant hurdle in the CNS drug discovery process.  On the other hand, BBB penetration may be a liability for many of the non-CNS drug targets, and a clear understanding of the physicochem. and structural differences between CNS and non-CNS drugs may assist both research areas.  Because of the numerous and challenging issues in CNS drug discovery and the low success rates, pharmaceutical companies are beginning to deprioritize their drug discovery efforts in the CNS arena.  Prompted by these challenges and to aid in the design of high-quality, efficacious CNS compds., we analyzed the physicochem. property and the chem. structural profiles of 317 CNS and 626 non-CNS oral drugs.  The conclusions derived provide an ideal property profile for lead selection and the property modification strategy during the lead optimization process.  A list of substructural units that may be useful for CNS drug design was also provided here.  A classification tree was also developed to differentiate between CNS drugs and non-CNS oral drugs.  The combined anal. provided the following guidelines for designing high-quality CNS drugs: (i) topol. mol. polar surface area of <76 Å2 (25-60 Å2), (ii) at least one (one or two, including one aliph. amine) nitrogen, (iii) fewer than seven (two to four) linear chains outside of rings, (iv) fewer than three (zero or one) polar hydrogen atoms, (v) vol. of 740-970 Å3, (vi) solvent accessible surface area of 460-580 Å2, and (vii) pos. QikProp parameter CNS.  The ranges within parentheses may be used during lead optimization.  One violation to this proposed profile may be acceptable.  The chemoinformatics approaches for graphically analyzing multiple properties efficiently are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozqfO0vq2i5bVg90H21EOLACvtfcHk0lj9bCaLT4PC5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO&md5=4c20ba34c3d5397170b50242975ce25d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fcn200100h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn200100h%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge-based%252C%2520central%2520nervous%2520system%2520%2528CNS%2529%2520lead%2520selection%2520and%2520lead%2520optimization%2520for%2520CNS%2520drug%2520discovery%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D50%26epage%3D68%26doi%3D10.1021%2Fcn200100h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">CNS drug design: balancing physicochemical properties for optimal brain exposure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2584</span><span class="NLM_x">–</span> <span class="NLM_lpage">2608</span><span class="refDoi"> DOI: 10.1021/jm501535r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501535r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2584-2608&author=Z.+Rankovic&title=CNS+drug+design%3A+balancing+physicochemical+properties+for+optimal+brain+exposure&doi=10.1021%2Fjm501535r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure</span></div><div class="casAuthors">Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2584-2608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to prevent injury from external insults and toxins.  Designing mols. that can overcome this protection system and achieve optimal concn. at the desired therapeutic target in the brain is a specific and major challenge for medicinal chemists working in CNS drug discovery.  Analogous to the now widely accepted rule of 5 in the design of oral drugs, the physicochem. properties required for optimal brain exposure have been extensively studied in an attempt to similarly define the attributes of successful CNS drugs and drug candidates.  This body of work is systematically reviewed here, with a particular emphasis on the interplay between the most crit. physicochem. and pharmacokinetic parameters of CNS drugs as well as their impact on medicinal chem. strategies toward mols. with optimal brain exposure.  A summary of modern CNS pharmacokinetic concepts and methods is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8V0N1j49uuLVg90H21EOLACvtfcHk0lj9bCaLT4PC5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP&md5=f01e3f2dc4e2eff7b0618124277a5cf8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm501535r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501535r%26sid%3Dliteratum%253Aachs%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DCNS%2520drug%2520design%253A%2520balancing%2520physicochemical%2520properties%2520for%2520optimal%2520brain%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2584%26epage%3D2608%26doi%3D10.1021%2Fjm501535r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.-H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lj9bCaLT4PC5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennequin, L. F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettle, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, I.</span><span> </span><span class="NLM_article-title">Inhibitors of epidermal growth factor receptor tyrosine kinase: optimization of potency and in vivo pharmacokinetics</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4908</span><span class="NLM_x">–</span> <span class="NLM_lpage">4912</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.06.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2Fj.bmcl.2006.06.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=16806916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD28XotlSgsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4908-4912&author=P.+Ballardauthor=R.+H.+Bradburyauthor=C.+S.+Harrisauthor=L.+F.+A.+Hennequinauthor=M.+Hickinsonauthor=J.+G.+Kettleauthor=J.+Kendrewauthor=T.+Klinowskaauthor=D.+J.+Ogilvieauthor=S.+E.+Pearsonauthor=E.+J.+Williamsauthor=I.+Wilson&title=Inhibitors+of+epidermal+growth+factor+receptor+tyrosine+kinase%3A+optimization+of+potency+and+in+vivo+pharmacokinetics&doi=10.1016%2Fj.bmcl.2006.06.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of epidermal growth factor receptor tyrosine kinase: Optimization of potency and in vivo pharmacokinetics</span></div><div class="casAuthors">Ballard, Peter; Bradbury, Robert H.; Harris, Craig S.; Hennequin, Laurent F. A.; Hickinson, Mark; Kettle, Jason G.; Kendrew, Jane; Klinowska, Teresa; Ogilvie, Donald J.; Pearson, Stuart E.; Williams, Emma J.; Wilson, Ingrid</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4908-4912</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure-activity and structure-property relationships of anilinoquinazoline inhibitors of EGFR were investigated.  Strategies to lower vol. of distribution and shorten half-life through structure and pKa modulation are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG_WeMAluLubVg90H21EOLACvtfcHk0lgM6alS2u-WIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotlSgsbg%253D&md5=1e126a9191432d33cd0bec15e155fec5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.06.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.06.054%26sid%3Dliteratum%253Aachs%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DHarris%26aufirst%3DC.%2BS.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%2BA.%26aulast%3DHickinson%26aufirst%3DM.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DOgilvie%26aufirst%3DD.%2BJ.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DWilliams%26aufirst%3DE.%2BJ.%26aulast%3DWilson%26aufirst%3DI.%26atitle%3DInhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%253A%2520optimization%2520of%2520potency%2520and%2520in%2520vivo%2520pharmacokinetics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4908%26epage%3D4912%26doi%3D10.1016%2Fj.bmcl.2006.06.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Pankratov, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shalabay, A. V.</span><span> </span><span class="NLM_article-title">Effect of the intramolecular hydrogen bond on the electronic structure of the organic molecules with a planar quasicycle</span> <span class="citation_source-journal">J. Struct. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span><span class="refDoi"> DOI: 10.1007/s10947-007-0064-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1007%2Fs10947-007-0064-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSktb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=427-432&author=A.+N.+Pankratovauthor=A.+V.+Shalabay&title=Effect+of+the+intramolecular+hydrogen+bond+on+the+electronic+structure+of+the+organic+molecules+with+a+planar+quasicycle&doi=10.1007%2Fs10947-007-0064-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the intramolecular hydrogen bond on the electronic structure of organic molecules with a planar quasicycle</span></div><div class="casAuthors">Pankratov, A. N.; Shalabay, A. V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Structural Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-432</span>CODEN:
                <span class="NLM_cas:coden">JSTCAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-4766</span>.
    
            (<span class="NLM_cas:orgname">Pleiades Publishing, Ltd.</span>)
        </div><div class="casAbstract">The electronic structure of the following org. mols. is studied using the HF/6-311G(d,p) method: malonic dialdehyde, acetylacetone, thiomalonic aldehyde, 2-XC6H4NH2 aniline derivs., 2-XC6H4OH phenol derivs., 2-XC6H4SH thiophenol derivs. (X = CHO, COOH, COO-, NO, NO2, OH, OCH3, SH, SCH3, F, Cl, Br), 8-hydroxyquinoline, 8-mercaptoquinoline, tropolone.  It is found that the intramol. hydrogen bond (IHB) leads to a local electronic redistribution in the quasi-cycle, and above all to the electron d. transfer among the immediate participants of IHB - from the hydrogen atom to the proton-acceptor atom.  When the IHB of the S-H···O type forms, the electron d. mainly decreases on sulfhydryl hydrogen atom and increases on sulfur atom.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeEyyfjJACFLVg90H21EOLACvtfcHk0lgM6alS2u-WIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSktb7J&md5=59f81fb4b1ad0a45465da865723bfb38</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs10947-007-0064-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10947-007-0064-2%26sid%3Dliteratum%253Aachs%26aulast%3DPankratov%26aufirst%3DA.%2BN.%26aulast%3DShalabay%26aufirst%3DA.%2BV.%26atitle%3DEffect%2520of%2520the%2520intramolecular%2520hydrogen%2520bond%2520on%2520the%2520electronic%2520structure%2520of%2520the%2520organic%2520molecules%2520with%2520a%2520planar%2520quasicycle%26jtitle%3DJ.%2520Struct.%2520Chem.%26date%3D2007%26volume%3D48%26spage%3D427%26epage%3D432%26doi%3D10.1007%2Fs10947-007-0064-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Galan, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wildin, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pophristic, V.</span><span> </span><span class="NLM_article-title">Intramolecular hydrogen bonding in <i>ortho</i>-substituted arylamide oligomers: a computational and experimental study of <i>ortho</i>-fluoro- and ortho-chloro-N-methylbenzamide</span> <span class="citation_source-journal">J. Phys. Chem. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">12809</span><span class="NLM_x">–</span> <span class="NLM_lpage">12815</span><span class="refDoi"> DOI: 10.1021/jp905261p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp905261p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=12809-12815&author=J.+F.+Galanauthor=J.+Brownauthor=J.+L.+Wildinauthor=Z.+Liuauthor=D.+Liuauthor=G.+Moynaauthor=V.+Pophristic&title=Intramolecular+hydrogen+bonding+in+ortho-substituted+arylamide+oligomers%3A+a+computational+and+experimental+study+of+ortho-fluoro-+and+ortho-chloro-N-methylbenzamide&doi=10.1021%2Fjp905261p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjp905261p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp905261p%26sid%3Dliteratum%253Aachs%26aulast%3DGalan%26aufirst%3DJ.%2BF.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DWildin%26aufirst%3DJ.%2BL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMoyna%26aufirst%3DG.%26aulast%3DPophristic%26aufirst%3DV.%26atitle%3DIntramolecular%2520hydrogen%2520bonding%2520in%2520ortho-substituted%2520arylamide%2520oligomers%253A%2520a%2520computational%2520and%2520experimental%2520study%2520of%2520ortho-fluoro-%2520and%2520ortho-chloro-N-methylbenzamide%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2009%26volume%3D113%26spage%3D12809%26epage%3D12815%26doi%3D10.1021%2Fjp905261p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Weiss, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williamson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babu-Khan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartberger, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Citron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croghan, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dineen, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esmay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harried, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbeah-Ampiah, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judd, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaller, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreiman, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monenschein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennington, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rattan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San Miguel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sickmier, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, W.</span><span> </span><span class="NLM_article-title">Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">9009</span><span class="NLM_x">–</span> <span class="NLM_lpage">9024</span><span class="refDoi"> DOI: 10.1021/jm300119p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300119p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9009-9024&author=M.+M.+Weissauthor=T.+Williamsonauthor=S.+Babu-Khanauthor=M.+D.+Bartbergerauthor=J.+Brownauthor=K.+Chenauthor=Y.+Chengauthor=M.+Citronauthor=M.+D.+Croghanauthor=T.+A.+Dineenauthor=J.+Esmayauthor=R.+F.+Graceffaauthor=S.+S.+Harriedauthor=D.+Hickmanauthor=S.+A.+Hitchcockauthor=D.+B.+Horneauthor=H.+Huangauthor=R.+Imbeah-Ampiahauthor=T.+Juddauthor=M.+R.+Kallerauthor=C.+R.+Kreimanauthor=D.+S.+Laauthor=V.+Liauthor=P.+Lopezauthor=S.+Louieauthor=H.+Monenscheinauthor=T.+T.+Nguyenauthor=L.+D.+Penningtonauthor=C.+Rattanauthor=T.+San+Miguelauthor=E.+A.+Sickmierauthor=R.+C.+Wahlauthor=P.+H.+Wenauthor=S.+Woodauthor=Q.+Xueauthor=B.+H.+Yangauthor=V.+F.+Patelauthor=W.+Zhong&title=Design+and+preparation+of+a+potent+series+of+hydroxyethylamine+containing+%CE%B2-secretase+inhibitors+that+demonstrate+robust+reduction+of+central+%CE%B2-amyloid&doi=10.1021%2Fjm300119p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm300119p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300119p%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DWilliamson%26aufirst%3DT.%26aulast%3DBabu-Khan%26aufirst%3DS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCitron%26aufirst%3DM.%26aulast%3DCroghan%26aufirst%3DM.%2BD.%26aulast%3DDineen%26aufirst%3DT.%2BA.%26aulast%3DEsmay%26aufirst%3DJ.%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DHarried%26aufirst%3DS.%2BS.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DHorne%26aufirst%3DD.%2BB.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DImbeah-Ampiah%26aufirst%3DR.%26aulast%3DJudd%26aufirst%3DT.%26aulast%3DKaller%26aufirst%3DM.%2BR.%26aulast%3DKreiman%26aufirst%3DC.%2BR.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLi%26aufirst%3DV.%26aulast%3DLopez%26aufirst%3DP.%26aulast%3DLouie%26aufirst%3DS.%26aulast%3DMonenschein%26aufirst%3DH.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DRattan%26aufirst%3DC.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DSickmier%26aufirst%3DE.%2BA.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWen%26aufirst%3DP.%2BH.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DXue%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DB.%2BH.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DZhong%26aufirst%3DW.%26atitle%3DDesign%2520and%2520preparation%2520of%2520a%2520potent%2520series%2520of%2520hydroxyethylamine%2520containing%2520%25CE%25B2-secretase%2520inhibitors%2520that%2520demonstrate%2520robust%2520reduction%2520of%2520central%2520%25CE%25B2-amyloid%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9009%26epage%3D9024%26doi%3D10.1021%2Fjm300119p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callegari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianfrogna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doran, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doran, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosea, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewc, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deusen, J. V.</span><span> </span><span class="NLM_article-title">Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1443</span><span class="NLM_x">–</span> <span class="NLM_lpage">1447</span><span class="refDoi"> DOI: 10.1124/dmd.105.008201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1124%2Fdmd.105.008201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=16760229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1Sksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=1443-1447&author=X.+Liuauthor=B.+J.+Smithauthor=C.+Chenauthor=E.+Callegariauthor=S.+I.+Beckerauthor=X.+Chenauthor=J.+Cianfrognaauthor=A.+C.+Doranauthor=S.+D.+Doranauthor=J.+P.+Gibbsauthor=N.+Hoseaauthor=J.+Liuauthor=F.+R.+Nelsonauthor=M.+A.+Szewcauthor=J.+V.+Deusen&title=Evaluation+of+cerebrospinal+fluid+concentration+and+plasma+free+concentration+as+a+surrogate+measurement+for+brain+free+concentration&doi=10.1124%2Fdmd.105.008201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration</span></div><div class="casAuthors">Liu, Xingrong; Smith, Bill J.; Chen, Cuiping; Callegari, Ernesto; Becker, Stacey L.; Chen, Xi; Cianfrogna, Julie; Doran, Angela C.; Doran, Shawn D.; Gibbs, John P.; Hosea, Natilie; Liu, Jianhua; Nelson, Frederick R.; Szewc, Mark A.; Van Deusen, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1443-1447</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study was designed to evaluate the use of cerebrospinal fluid (CSF) drug concn. and plasma unbound concn. (Cu,plasma) to predict brain unbound concn. (Cu,brain).  The concn.-time profiles in CSF, plasma, and brain of seven model compds. were detd. after s.c. administration in rats.  The Cu,brain was estd. from the product of total brain concns. and unbound fractions, which were detd. using brain tissue slice and brain homogenate methods.  For theobromine, theophylline, caffeine, fluoxetine, and propranolol, which represent rapid brain penetration compds. with a simple diffusion mechanism, the ratios of the area under the curve of Cu,brain/CCSF and Cu,brain/Cu,plasma were 0.27 to 1.5 and 0.29 to 2.1, resp., using the brain slice method, and were 0.27 to 2.9 and 0.36 to 3.9, resp., using the brain homogenate method.  A P-glycoprotein substrate, CP-141938 (methoxy-3-[(2-phenyl-piperidinyl-3-amino)-methyl]-phenyl-N-methyl-methane-sulfonamide), had Cu,brain/CCSF and Cu,brain/Cu,plasma ratios of 0.57 and 0.066, using the brain slice method, and 1.1 and 0.13, using the brain homogenate method, resp.  The slow brain-penetrating compd., N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine, had Cu,brain/CCSF and Cu,brain/Cu,plasma ratios of 0.94 and 0.12 using the brain slice method and 0.15 and 0.018 using the brain homogenate method, resp.  Therefore, for quick brain penetration with simple diffusion mechanism compds., CCSF and Cu,plasma represent Cu,brain equally well; for efflux substrates or slow brain penetration compds., CCSF appears to be equiv. to or more accurate than Cu,plasma to represent Cu,brain.  Thus, we hypothesize that CCSF is equiv. to or better than Cu,plasma to predict Cu,brain.  This hypothesis is supported by the literature data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw43dRkq9lx7Vg90H21EOLACvtfcHk0liEy6uVrROefA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1Sksrc%253D&md5=cef079e1a667dbddf9d5a2f7d01889e8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.008201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.008201%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DBecker%26aufirst%3DS.%2BI.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCianfrogna%26aufirst%3DJ.%26aulast%3DDoran%26aufirst%3DA.%2BC.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DGibbs%26aufirst%3DJ.%2BP.%26aulast%3DHosea%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DF.%2BR.%26aulast%3DSzewc%26aufirst%3DM.%2BA.%26aulast%3DDeusen%26aufirst%3DJ.%2BV.%26atitle%3DEvaluation%2520of%2520cerebrospinal%2520fluid%2520concentration%2520and%2520plasma%2520free%2520concentration%2520as%2520a%2520surrogate%2520measurement%2520for%2520brain%2520free%2520concentration%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D1443%26epage%3D1447%26doi%3D10.1124%2Fdmd.105.008201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span> </span><span class="NLM_article-title">Demystifying brain penetration in central nervous system drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1021/jm301297f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301297f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2-12&author=L.+Diauthor=H.+Rongauthor=B.+Feng&title=Demystifying+brain+penetration+in+central+nervous+system+drug+discovery&doi=10.1021%2Fjm301297f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Demystifying Brain Penetration in Central Nervous System Drug Discovery</span></div><div class="casAuthors">Di, Li; Rong, Haojing; Feng, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-12</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This Perspective provides important concepts about the blood-brain barrier (BBB) in drug discovery and how they should be applied effectively in designing successful CNS drugs.  Key parameters for brain penetration are discussed, including unbound brain concn., unbound brain-to-plasma ratio, BBB permeability, fraction unbound in brain and plasma, and transporters.  Results from a retrospective anal. of 32 Pfizer CNS clin. drug candidates are described.  Frequently encountered misconceptions about brain penetration in drug discovery programs are clarified.  Strategies and guidance are provided to enhance or minimize brain exposure for CNS or peripheral targets, resp.  Recommendations for screening methodologies and a cascade in assessing brain penetration potential are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmurs7cfju37Vg90H21EOLACvtfcHk0liEy6uVrROefA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ&md5=8b88e2044bf41898ab40c45e18f2a20d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm301297f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301297f%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DB.%26atitle%3DDemystifying%2520brain%2520penetration%2520in%2520central%2520nervous%2520system%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2%26epage%3D12%26doi%3D10.1021%2Fjm301297f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Riley, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnity, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, R. P.</span><span> </span><span class="NLM_article-title">A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1304</span><span class="NLM_x">–</span> <span class="NLM_lpage">1311</span><span class="refDoi"> DOI: 10.1124/dmd.105.004259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1124%2Fdmd.105.004259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=15932954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFamt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=1304-1311&author=R.+J.+Rileyauthor=D.+F.+McGinnityauthor=R.+P.+Austin&title=A+unified+model+for+predicting+human+hepatic%2C+metabolic+clearance+from+in+vitro+intrinsic+clearance+data+in+hepatocytes+and+microsomes&doi=10.1124%2Fdmd.105.004259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes</span></div><div class="casAuthors">Riley, Robert J.; McGinnity, D. F.; Austin, R. P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1304-1311</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate a unified method for predicting human in vivo intrinsic clearance (CLint, in vivo) and hepatic clearance (CLh) from in vitro data in hepatocytes and microsomes by applying the unbound fraction in blood (fub) and in vitro incubations (fuinc).  Human CLint, in vivo was projected using in vitro data together with biol. scaling factors and compared with the unbound intrinsic clearance (CLint, ub, in vivo) estd. from clin. data using liver models with and without the various fu terms.  For incubations conducted with fetal calf serum (n = 14), the obsd. CLint, in vivo was modeled well assuming fuinc and fub were equiv.  CLint, ub, in vivo was predicted best using both fub and fuinc for other hepatocyte data (n = 56; r2 = 0.78, p = 3.3×10-19, av. fold error = 5.2).  A similar model for CLint, ub, in vivo was established for microsomal data (n = 37; r2 = 0.77, p = 1.2×10-12, av. fold error = 6.1).  Using the model for CLint, ub, in vivo (including a further empirical scaling factor), the CLh in humans was also calcd. according to the well stirred liver model for the most extensive dataset.  CLint, in vivo and CLh were both predicted well using in vitro human data from several labs. for acidic, basic, and neutral drugs.  The direct use of this model using only in vitro human data to predict the metabolic component of CLh is attractive, as it does not require extra information from preclin. studies in animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnrU05rRTm6LVg90H21EOLACvtfcHk0lgrwCQrQJ5wHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFamt74%253D&md5=79b80848977739267e4dd0ae82e5cbab</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.004259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.004259%26sid%3Dliteratum%253Aachs%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26aulast%3DAustin%26aufirst%3DR.%2BP.%26atitle%3DA%2520unified%2520model%2520for%2520predicting%2520human%2520hepatic%252C%2520metabolic%2520clearance%2520from%2520in%2520vitro%2520intrinsic%2520clearance%2520data%2520in%2520hepatocytes%2520and%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D1304%26epage%3D1311%26doi%3D10.1124%2Fdmd.105.004259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Sohlenius-Sternbeck, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Projean, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floby, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bylund, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afzelius, L.</span><span> </span><span class="NLM_article-title">Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">841</span><span class="NLM_x">–</span> <span class="NLM_lpage">853</span><span class="refDoi"> DOI: 10.3109/00498254.2012.669080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.3109%2F00498254.2012.669080" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=841-853&author=A.+K.+Sohlenius-Sternbeckauthor=C.+Jonesauthor=D.+Fergusonauthor=B.+J.+Middletonauthor=D.+Projeanauthor=E.+Flobyauthor=J.+Bylundauthor=L.+Afzelius&title=Practical+use+of+the+regression+offset+approach+for+the+prediction+of+in+vivo+intrinsic+clearance+from+hepatocytes&doi=10.3109%2F00498254.2012.669080"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3109%2F00498254.2012.669080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2012.669080%26sid%3Dliteratum%253Aachs%26aulast%3DSohlenius-Sternbeck%26aufirst%3DA.%2BK.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DMiddleton%26aufirst%3DB.%2BJ.%26aulast%3DProjean%26aufirst%3DD.%26aulast%3DFloby%26aufirst%3DE.%26aulast%3DBylund%26aufirst%3DJ.%26aulast%3DAfzelius%26aufirst%3DL.%26atitle%3DPractical%2520use%2520of%2520the%2520regression%2520offset%2520approach%2520for%2520the%2520prediction%2520of%2520in%2520vivo%2520intrinsic%2520clearance%2520from%2520hepatocytes%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26spage%3D841%26epage%3D853%26doi%3D10.3109%2F00498254.2012.669080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Mahmood, I.</span><span> </span><span class="NLM_article-title">Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches</span> <span class="citation_source-journal">Drug Metab. Drug Interact.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span><span class="refDoi"> DOI: 10.1515/DMDI.2002.19.1.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1515%2FDMDI.2002.19.1.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=12222754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvFWhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=49-64&author=I.+Mahmood&title=Prediction+of+clearance+in+humans+from+in+vitro+human+liver+microsomes+and+allometric+scaling.+A+comparative+study+of+the+two+approaches&doi=10.1515%2FDMDI.2002.19.1.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches</span></div><div class="casAuthors">Mahmood, Iftekhar</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Drug Interactions</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-64</span>CODEN:
                <span class="NLM_cas:coden">DMDIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0792-5077</span>.
    
            (<span class="NLM_cas:orgname">Freund Publishing House Ltd.</span>)
        </div><div class="casAbstract">The objective of this study was to evaluate whether the predicted clearance of a drug in humans from in vitro human liver microsomes was comparable with the predicted clearance in humans obtained by allometric scaling.  Sixteen drugs were randomly selected from the literature and their hepatic clearances were predicted using human liver microsomes.  For allometric scaling at least three animal species were used and three methods were utilized to generate allometric equations to predict the clearance in humans: (i) clearance vs. body wt. (simple allometry); (ii) product of the clearance and max. life-span potential (MLP) vs. body wt.; and (iii) the product of clearance and brain wt. vs. body wt.  The choice of one of the methods was based on the "rule of exponents" as described by Mahmood and Balian.  The results of this study indicated that the use of human liver microsomes to predict hepatic clearance in humans may not provide reliable predictions.  The prediction of clearance in humans using allometric scaling combined with the "rule of exponents" can provide comparatively better prediction of clearance in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAEtC7Bfrx_rVg90H21EOLACvtfcHk0lgrwCQrQJ5wHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvFWhu7k%253D&md5=ec50ac9cc77f3db2a020cda9245ae705</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1515%2FDMDI.2002.19.1.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FDMDI.2002.19.1.49%26sid%3Dliteratum%253Aachs%26aulast%3DMahmood%26aufirst%3DI.%26atitle%3DPrediction%2520of%2520clearance%2520in%2520humans%2520from%2520in%2520vitro%2520human%2520liver%2520microsomes%2520and%2520allometric%2520scaling.%2520A%2520comparative%2520study%2520of%2520the%2520two%2520approaches%26jtitle%3DDrug%2520Metab.%2520Drug%2520Interact.%26date%3D2002%26volume%3D19%26spage%3D49%26epage%3D64%26doi%3D10.1515%2FDMDI.2002.19.1.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Mahmood, I.</span><span> </span><span class="NLM_article-title">Prediction of human drug clearance from animal data: Application of the rule of exponent and fu corrected intercept method (FCIM)</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">1810</span><span class="NLM_x">–</span> <span class="NLM_lpage">1821</span><span class="refDoi"> DOI: 10.1002/jps.20650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1002%2Fjps.20650" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2006&pages=1810-1821&author=I.+Mahmood&title=Prediction+of+human+drug+clearance+from+animal+data%3A+Application+of+the+rule+of+exponent+and+fu+corrected+intercept+method+%28FCIM%29&doi=10.1002%2Fjps.20650"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fjps.20650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20650%26sid%3Dliteratum%253Aachs%26aulast%3DMahmood%26aufirst%3DI.%26atitle%3DPrediction%2520of%2520human%2520drug%2520clearance%2520from%2520animal%2520data%253A%2520Application%2520of%2520the%2520rule%2520of%2520exponent%2520and%2520fu%2520corrected%2520intercept%2520method%2520%2528FCIM%2529%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2006%26volume%3D95%26spage%3D1810%26epage%3D1821%26doi%3D10.1002%2Fjps.20650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Ward, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. R.</span><span> </span><span class="NLM_article-title">A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog and monkey to humans. I. Clearance</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">–</span> <span class="NLM_lpage">611</span><span class="refDoi"> DOI: 10.1124/dmd.32.6.603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1124%2Fdmd.32.6.603" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=603-611&author=K.+W.+Wardauthor=B.+R.+Smith&title=A+comprehensive+quantitative+and+qualitative+evaluation+of+extrapolation+of+intravenous+pharmacokinetic+parameters+from+rat%2C+dog+and+monkey+to+humans.+I.+Clearance&doi=10.1124%2Fdmd.32.6.603"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fdmd.32.6.603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.32.6.603%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26atitle%3DA%2520comprehensive%2520quantitative%2520and%2520qualitative%2520evaluation%2520of%2520extrapolation%2520of%2520intravenous%2520pharmacokinetic%2520parameters%2520from%2520rat%252C%2520dog%2520and%2520monkey%2520to%2520humans.%2520I.%2520Clearance%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2004%26volume%3D32%26spage%3D603%26epage%3D611%26doi%3D10.1124%2Fdmd.32.6.603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">FDA</span><span class="NLM_x"> guidance for industry (</span><span class="NLM_x"> (</span><span class="NLM_year">2012</span><span class="NLM_x">) </span>on drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. <a href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf" class="extLink">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+guidance+for+industry+%28+%282012%29+on+drug+interaction+studies-study+design%2C+data+analysis%2C+implications+for+dosing%2C+and+labeling+recommendations.+http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FGuidanceComplianceRegulatoryInformation%2FGuidances%2Fucm292362.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Fahmi, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug metabolizing enzymes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1605</span><span class="NLM_x">–</span> <span class="NLM_lpage">1611</span><span class="refDoi"> DOI: 10.1124/dmd.110.033126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1124%2Fdmd.110.033126" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1605-1611&author=O.+A.+Fahmiauthor=M.+Kishauthor=S.+Boldtauthor=R.+S.+Obach&title=Cytochrome+P450+3A4+mRNA+is+a+more+reliable+marker+than+CYP3A4+activity+for+detecting+pregnane+X+receptor-activated+induction+of+drug+metabolizing+enzymes&doi=10.1124%2Fdmd.110.033126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.033126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.033126%26sid%3Dliteratum%253Aachs%26aulast%3DFahmi%26aufirst%3DO.%2BA.%26aulast%3DKish%26aufirst%3DM.%26aulast%3DBoldt%26aufirst%3DS.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DCytochrome%2520P450%25203A4%2520mRNA%2520is%2520a%2520more%2520reliable%2520marker%2520than%2520CYP3A4%2520activity%2520for%2520detecting%2520pregnane%2520X%2520receptor-activated%2520induction%2520of%2520drug%2520metabolizing%2520enzymes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1605%26epage%3D1611%26doi%3D10.1124%2Fdmd.110.033126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Varnäs, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varrone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farde, L.</span><span> </span><span class="NLM_article-title">Modeling of PET data in CNS drug discovery and development</span> <span class="citation_source-journal">J. Pharmacokinet. Pharmacodyn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span><span class="refDoi"> DOI: 10.1007/s10928-013-9320-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1007%2Fs10928-013-9320-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=23660778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BC3snisVajtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2013&pages=267-279&author=K.+Varn%C3%A4sauthor=A.+Varroneauthor=L.+Farde&title=Modeling+of+PET+data+in+CNS+drug+discovery+and+development&doi=10.1007%2Fs10928-013-9320-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling of PET data in CNS drug discovery and development</span></div><div class="casAuthors">Varnas Katarina; Varrone Andrea; Farde Lars</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacokinetics and pharmacodynamics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Positron emission tomography (PET) is increasingly used in drug discovery and development for evaluation of CNS drug disposition and for studies of disease biomarkers to monitor drug effects on brain pathology.  The quantitative analysis of PET data is based on kinetic modeling of radioactivity concentrations in plasma and brain tissue compartments.  A number of quantitative methods of analysis have been developed that allow the determination of parameters describing drug pharmacokinetics and interaction with target binding sites in the brain.  The optimal method of quantification depends on the properties of the radiolabeled drug or radioligand and the binding site studied.  We here review the most frequently used methods for quantification of PET data in relation to CNS drug discovery and development.  The utility of PET kinetic modeling in the development of novel CNS drugs is illustrated by examples from studies of the brain kinetic properties of radiolabeled drug molecules.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLO3rZf95a5PEeosoOnpOLfW6udTcc2eaBRzBpXK9xsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snisVajtQ%253D%253D&md5=8afb967eb7584f68ed62fa08f7907a74</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10928-013-9320-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10928-013-9320-6%26sid%3Dliteratum%253Aachs%26aulast%3DVarn%25C3%25A4s%26aufirst%3DK.%26aulast%3DVarrone%26aufirst%3DA.%26aulast%3DFarde%26aufirst%3DL.%26atitle%3DModeling%2520of%2520PET%2520data%2520in%2520CNS%2520drug%2520discovery%2520and%2520development%26jtitle%3DJ.%2520Pharmacokinet.%2520Pharmacodyn.%26date%3D2013%26volume%3D40%26spage%3D267%26epage%3D279%26doi%3D10.1007%2Fs10928-013-9320-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umland, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span> </span><span class="NLM_article-title">Species independence in brain tissue binding using brain homogenates</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1270</span><span class="NLM_x">–</span> <span class="NLM_lpage">1277</span><span class="refDoi"> DOI: 10.1124/dmd.111.038778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1124%2Fdmd.111.038778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=21474681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFWktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1270-1277&author=L.+Diauthor=J.+P.+Umlandauthor=G.+Changauthor=Y.+Huangauthor=Z.+Linauthor=D.+O.+Scottauthor=M.+D.+Troutmanauthor=T.+E.+Liston&title=Species+independence+in+brain+tissue+binding+using+brain+homogenates&doi=10.1124%2Fdmd.111.038778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Species independence in brain tissue binding using brain homogenates</span></div><div class="casAuthors">Di, Li; Umland, John P.; Chang, George; Huang, Youping; Lin, Zhen; Scott, Dennis O.; Troutman, Matthew D.; Liston, Theodore E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1270-1277</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Species independence of brain tissue binding was assessed with a large no. of structurally diverse compds. using equil. dialysis with brain homogenates of seven species and strains (Wistar Han rat, Sprague-Dawley rat, CD-1 mouse, Hartley guinea pig, beagle dog, cynomolgus monkey, and human).  The results showed that the fractions unbound of the seven species and strains were strongly correlated with correlation coeffs. ranging from 0.93 to 0.99.  The cross-species/strain correlations were not significantly different from the interassay correlation with the same species.  The linear correlation between Wistar Han and other species had a slope close to 1 and an intercept near 0.  Based on orthogonal statistical anal., no correction is needed for extrapolation of fraction unbound from Wistar Han rat to the other species or strains.  Hence, brain tissue binding of Wistar Han rat can be used to obtain binding of other species and strains in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoub4FiLWkAFrVg90H21EOLACvtfcHk0lhJnSc3e_ZCnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFWktrg%253D&md5=93a51addedb22de4648e6e5ee39c6c81</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.038778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.038778%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DChang%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DScott%26aufirst%3DD.%2BO.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3DListon%26aufirst%3DT.%2BE.%26atitle%3DSpecies%2520independence%2520in%2520brain%2520tissue%2520binding%2520using%2520brain%2520homogenates%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1270%26epage%3D1277%26doi%3D10.1124%2Fdmd.111.038778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Helal, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandit, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chappie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphrey, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marr, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenard, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapin, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siuciak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menniti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianfrogna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonseca, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDougall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDowell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span> </span><span class="NLM_article-title">Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10a inhibitor lead series for the treatment of schizophrenia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4536</span><span class="NLM_x">–</span> <span class="NLM_lpage">4547</span><span class="refDoi"> DOI: 10.1021/jm2001508</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2001508" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1ahtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4536-4547&author=C.+J.+Helalauthor=Z.+Kangauthor=X.+Houauthor=J.+Panditauthor=T.+A.+Chappieauthor=J.+M.+Humphreyauthor=E.+S.+Marrauthor=K.+F.+Fennellauthor=L.+K.+Chenardauthor=C.+Foxauthor=C.+J.+Schmidtauthor=R.+D.+Williamsauthor=D.+S.+Chapinauthor=J.+Siuciakauthor=L.+Lebelauthor=F.+Mennitiauthor=J.+Cianfrognaauthor=K.+R.+Fonsecaauthor=F.+R.+Nelsonauthor=R.+O%E2%80%99Connorauthor=M.+MacDougallauthor=L.+McDowellauthor=S.+Liras&title=Use+of+structure-based+design+to+discover+a+potent%2C+selective%2C+in+vivo+active+phosphodiesterase+10a+inhibitor+lead+series+for+the+treatment+of+schizophrenia&doi=10.1021%2Fjm2001508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia</span></div><div class="casAuthors">Helal, Christopher J.; Kang, Zhijun; Hou, Xinjun; Pandit, Jayvardhan; Chappie, Thomas A.; Humphrey, John M.; Marr, Eric S.; Fennell, Kimberly F.; Chenard, Lois K.; Fox, Carol; Schmidt, Christopher J.; Williams, Robert D.; Chapin, Douglas S.; Siuciak, Judith; Lebel, Lorraine; Menniti, Frank; Cianfrogna, Julia; Fonseca, Kari R.; Nelson, Frederick R.; O'Connor, Rebecca; MacDougall, Mary; McDowell, Laura; Liras, Spiros</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4536-4547</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Utilizing structure-based virtual library design and scoring, a novel chimeric series of phosphodiesterase 10A (PDE10A) inhibitors was discovered by synergizing binding site interactions and ADME properties of two chemotypes.  Virtual libraries were docked and scored for potential binding ability, followed by visual inspection to prioritize analogs for parallel and directed synthesis.  The process yielded highly potent and selective compds. such as 16.  New X-ray cocrystal structures enabled rational design of substituents that resulted in the successful optimization of phys. properties to produce in vivo activity and to modulate microsomal clearance and permeability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqicmqMcqmW6rVg90H21EOLACvtfcHk0lhJnSc3e_ZCnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1ahtb8%253D&md5=8df1d09717074a5c468ca017031fed65</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm2001508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2001508%26sid%3Dliteratum%253Aachs%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DKang%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DPandit%26aufirst%3DJ.%26aulast%3DChappie%26aufirst%3DT.%2BA.%26aulast%3DHumphrey%26aufirst%3DJ.%2BM.%26aulast%3DMarr%26aufirst%3DE.%2BS.%26aulast%3DFennell%26aufirst%3DK.%2BF.%26aulast%3DChenard%26aufirst%3DL.%2BK.%26aulast%3DFox%26aufirst%3DC.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26aulast%3DWilliams%26aufirst%3DR.%2BD.%26aulast%3DChapin%26aufirst%3DD.%2BS.%26aulast%3DSiuciak%26aufirst%3DJ.%26aulast%3DLebel%26aufirst%3DL.%26aulast%3DMenniti%26aufirst%3DF.%26aulast%3DCianfrogna%26aufirst%3DJ.%26aulast%3DFonseca%26aufirst%3DK.%2BR.%26aulast%3DNelson%26aufirst%3DF.%2BR.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%26aulast%3DMacDougall%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DL.%26aulast%3DLiras%26aufirst%3DS.%26atitle%3DUse%2520of%2520structure-based%2520design%2520to%2520discover%2520a%2520potent%252C%2520selective%252C%2520in%2520vivo%2520active%2520phosphodiesterase%252010a%2520inhibitor%2520lead%2520series%2520for%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4536%26epage%3D4547%26doi%3D10.1021%2Fjm2001508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, C.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of novel F-18 labeled 4-aminoquinazoline derivatives: Potential PET imaging agents for tumor detection</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4745</span><span class="NLM_x">–</span> <span class="NLM_lpage">4749</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2Fj.bmcl.2012.05.069" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4745-4749&author=Y.+Chenauthor=M.+Fengauthor=S.+Liauthor=J.+Xuauthor=H.+Ningauthor=Y.+Heauthor=X.+Wangauthor=R.+Dingauthor=C.+Qi&title=Synthesis+and+evaluation+of+novel+F-18+labeled+4-aminoquinazoline+derivatives%3A+Potential+PET+imaging+agents+for+tumor+detection&doi=10.1016%2Fj.bmcl.2012.05.069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.069%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DNing%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DR.%26aulast%3DQi%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%2520F-18%2520labeled%25204-aminoquinazoline%2520derivatives%253A%2520Potential%2520PET%2520imaging%2520agents%2520for%2520tumor%2520detection%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4745%26epage%3D4749%26doi%3D10.1016%2Fj.bmcl.2012.05.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Rice, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangloff, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, E. Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dener, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newcomb, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Putnam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cregar, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, R. L.</span><span> </span><span class="NLM_article-title">Dibasic inhibitors of human mast cell tryptase. part 1: synthesis and optimization of a novel class of inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2357</span><span class="NLM_x">–</span> <span class="NLM_lpage">2360</span><span class="refDoi"> DOI: 10.1016/S0960-894X(00)00484-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2FS0960-894X%2800%2900484-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=2357-2360&author=K.+D.+Riceauthor=A.+R.+Gangloffauthor=E.+Y.-L.+Kuoauthor=J.+M.+Denerauthor=V.+R.+Wangauthor=R.+Lumauthor=W.+S.+Newcombauthor=C.+Havelauthor=D.+Putnamauthor=L.+Cregarauthor=M.+Wongauthor=R.+L.+Warne&title=Dibasic+inhibitors+of+human+mast+cell+tryptase.+part+1%3A+synthesis+and+optimization+of+a+novel+class+of+inhibitors&doi=10.1016%2FS0960-894X%2800%2900484-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900484-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900484-4%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DK.%2BD.%26aulast%3DGangloff%26aufirst%3DA.%2BR.%26aulast%3DKuo%26aufirst%3DE.%2BY.-L.%26aulast%3DDener%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DV.%2BR.%26aulast%3DLum%26aufirst%3DR.%26aulast%3DNewcomb%26aufirst%3DW.%2BS.%26aulast%3DHavel%26aufirst%3DC.%26aulast%3DPutnam%26aufirst%3DD.%26aulast%3DCregar%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DWarne%26aufirst%3DR.%2BL.%26atitle%3DDibasic%2520inhibitors%2520of%2520human%2520mast%2520cell%2520tryptase.%2520part%25201%253A%2520synthesis%2520and%2520optimization%2520of%2520a%2520novel%2520class%2520of%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D2357%26epage%3D2360%26doi%3D10.1016%2FS0960-894X%2800%2900484-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tilley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trilles, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwinge, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R.</span><span> </span><span class="NLM_article-title">N-Acyl-L-phenylalanine derivatives as potent VLA-4 antagonists that mimic a cyclic peptide conformation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00711-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2FS0960-894X%2801%2900711-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=137-140&author=L.+Chenauthor=J.+Tilleyauthor=R.+V.+Trillesauthor=W.+Yunauthor=D.+Fryauthor=C.+Cookauthor=K.+Rowanauthor=V.+Schwingeauthor=R.+Campbell&title=N-Acyl-L-phenylalanine+derivatives+as+potent+VLA-4+antagonists+that+mimic+a+cyclic+peptide+conformation&doi=10.1016%2FS0960-894X%2801%2900711-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900711-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900711-9%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DTilley%26aufirst%3DJ.%26aulast%3DTrilles%26aufirst%3DR.%2BV.%26aulast%3DYun%26aufirst%3DW.%26aulast%3DFry%26aufirst%3DD.%26aulast%3DCook%26aufirst%3DC.%26aulast%3DRowan%26aufirst%3DK.%26aulast%3DSchwinge%26aufirst%3DV.%26aulast%3DCampbell%26aufirst%3DR.%26atitle%3DN-Acyl-L-phenylalanine%2520derivatives%2520as%2520potent%2520VLA-4%2520antagonists%2520that%2520mimic%2520a%2520cyclic%2520peptide%2520conformation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D137%26epage%3D140%26doi%3D10.1016%2FS0960-894X%2801%2900711-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Kemper, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leenders, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Küsters, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerschap, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boogerd, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Tellingen, O.</span><span> </span><span class="NLM_article-title">Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">3294</span><span class="NLM_x">–</span> <span class="NLM_lpage">3303</span><span class="refDoi"> DOI: 10.1016/j.ejca.2006.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2Fj.ejca.2006.07.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=3294-3303&author=E.+M.+Kemperauthor=W.+Leendersauthor=B.+K%C3%BCstersauthor=S.+Lyonsauthor=T.+Buckleauthor=A.+Heerschapauthor=W.+Boogerdauthor=J.+H.+Beijnenauthor=O.+van+Tellingen&title=Development+of+luciferase+tagged+brain+tumour+models+in+mice+for+chemotherapy+intervention+studies&doi=10.1016%2Fj.ejca.2006.07.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2006.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2006.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DKemper%26aufirst%3DE.%2BM.%26aulast%3DLeenders%26aufirst%3DW.%26aulast%3DK%25C3%25BCsters%26aufirst%3DB.%26aulast%3DLyons%26aufirst%3DS.%26aulast%3DBuckle%26aufirst%3DT.%26aulast%3DHeerschap%26aufirst%3DA.%26aulast%3DBoogerd%26aufirst%3DW.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3Dvan%2BTellingen%26aufirst%3DO.%26atitle%3DDevelopment%2520of%2520luciferase%2520tagged%2520brain%2520tumour%2520models%2520in%2520mice%2520for%2520chemotherapy%2520intervention%2520studies%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26spage%3D3294%26epage%3D3303%26doi%3D10.1016%2Fj.ejca.2006.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Lal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacroix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tofilon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuller, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawaya, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, F. F.</span><span> </span><span class="NLM_article-title">An implantable guide-screw system for brain tumor studies in small animals</span> <span class="citation_source-journal">J. Neurosurg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">326</span><span class="NLM_x">–</span> <span class="NLM_lpage">333</span><span class="refDoi"> DOI: 10.3171/jns.2000.92.2.0326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.3171%2Fjns.2000.92.2.0326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10659021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BD3c7it1Wgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2000&pages=326-333&author=S.+Lalauthor=M.+Lacroixauthor=P.+Tofilonauthor=G.+N.+Fullerauthor=R.+Sawayaauthor=F.+F.+Lang&title=An+implantable+guide-screw+system+for+brain+tumor+studies+in+small+animals&doi=10.3171%2Fjns.2000.92.2.0326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">An implantable guide-screw system for brain tumor studies in small animals</span></div><div class="casAuthors">Lal S; Lacroix M; Tofilon P; Fuller G N; Sawaya R; Lang F F</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurosurgery</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">326-33</span>
        ISSN:<span class="NLM_cas:issn">0022-3085</span>.
    </div><div class="casAbstract">OBJECT:  To overcome the problems associated with using stereotactic techniques to establish intracranial xenografts in nude mice and to treat engrafted tumors with intratumoral therapies (such as gene or viral therapies), the authors developed an implantable guide-screw system.  In this study, they describe the guide-screw system, its method of implantation, and their experience with establishing xenografts and delivering intratumoral therapy.  METHODS:  The system consists of a 2.6-mm guide screw with a central 0.5-mm diameter hole that accepts the 26-gauge needle of a Hamilton syringe.  The screw is implanted into a small drill hole made 2.5 mm lateral and 1 mm anterior to the bregma.  A stylet is used to cap the screw between treatments.  Tumor cells or therapeutic agents are injected in a freehand fashion by using a Hamilton syringe and a 26-gauge needle fitted with a cuff to determine the depth of injection.  To test this system, guide screws were successfully implanted in 44 (98%) of 45 nude mice.  After 1 to 2 weeks of recovery, 38 mice were inoculated with U87MG cells and killed 5 days later.  On histological studies in 37 (97%) of these animals, xenografts were evident within the caudate nucleus (mean diameter 2.5 mm).  To determine whether injections into the center of an established xenograft could be reproducibly achieved with the guide-screw system, an adenovirus vector containing the beta-galactosidase gene was injected 3 days after cell implantation in 15 of the mice.  All of these animals demonstrated transduced cells within the tumor.  To demonstrate that engrafted animals have a uniform survival time that is indicative of reproducible tumor growth, the survival of six mice was assessed after engraftment with U87MG cells.  All six animals died within 28 to 35 days.  CONCLUSIONS:  The guide-screw system allows a large number of animals to be rapidly and reproducibly engrafted and for intratumoral treatments to be accurately delivered into established xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCBLvcGyXMxL7NkxioyDXTfW6udTcc2eYcfsnmyml6Ubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7it1Wgsw%253D%253D&md5=b382d2e29677f71b8e9672951f4b2e33</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3171%2Fjns.2000.92.2.0326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3171%252Fjns.2000.92.2.0326%26sid%3Dliteratum%253Aachs%26aulast%3DLal%26aufirst%3DS.%26aulast%3DLacroix%26aufirst%3DM.%26aulast%3DTofilon%26aufirst%3DP.%26aulast%3DFuller%26aufirst%3DG.%2BN.%26aulast%3DSawaya%26aufirst%3DR.%26aulast%3DLang%26aufirst%3DF.%2BF.%26atitle%3DAn%2520implantable%2520guide-screw%2520system%2520for%2520brain%2520tumor%2520studies%2520in%2520small%2520animals%26jtitle%3DJ.%2520Neurosurg.%26date%3D2000%26volume%3D92%26spage%3D326%26epage%3D333%26doi%3D10.3171%2Fjns.2000.92.2.0326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 64 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jonathan E. Tsang, Lorenz M. Urner, Gyudong Kim, Kingsley Chow, Lynn Baufeld, Kym Faull, Timothy F. Cloughesy, Peter M. Clark, Michael E. Jung, <span class="NLM_string-name hlFld-ContribAuthor">David A. Nathanson</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1799-1809. <a href="https://doi.org/10.1021/acsmedchemlett.9b00599" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00599</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00599%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDevelopment%252Bof%252Ba%252BPotent%252BBrain-Penetrant%252BEGFR%252BTyrosine%252BKinase%252BInhibitor%252Bagainst%252BMalignant%252BBrain%252BTumors%26aulast%3DTsang%26aufirst%3DJonathan%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D20122019%26date%3D01052020%26date%3D14052020%26date%3D01052020%26volume%3D11%26issue%3D10%26spage%3D1799%26epage%3D1809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Fang Dong, Jian-Quan Liu, <span class="NLM_string-name hlFld-ContribAuthor">Xiang-Shan Wang</span>. </span><span class="cited-content_cbyCitation_article-title">CuBr-Catalyzed α-Arylation and Aerobic Oxidative Dehydrogenative C–N Coupling for the Synthesis of Spiro[cyclohexane-1,12′-isoindolo[1,2-b]quinazolin]-10′-one Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (8)
                                     , 2887-2891. <a href="https://doi.org/10.1021/acs.orglett.0c00497" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c00497</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c00497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c00497%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DCuBr-Catalyzed%252B%2525CE%2525B1-Arylation%252Band%252BAerobic%252BOxidative%252BDehydrogenative%252BC%2525E2%252580%252593N%252BCoupling%252Bfor%252Bthe%252BSynthesis%252Bof%252BSpiro%25255Bcyclohexane-1%25252C12%2525E2%252580%2525B2-isoindolo%25255B1%25252C2-b%25255Dquinazolin%25255D-10%2525E2%252580%2525B2-one%252BDerivatives%26aulast%3DDong%26aufirst%3DFang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07022020%26date%3D31032020%26volume%3D22%26issue%3D8%26spage%3D2887%26epage%3D2891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kuen-Da Wu, Grace Shiahuy Chen, Jia-Rong Liu, Chen-En Hsieh, <span class="NLM_string-name hlFld-ContribAuthor">Ji-Wang Chern</span>. </span><span class="cited-content_cbyCitation_article-title">Acrylamide Functional Group Incorporation Improves Drug-like Properties: An Example with EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (1)
                                     , 22-26. <a href="https://doi.org/10.1021/acsmedchemlett.8b00270" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00270</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00270%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAcrylamide%252BFunctional%252BGroup%252BIncorporation%252BImproves%252BDrug-like%252BProperties%25253A%252BAn%252BExample%252Bwith%252BEGFR%252BInhibitors%26aulast%3DWu%26aufirst%3DKuen-Da%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D15062018%26date%3D06122018%26date%3D10122018%26date%3D06122018%26volume%3D10%26issue%3D1%26spage%3D22%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sébastien L. Degorce, Michael S. Bodnarchuk, Iain A. Cumming, <span class="NLM_string-name hlFld-ContribAuthor">James S. Scott</span>. </span><span class="cited-content_cbyCitation_article-title">Lowering Lipophilicity by Adding Carbon: One-Carbon Bridges of Morpholines and Piperazines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (19)
                                     , 8934-8943. <a href="https://doi.org/10.1021/acs.jmedchem.8b01148" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01148%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLowering%252BLipophilicity%252Bby%252BAdding%252BCarbon%25253A%252BOne-Carbon%252BBridges%252Bof%252BMorpholines%252Band%252BPiperazines%26aulast%3DDegorce%26aufirst%3DS%25C3%25A9bastien%2BL.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D23072018%26date%3D20092018%26date%3D06092018%26volume%3D61%26issue%3D19%26spage%3D8934%26epage%3D8943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng-yi  Chen</span>, <span class="hlFld-ContribAuthor ">Fengxian  He</span>, <span class="hlFld-ContribAuthor ">Guangrong  Tang</span>, <span class="hlFld-ContribAuthor ">Huiqing  Yuan</span>, <span class="hlFld-ContribAuthor ">Ning  Li</span>, <span class="hlFld-ContribAuthor ">Jinmin  Wang</span>, and <span class="hlFld-ContribAuthor ">Roger  Faessler</span>  . </span><span class="cited-content_cbyCitation_article-title">Synthesis of Quinazolines via an Iron-Catalyzed Oxidative Amination of N–H Ketimines. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (4)
                                     , 2395-2401. <a href="https://doi.org/10.1021/acs.joc.7b02943" title="DOI URL">https://doi.org/10.1021/acs.joc.7b02943</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.7b02943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.7b02943%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Bof%252BQuinazolines%252Bvia%252Ban%252BIron-Catalyzed%252BOxidative%252BAmination%252Bof%252BN%2525E2%252580%252593H%252BKetimines%26aulast%3DChen%26aufirst%3DCheng-yi%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D20112017%26date%3D29012018%26date%3D16022018%26date%3D17012018%26volume%3D83%26issue%3D4%26spage%3D2395%26epage%3D2401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter J.  Tonge</span>  . </span><span class="cited-content_cbyCitation_article-title">Drug–Target Kinetics in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2018,</strong> <em>9 </em>
                                    (1)
                                     , 29-39. <a href="https://doi.org/10.1021/acschemneuro.7b00185" title="DOI URL">https://doi.org/10.1021/acschemneuro.7b00185</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.7b00185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.7b00185%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DDrug%2525E2%252580%252593Target%252BKinetics%252Bin%252BDrug%252BDiscovery%26aulast%3DTonge%26aufirst%3DPeter%2BJ.%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D20052017%26date%3D22062017%26date%3D14072017%26date%3D17012018%26date%3D22062017%26volume%3D9%26issue%3D1%26spage%3D29%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (22)
                                     , 10030-10066. <a href="https://doi.org/10.1021/acs.jmedchem.6b00618" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BBrain%252BCancer%26aulast%3DHeffron%26aufirst%3DTimothy%2BP.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D21042016%26date%3D03082016%26date%3D23112016%26date%3D14072016%26volume%3D59%26issue%3D22%26spage%3D10030%26epage%3D10066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Shanke  Zha</span>, <span class="hlFld-ContribAuthor ">Kehao  Chen</span>, <span class="hlFld-ContribAuthor ">Feifei  Zhang</span>, <span class="hlFld-ContribAuthor ">Chao  Song</span>, and <span class="hlFld-ContribAuthor ">Jin  Zhu</span>  . </span><span class="cited-content_cbyCitation_article-title">Quinazoline Synthesis via Rh(III)-Catalyzed Intermolecular C–H Functionalization of Benzimidates with Dioxazolones. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2016,</strong> <em>18 </em>
                                    (9)
                                     , 2062-2065. <a href="https://doi.org/10.1021/acs.orglett.6b00691" title="DOI URL">https://doi.org/10.1021/acs.orglett.6b00691</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.6b00691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.6b00691%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DQuinazoline%252BSynthesis%252Bvia%252BRh%252528III%252529-Catalyzed%252BIntermolecular%252BC%2525E2%252580%252593H%252BFunctionalization%252Bof%252BBenzimidates%252Bwith%252BDioxazolones%26aulast%3DWang%26aufirst%3DJie%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D10032016%26date%3D08042016%26date%3D06052016%26volume%3D18%26issue%3D9%26spage%3D2062%26epage%3D2065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu-Li  Lo</span>, <span class="hlFld-ContribAuthor ">Hua-Ching  Lin</span>, <span class="hlFld-ContribAuthor ">Shu-Ting  Hong</span>, <span class="hlFld-ContribAuthor ">Chih-Hsien  Chang</span>, <span class="hlFld-ContribAuthor ">Chen-Shen  Wang</span>, <span class="hlFld-ContribAuthor ">Anya Maan-Yuh  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Lipid polymeric nanoparticles modified with tight junction-modulating peptides promote afatinib delivery across a blood–brain barrier model. </span><span class="cited-content_cbyCitation_journal-name">Cancer Nanotechnology</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12645-021-00084-w" title="DOI URL">https://doi.org/10.1186/s12645-021-00084-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12645-021-00084-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12645-021-00084-w%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Nanotechnology%26atitle%3DLipid%252Bpolymeric%252Bnanoparticles%252Bmodified%252Bwith%252Btight%252Bjunction-modulating%252Bpeptides%252Bpromote%252Bafatinib%252Bdelivery%252Bacross%252Ba%252Bblood%2525E2%252580%252593brain%252Bbarrier%252Bmodel%26aulast%3DLo%26aufirst%3DYu-Li%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ding  Li</span>, <span class="hlFld-ContribAuthor ">Zhenguo  Song</span>, <span class="hlFld-ContribAuthor ">Bingqi  Dong</span>, <span class="hlFld-ContribAuthor ">Wenping  Song</span>, <span class="hlFld-ContribAuthor ">Cheng  cheng</span>, <span class="hlFld-ContribAuthor ">Yongna  Zhang</span>, <span class="hlFld-ContribAuthor ">Wenzhou  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in targeted therapy in non‐small cell lung cancer with actionable mutations and leptomeningeal metastasis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Pharmacy and Therapeutics</span><span> <strong>2021,</strong> <em>43 </em><a href="https://doi.org/10.1111/jcpt.13489" title="DOI URL">https://doi.org/10.1111/jcpt.13489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jcpt.13489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjcpt.13489%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Pharmacy%2520and%2520Therapeutics%26atitle%3DAdvances%252Bin%252Btargeted%252Btherapy%252Bin%252Bnon%2525E2%252580%252590small%252Bcell%252Blung%252Bcancer%252Bwith%252Bactionable%252Bmutations%252Band%252Bleptomeningeal%252Bmetastasis%26aulast%3DLi%26aufirst%3DDing%26date%3D2021%26date%3D2021%26volume%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philip  Cohen</span>, <span class="hlFld-ContribAuthor ">Darren  Cross</span>, <span class="hlFld-ContribAuthor ">Pasi A.  Jänne</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase drug discovery 20 years after imatinib: progress and future directions. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2021,</strong> <em>20 </em>
                                    (7)
                                     , 551-569. <a href="https://doi.org/10.1038/s41573-021-00195-4" title="DOI URL">https://doi.org/10.1038/s41573-021-00195-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41573-021-00195-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41573-021-00195-4%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DKinase%252Bdrug%252Bdiscovery%252B20%252Byears%252Bafter%252Bimatinib%25253A%252Bprogress%252Band%252Bfuture%252Bdirections%26aulast%3DCohen%26aufirst%3DPhilip%26date%3D2021%26date%3D2021%26volume%3D20%26issue%3D7%26spage%3D551%26epage%3D569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sani H.  Kizilbash</span>, <span class="hlFld-ContribAuthor ">Shiv K.  Gupta</span>, <span class="hlFld-ContribAuthor ">Karen E.  Parrish</span>, <span class="hlFld-ContribAuthor ">Janice K.  Laramy</span>, <span class="hlFld-ContribAuthor ">Minjee  Kim</span>, <span class="hlFld-ContribAuthor ">Gautham  Gampa</span>, <span class="hlFld-ContribAuthor ">Brett L.  Carlson</span>, <span class="hlFld-ContribAuthor ">Katrina K.  Bakken</span>, <span class="hlFld-ContribAuthor ">Ann C.  Mladek</span>, <span class="hlFld-ContribAuthor ">Mark A.  Schroeder</span>, <span class="hlFld-ContribAuthor ">Paul A.  Decker</span>, <span class="hlFld-ContribAuthor ">William F.  Elmquist</span>, <span class="hlFld-ContribAuthor ">Jann N.  Sarkaria</span>. </span><span class="cited-content_cbyCitation_article-title">In Vivo
              Efficacy of Tesevatinib in
              EGFR
              -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2021,</strong> <em>20 </em>
                                    (6)
                                     , 1009-1018. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0640" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0640%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DIn%252BVivo%252BEfficacy%252Bof%252BTesevatinib%252Bin%252BEGFR%252B-Amplified%252BPatient-Derived%252BXenograft%252BGlioblastoma%252BModels%252BMay%252BBe%252BLimited%252Bby%252BTissue%252BBinding%252Band%252BCompensatory%252BSignaling%26aulast%3DKizilbash%26aufirst%3DSani%2BH.%26date%3D2021%26date%3D2021%26volume%3D20%26issue%3D6%26spage%3D1009%26epage%3D1018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Omid  Tavassoly</span>, <span class="hlFld-ContribAuthor ">Esther  del Cid Pellitero</span>, <span class="hlFld-ContribAuthor ">Frederique  Larroquette</span>, <span class="hlFld-ContribAuthor ">Eddie  Cai</span>, <span class="hlFld-ContribAuthor ">Rhalena A.  Thomas</span>, <span class="hlFld-ContribAuthor ">Vincent  Soubannier</span>, <span class="hlFld-ContribAuthor ">Wen  Luo</span>, <span class="hlFld-ContribAuthor ">Thomas M.  Durcan</span>, <span class="hlFld-ContribAuthor ">Edward A.  Fon</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein Propagation. </span><span class="cited-content_cbyCitation_journal-name">Neurotherapeutics</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.1007/s13311-021-01017-6" title="DOI URL">https://doi.org/10.1007/s13311-021-01017-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13311-021-01017-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13311-021-01017-6%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurotherapeutics%26atitle%3DPharmacological%252BInhibition%252Bof%252BBrain%252BEGFR%252BActivation%252BBy%252Ba%252BBBB-penetrating%252BInhibitor%25252C%252BAZD3759%25252C%252BAttenuates%252B%2525CE%2525B1-synuclein%252BPathology%252Bin%252Ba%252BMouse%252BModel%252Bof%252B%2525CE%2525B1-Synuclein%252BPropagation%26aulast%3DTavassoly%26aufirst%3DOmid%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gautham  Gampa</span>, <span class="hlFld-ContribAuthor ">Surabhi  Talele</span>, <span class="hlFld-ContribAuthor ">Minjee  Kim</span>, <span class="hlFld-ContribAuthor ">Afroz  Mohammad</span>, <span class="hlFld-ContribAuthor ">Jessica  Griffith</span>, <span class="hlFld-ContribAuthor ">William F.  Elmquist</span>. </span><span class="cited-content_cbyCitation_article-title">Influence of transporters in treating cancers in the CNS. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 277-301. <a href="https://doi.org/10.1016/B978-0-12-816434-1.00009-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-816434-1.00009-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-816434-1.00009-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-816434-1.00009-7%26sid%3Dliteratum%253Aachs%26atitle%3DInfluence%252Bof%252Btransporters%252Bin%252Btreating%252Bcancers%252Bin%252Bthe%252BCNS%26aulast%3DGampa%26aufirst%3DGautham%26date%3D2020%26spage%3D277%26epage%3D301%26pub%3DElsevier%26atitle%3DDrug%252BEfflux%252BPumps%252Bin%252BCancer%252BResistance%252BPathways%25253A%252BFrom%252BMolecular%252BRecognition%252Band%252BCharacterization%252Bto%252BPossible%252BInhibition%252BStrategies%252Bin%252BChemotherapy%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Zhang</span>, <span class="hlFld-ContribAuthor ">Natasha B.  Leighl</span>, <span class="hlFld-ContribAuthor ">Yi-Long  Wu</span>, <span class="hlFld-ContribAuthor ">Wen-Zhao  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging therapies for non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2019,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-019-0731-8" title="DOI URL">https://doi.org/10.1186/s13045-019-0731-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-019-0731-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-019-0731-8%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DEmerging%252Btherapies%252Bfor%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DZhang%26aufirst%3DChao%26date%3D2019%26date%3D2019%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rowland H.  Han</span>, <span class="hlFld-ContribAuthor ">Gavin P.  Dunn</span>, <span class="hlFld-ContribAuthor ">Milan G.  Chheda</span>, <span class="hlFld-ContribAuthor ">Albert H.  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">The impact of systemic precision medicine and immunotherapy treatments on brain metastases. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2019,</strong> <em>10 </em>
                                    (62)
                                     , 6739-6753. <a href="https://doi.org/10.18632/oncotarget.27328" title="DOI URL">https://doi.org/10.18632/oncotarget.27328</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.27328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.27328%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DThe%252Bimpact%252Bof%252Bsystemic%252Bprecision%252Bmedicine%252Band%252Bimmunotherapy%252Btreatments%252Bon%252Bbrain%252Bmetastases%26aulast%3DHan%26aufirst%3DRowland%2BH.%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D62%26spage%3D6739%26epage%3D6753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuo  Yuan</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong‐Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">“On‐Water” Palladium‐Catalyzed Tandem Cyclization Reaction for the Synthesis of Biologically Relevant 4‐Arylquinazolines. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2019,</strong> <em>25 </em>
                                    (57)
                                     , 13109-13113. <a href="https://doi.org/10.1002/chem.201903464" title="DOI URL">https://doi.org/10.1002/chem.201903464</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201903464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201903464%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3D%2525E2%252580%25259COn%2525E2%252580%252590Water%2525E2%252580%25259D%252BPalladium%2525E2%252580%252590Catalyzed%252BTandem%252BCyclization%252BReaction%252Bfor%252Bthe%252BSynthesis%252Bof%252BBiologically%252BRelevant%252B4%2525E2%252580%252590Arylquinazolines%26aulast%3DYuan%26aufirst%3DShuo%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D57%26spage%3D13109%26epage%3D13113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dennis A.  Smith</span>, <span class="hlFld-ContribAuthor ">Malcolm  Rowland</span>. </span><span class="cited-content_cbyCitation_article-title">Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2019,</strong> <em>47 </em>
                                    (6)
                                     , 665-672. <a href="https://doi.org/10.1124/dmd.118.085951" title="DOI URL">https://doi.org/10.1124/dmd.118.085951</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.118.085951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.118.085951%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DIntracellular%252Band%252BIntraorgan%252BConcentrations%252Bof%252BSmall%252BMolecule%252BDrugs%25253A%252BTheory%25252C%252BUncertainties%252Bin%252BInfectious%252BDiseases%252Band%252BOncology%25252C%252Band%252BPromise%26aulast%3DSmith%26aufirst%3DDennis%2BA.%26date%3D2019%26date%3D2019%26volume%3D47%26issue%3D6%26spage%3D665%26epage%3D672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicola  Colclough</span>, <span class="hlFld-ContribAuthor ">Kan  Chen</span>, <span class="hlFld-ContribAuthor ">Peter  Johnström</span>, <span class="hlFld-ContribAuthor ">Markus  Fridén</span>, <span class="hlFld-ContribAuthor ">Dermot F.  McGinnity</span>. </span><span class="cited-content_cbyCitation_article-title">Building on the success of osimertinib: achieving CNS exposure in oncology drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2019,</strong> <em>24 </em>
                                    (5)
                                     , 1067-1073. <a href="https://doi.org/10.1016/j.drudis.2019.01.015" title="DOI URL">https://doi.org/10.1016/j.drudis.2019.01.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2019.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2019.01.015%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DBuilding%252Bon%252Bthe%252Bsuccess%252Bof%252Bosimertinib%25253A%252Bachieving%252BCNS%252Bexposure%252Bin%252Boncology%252Bdrug%252Bdiscovery%26aulast%3DColclough%26aufirst%3DNicola%26date%3D2019%26volume%3D24%26issue%3D5%26spage%3D1067%26epage%3D1073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>170 </em>, 55-72. <a href="https://doi.org/10.1016/j.ejmech.2019.03.004" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.004%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvancements%252Bof%252B4-aminoquinazoline%252Bderivatives%252Bas%252Bkinase%252Binhibitors%252Band%252Btheir%252Bapplications%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2019%26volume%3D170%26spage%3D55%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minjee  Kim</span>, <span class="hlFld-ContribAuthor ">Janice K.  Laramy</span>, <span class="hlFld-ContribAuthor ">Afroz S.  Mohammad</span>, <span class="hlFld-ContribAuthor ">Surabhi  Talele</span>, <span class="hlFld-ContribAuthor ">James  Fisher</span>, <span class="hlFld-ContribAuthor ">Jann N.  Sarkaria</span>, <span class="hlFld-ContribAuthor ">William F.  Elmquist</span>. </span><span class="cited-content_cbyCitation_article-title">Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and
              Abcb1/Abcg2
              -Deficient Mice. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2019,</strong> <em>47 </em>
                                    (4)
                                     , 393-404. <a href="https://doi.org/10.1124/dmd.118.084210" title="DOI URL">https://doi.org/10.1124/dmd.118.084210</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.118.084210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.118.084210%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DBrain%252BDistribution%252Bof%252Ba%252BPanel%252Bof%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitors%252BUsing%252BCassette%252BDosing%252Bin%252BWild-Type%252Band%252BAbcb1%25252FAbcg2%252B-Deficient%252BMice%26aulast%3DKim%26aufirst%3DMinjee%26date%3D2019%26date%3D2019%26volume%3D47%26issue%3D4%26spage%3D393%26epage%3D404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Danyang  Chao</span>, <span class="hlFld-ContribAuthor ">Lijun  Pang</span>, <span class="hlFld-ContribAuthor ">Ying  Shi</span>, <span class="hlFld-ContribAuthor ">Wenjing  Wang</span>, <span class="hlFld-ContribAuthor ">Kai  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">AZD3759 induces apoptosis in hepatoma cells by activating a p53-SMAD4 positive feedback loop. </span><span class="cited-content_cbyCitation_journal-name">Biochemical and Biophysical Research Communications</span><span> <strong>2019,</strong> <em>509 </em>
                                    (2)
                                     , 535-540. <a href="https://doi.org/10.1016/j.bbrc.2018.12.102" title="DOI URL">https://doi.org/10.1016/j.bbrc.2018.12.102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbrc.2018.12.102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbrc.2018.12.102%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520and%2520Biophysical%2520Research%2520Communications%26atitle%3DAZD3759%252Binduces%252Bapoptosis%252Bin%252Bhepatoma%252Bcells%252Bby%252Bactivating%252Ba%252Bp53-SMAD4%252Bpositive%252Bfeedback%252Bloop%26aulast%3DChao%26aufirst%3DDanyang%26date%3D2019%26volume%3D509%26issue%3D2%26spage%3D535%26epage%3D540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arrvind  Raghunath</span>, <span class="hlFld-ContribAuthor ">Vyshak Alva  Venur</span>, <span class="hlFld-ContribAuthor ">Manmeet S.  Ahluwalia</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Agents and Immunotherapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 381-388. <a href="https://doi.org/10.1007/978-3-030-16924-4_32" title="DOI URL">https://doi.org/10.1007/978-3-030-16924-4_32</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-030-16924-4_32&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-030-16924-4_32%26sid%3Dliteratum%253Aachs%26atitle%3DTargeted%252BAgents%252Band%252BImmunotherapy%26aulast%3DRaghunath%26aufirst%3DArrvind%26date%3D2019%26date%3D2019%26spage%3D381%26epage%3D388%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DStereotactic%252BRadiosurgery%252Band%252BStereotactic%252BBody%252BRadiation%252BTherapy%26aulast%3DTrifiletti%26aufirst%3DDaniel%2BM.%26date%3D2019%26volume%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Cai</span>, <span class="hlFld-ContribAuthor ">Payal  Grover</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Mark I.  Greene</span>, <span class="hlFld-ContribAuthor ">Hongtao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Signaling of the ErbB Receptor Family in Carcinogenesis and the Development of Targeted Therapies. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 231-242. <a href="https://doi.org/10.1007/978-3-319-95228-4_18" title="DOI URL">https://doi.org/10.1007/978-3-319-95228-4_18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-95228-4_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-95228-4_18%26sid%3Dliteratum%253Aachs%26atitle%3DSignaling%252Bof%252Bthe%2525C2%2525A0ErbB%252BReceptor%252BFamily%252Bin%252BCarcinogenesis%252Band%252Bthe%2525C2%2525A0Development%252Bof%252BTargeted%252BTherapies%26aulast%3DCai%26aufirst%3DZheng%26date%3D2019%26date%3D2018%26spage%3D231%26epage%3D242%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DPredictive%252BBiomarkers%252Bin%252BOncology%26aulast%3DBadve%26aufirst%3DSunil%26date%3D2019%26volume%3D307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qingjun  Wu</span>, <span class="hlFld-ContribAuthor ">Ailian  Hua</span>, <span class="hlFld-ContribAuthor ">Yaoguang  Sun</span>, <span class="hlFld-ContribAuthor ">Chao  Ma</span>, <span class="hlFld-ContribAuthor ">Wenxin  Tian</span>, <span class="hlFld-ContribAuthor ">Chuan  Huang</span>, <span class="hlFld-ContribAuthor ">Hanbo  Yu</span>, <span class="hlFld-ContribAuthor ">Peng  Jiao</span>, <span class="hlFld-ContribAuthor ">Shuanghu  Wang</span>, <span class="hlFld-ContribAuthor ">Hongfeng  Tong</span>, <span class="hlFld-ContribAuthor ">Weiwen  Qiu</span>. </span><span class="cited-content_cbyCitation_article-title">Determination and pharmacokinetic study of AZD-3759 in rat plasma by ultra performance liquid chromatography with triple quadrupole mass spectrometer. </span><span class="cited-content_cbyCitation_journal-name">Thoracic Cancer</span><span> <strong>2018,</strong> <em>9 </em>
                                    (11)
                                     , 1383-1389. <a href="https://doi.org/10.1111/1759-7714.12843" title="DOI URL">https://doi.org/10.1111/1759-7714.12843</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/1759-7714.12843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2F1759-7714.12843%26sid%3Dliteratum%253Aachs%26jtitle%3DThoracic%2520Cancer%26atitle%3DDetermination%252Band%252Bpharmacokinetic%252Bstudy%252Bof%252BAZD-3759%252Bin%252Brat%252Bplasma%252Bby%252Bultra%252Bperformance%252Bliquid%252Bchromatography%252Bwith%252Btriple%252Bquadrupole%252Bmass%252Bspectrometer%26aulast%3DWu%26aufirst%3DQingjun%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D11%26spage%3D1383%26epage%3D1389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emma C.  Martin</span>, <span class="hlFld-ContribAuthor ">Leon  Aarons</span>, <span class="hlFld-ContribAuthor ">James W. T.  Yates</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models. </span><span class="cited-content_cbyCitation_journal-name">Cancer Chemotherapy and Pharmacology</span><span> <strong>2018,</strong> <em>82 </em>
                                    (4)
                                     , 669-675. <a href="https://doi.org/10.1007/s00280-018-3630-8" title="DOI URL">https://doi.org/10.1007/s00280-018-3630-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00280-018-3630-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00280-018-3630-8%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Chemotherapy%2520and%2520Pharmacology%26atitle%3DPharmacodynamic%252Bmodelling%252Bof%252Bresistance%252Bto%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Binhibition%252Bin%252Bbrain%252Bmetastasis%252Bmouse%252Bmodels%26aulast%3DMartin%26aufirst%3DEmma%2BC.%26date%3D2018%26date%3D2018%26volume%3D82%26issue%3D4%26spage%3D669%26epage%3D675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manmeet S.  Ahluwalia</span>, <span class="hlFld-ContribAuthor ">Kevin  Becker</span>, <span class="hlFld-ContribAuthor ">Benjamin P.  Levy</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non‐Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">The Oncologist</span><span> <strong>2018,</strong> <em>23 </em>
                                    (10)
                                     , 1199-1209. <a href="https://doi.org/10.1634/theoncologist.2017-0572" title="DOI URL">https://doi.org/10.1634/theoncologist.2017-0572</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1634/theoncologist.2017-0572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1634%2Ftheoncologist.2017-0572%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Oncologist%26atitle%3DEpidermal%252BGrowth%252BFactor%252BReceptor%252BTyrosine%252BKinase%252BInhibitors%252Bfor%252BCentral%252BNervous%252BSystem%252BMetastases%252Bfrom%252BNon%2525E2%252580%252590Small%252BCell%252BLung%252BCancer%26aulast%3DAhluwalia%26aufirst%3DManmeet%2BS.%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D10%26spage%3D1199%26epage%3D1209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minjee  Kim</span>, <span class="hlFld-ContribAuthor ">Sani H.  Kizilbash</span>, <span class="hlFld-ContribAuthor ">Janice K.  Laramy</span>, <span class="hlFld-ContribAuthor ">Gautham  Gampa</span>, <span class="hlFld-ContribAuthor ">Karen E.  Parrish</span>, <span class="hlFld-ContribAuthor ">Jann N.  Sarkaria</span>, <span class="hlFld-ContribAuthor ">William F.  Elmquist</span>. </span><span class="cited-content_cbyCitation_article-title">Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Research</span><span> <strong>2018,</strong> <em>35 </em>
                                    (9)
                                     <a href="https://doi.org/10.1007/s11095-018-2455-9" title="DOI URL">https://doi.org/10.1007/s11095-018-2455-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11095-018-2455-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11095-018-2455-9%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Research%26atitle%3DBarriers%252Bto%252BEffective%252BDrug%252BTreatment%252Bfor%252BBrain%252BMetastases%25253A%252BA%252BMultifactorial%252BProblem%252Bin%252Bthe%252BDelivery%252Bof%252BPrecision%252BMedicine%26aulast%3DKim%26aufirst%3DMinjee%26date%3D2018%26date%3D2018%26volume%3D35%26issue%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Handeng  Lv</span>, <span class="hlFld-ContribAuthor ">Lu  Luo</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Yaqian  Pan</span>, <span class="hlFld-ContribAuthor ">Yuewu  Wang</span>, <span class="hlFld-ContribAuthor ">Han  Lin</span>, <span class="hlFld-ContribAuthor ">Jianhua  Xiong</span>, <span class="hlFld-ContribAuthor ">Ping  Guo</span>, <span class="hlFld-ContribAuthor ">Jinsan  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaokun  Li</span>, <span class="hlFld-ContribAuthor ">Faqing  Ye</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>157 </em>, 1300-1325. <a href="https://doi.org/10.1016/j.ejmech.2018.08.031" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.08.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.08.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.08.031%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bpharmacological%252Bevaluation%252Bof%252BN4%25252CN6-disubstituted%252Bpyrimidine-4%25252C6-diamine%252Bderivatives%252Bas%252Bpotent%252BEGFR%252Binhibitors%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DZhang%26aufirst%3DYuan%26date%3D2018%26volume%3D157%26spage%3D1300%26epage%3D1325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William J.  Kelly</span>, <span class="hlFld-ContribAuthor ">Neil J.  Shah</span>, <span class="hlFld-ContribAuthor ">Deepa S.  Subramaniam</span>. </span><span class="cited-content_cbyCitation_article-title">Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2018,</strong> <em>8 </em><a href="https://doi.org/10.3389/fonc.2018.00208" title="DOI URL">https://doi.org/10.3389/fonc.2018.00208</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2018.00208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2018.00208%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DManagement%252Bof%252BBrain%252BMetastases%252Bin%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BMutant%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DKelly%26aufirst%3DWilliam%2BJ.%26date%3D2018%26date%3D2018%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xue  Li</span>, <span class="hlFld-ContribAuthor ">Yingchun  Wang</span>, <span class="hlFld-ContribAuthor ">Jia  Wang</span>, <span class="hlFld-ContribAuthor ">Tianwei  Zhang</span>, <span class="hlFld-ContribAuthor ">Li  Zheng</span>, <span class="hlFld-ContribAuthor ">Zhenfan  Yang</span>, <span class="hlFld-ContribAuthor ">Ligang  Xing</span>, <span class="hlFld-ContribAuthor ">Jinming  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Cancer</span><span> <strong>2018,</strong> <em>143 </em>
                                    (1)
                                     , 212-224. <a href="https://doi.org/10.1002/ijc.31303" title="DOI URL">https://doi.org/10.1002/ijc.31303</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ijc.31303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fijc.31303%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Cancer%26atitle%3DEnhanced%252Befficacy%252Bof%252BAZD3759%252Band%252Bradiation%252Bon%252Bbrain%252Bmetastasis%252Bfrom%252BEGFR%252Bmutant%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DLi%26aufirst%3DXue%26date%3D2018%26date%3D2018%26volume%3D143%26issue%3D1%26spage%3D212%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maximilian  Hochmair</span>. </span><span class="cited-content_cbyCitation_article-title">Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease. </span><span class="cited-content_cbyCitation_journal-name">Targeted Oncology</span><span> <strong>2018,</strong> <em>13 </em>
                                    (3)
                                     , 269-285. <a href="https://doi.org/10.1007/s11523-018-0566-1" title="DOI URL">https://doi.org/10.1007/s11523-018-0566-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11523-018-0566-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11523-018-0566-1%26sid%3Dliteratum%253Aachs%26jtitle%3DTargeted%2520Oncology%26atitle%3DMedical%252BTreatment%252BOptions%252Bfor%252BPatients%252Bwith%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BMutation-Positive%252BNon-Small%252BCell%252BLung%252BCancer%252BSuffering%252Bfrom%252BBrain%252BMetastases%252Band%25252For%252BLeptomeningeal%252BDisease%26aulast%3DHochmair%26aufirst%3DMaximilian%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D3%26spage%3D269%26epage%3D285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefano  Fogli</span>, <span class="hlFld-ContribAuthor ">Beatrice  Polini</span>, <span class="hlFld-ContribAuthor ">Marzia Del  Re</span>, <span class="hlFld-ContribAuthor ">Iacopo  Petrini</span>, <span class="hlFld-ContribAuthor ">Antonio  Passaro</span>, <span class="hlFld-ContribAuthor ">Stefania  Crucitta</span>, <span class="hlFld-ContribAuthor ">Eleonora  Rofi</span>, <span class="hlFld-ContribAuthor ">Romano  Danesi</span>. </span><span class="cited-content_cbyCitation_article-title">EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. </span><span class="cited-content_cbyCitation_journal-name">Pharmacogenomics</span><span> <strong>2018,</strong> <em>19 </em>
                                    (8)
                                     , 727-740. <a href="https://doi.org/10.2217/pgs-2018-0038" title="DOI URL">https://doi.org/10.2217/pgs-2018-0038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/pgs-2018-0038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Fpgs-2018-0038%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacogenomics%26atitle%3DEGFR-TKIs%252Bin%252Bnon-small-cell%252Blung%252Bcancer%25253A%252Bfocus%252Bon%252Bclinical%252Bpharmacology%252Band%252Bmechanisms%252Bof%252Bresistance%26aulast%3DFogli%26aufirst%3DStefano%26date%3D2018%26volume%3D19%26issue%3D8%26spage%3D727%26epage%3D740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin-Chi  Liao</span>, <span class="hlFld-ContribAuthor ">Chia-Chi  Lin</span>, <span class="hlFld-ContribAuthor ">James Chih-Hsin  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2018,</strong> <em>19 </em>
                                    (8)
                                     , 851-864. <a href="https://doi.org/10.1080/14656566.2018.1472765" title="DOI URL">https://doi.org/10.1080/14656566.2018.1472765</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2018.1472765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2018.1472765%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DTreating%252Bbrain%252Bmetastases%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bpatients%25253A%252Bwhat%252Bhave%252Bwe%252Blearnt%252Bfrom%252Bpharmaceutical%252Brecent%252Bclinical%252Btrials%25253F%26aulast%3DLiao%26aufirst%3DBin-Chi%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D8%26spage%3D851%26epage%3D864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gautham  Gampa</span>, <span class="hlFld-ContribAuthor ">Minjee  Kim</span>, <span class="hlFld-ContribAuthor ">Nicholas  Cook-Rostie</span>, <span class="hlFld-ContribAuthor ">Janice K.  Laramy</span>, <span class="hlFld-ContribAuthor ">Jann N.  Sarkaria</span>, <span class="hlFld-ContribAuthor ">Linda  Paradiso</span>, <span class="hlFld-ContribAuthor ">Louis  DePalatis</span>, <span class="hlFld-ContribAuthor ">William F.  Elmquist</span>. </span><span class="cited-content_cbyCitation_article-title">Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2018,</strong> <em>46 </em>
                                    (5)
                                     , 658-666. <a href="https://doi.org/10.1124/dmd.117.079194" title="DOI URL">https://doi.org/10.1124/dmd.117.079194</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.117.079194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.117.079194%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DBrain%252BDistribution%252Bof%252Ba%252BNovel%252BMEK%252BInhibitor%252BE6201%25253A%252BImplications%252Bin%252Bthe%252BTreatment%252Bof%252BMelanoma%252BBrain%252BMetastases%26aulast%3DGampa%26aufirst%3DGautham%26date%3D2018%26date%3D2018%26volume%3D46%26issue%3D5%26spage%3D658%26epage%3D666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stijn J.H.  Waaijer</span>, <span class="hlFld-ContribAuthor ">Iris C.  Kok</span>, <span class="hlFld-ContribAuthor ">Bertha  Eisses</span>, <span class="hlFld-ContribAuthor ">Carolina P.  Schröder</span>, <span class="hlFld-ContribAuthor ">Mathilde  Jalving</span>, <span class="hlFld-ContribAuthor ">Adrienne H.  Brouwers</span>, <span class="hlFld-ContribAuthor ">Marjolijn N.  Lub-de Hooge</span>, <span class="hlFld-ContribAuthor ">Elisabeth G.E.  de Vries</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Imaging in Cancer Drug Development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Nuclear Medicine</span><span> <strong>2018,</strong> <em>59 </em>
                                    (5)
                                     , 726-732. <a href="https://doi.org/10.2967/jnumed.116.188045" title="DOI URL">https://doi.org/10.2967/jnumed.116.188045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2967/jnumed.116.188045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2967%2Fjnumed.116.188045%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Nuclear%2520Medicine%26atitle%3DMolecular%252BImaging%252Bin%252BCancer%252BDrug%252BDevelopment%26aulast%3DWaaijer%26aufirst%3DStijn%2BJ.H.%26date%3D2018%26date%3D2018%26volume%3D59%26issue%3D5%26spage%3D726%26epage%3D732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy P  Heffron</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges of developing small-molecule kinase inhibitors for brain tumors and the need for emphasis on free drug levels. </span><span class="cited-content_cbyCitation_journal-name">Neuro-Oncology</span><span> <strong>2018,</strong> <em>20 </em>
                                    (3)
                                     , 307-312. <a href="https://doi.org/10.1093/neuonc/nox179" title="DOI URL">https://doi.org/10.1093/neuonc/nox179</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/neuonc/nox179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fneuonc%2Fnox179%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuro-Oncology%26atitle%3DChallenges%252Bof%252Bdeveloping%252Bsmall-molecule%252Bkinase%252Binhibitors%252Bfor%252Bbrain%252Btumors%252Band%252Bthe%252Bneed%252Bfor%252Bemphasis%252Bon%252Bfree%252Bdrug%252Blevels%26aulast%3DHeffron%26aufirst%3DTimothy%2BP%26date%3D2018%26date%3D2017%26volume%3D20%26issue%3D3%26spage%3D307%26epage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haiying  Cheng</span>, <span class="hlFld-ContribAuthor ">Roman  Perez-Soler</span>. </span><span class="cited-content_cbyCitation_article-title">Leptomeningeal metastases in non-small-cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">The Lancet Oncology</span><span> <strong>2018,</strong> <em>19 </em>
                                    (1)
                                     , e43-e55. <a href="https://doi.org/10.1016/S1470-2045(17)30689-7" title="DOI URL">https://doi.org/10.1016/S1470-2045(17)30689-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S1470-2045(17)30689-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS1470-2045%2817%2930689-7%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Lancet%2520Oncology%26atitle%3DLeptomeningeal%252Bmetastases%252Bin%252Bnon-small-cell%252Blung%252Bcancer%26aulast%3DCheng%26aufirst%3DHaiying%26date%3D2018%26volume%3D19%26issue%3D1%26spage%3De43%26epage%3De55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rodica  Di Lorenzo</span>, <span class="hlFld-ContribAuthor ">Manmeet S.  Ahluwalia</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted therapy of brain metastases: latest evidence and clinical implications. </span><span class="cited-content_cbyCitation_journal-name">Therapeutic Advances in Medical Oncology</span><span> <strong>2017,</strong> <em>9 </em>
                                    (12)
                                     , 781-796. <a href="https://doi.org/10.1177/1758834017736252" title="DOI URL">https://doi.org/10.1177/1758834017736252</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1758834017736252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1758834017736252%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapeutic%2520Advances%2520in%2520Medical%2520Oncology%26atitle%3DTargeted%252Btherapy%252Bof%252Bbrain%252Bmetastases%25253A%252Blatest%252Bevidence%252Band%252Bclinical%252Bimplications%26aulast%3DDi%2BLorenzo%26aufirst%3DRodica%26date%3D2017%26date%3D2017%26volume%3D9%26issue%3D12%26spage%3D781%26epage%3D796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Myung-Ju  Ahn</span>, <span class="hlFld-ContribAuthor ">Dong-Wan  Kim</span>, <span class="hlFld-ContribAuthor ">Byoung Chul  Cho</span>, <span class="hlFld-ContribAuthor ">Sang-We  Kim</span>, <span class="hlFld-ContribAuthor ">Jong Seok  Lee</span>, <span class="hlFld-ContribAuthor ">Jin-Seok  Ahn</span>, <span class="hlFld-ContribAuthor ">Tae Min  Kim</span>, <span class="hlFld-ContribAuthor ">Chia-Chi  Lin</span>, <span class="hlFld-ContribAuthor ">Hye Ryun  Kim</span>, <span class="hlFld-ContribAuthor ">Thomas  John</span>, <span class="hlFld-ContribAuthor ">Steven  Kao</span>, <span class="hlFld-ContribAuthor ">Jonathan W  Goldman</span>, <span class="hlFld-ContribAuthor ">Wu-Chou  Su</span>, <span class="hlFld-ContribAuthor ">Ronald  Natale</span>, <span class="hlFld-ContribAuthor ">Sarit  Rabbie</span>, <span class="hlFld-ContribAuthor ">Bryony  Harrop</span>, <span class="hlFld-ContribAuthor ">Philip  Overend</span>, <span class="hlFld-ContribAuthor ">Zhenfan  Yang</span>, <span class="hlFld-ContribAuthor ">James Chih-Hsin  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. </span><span class="cited-content_cbyCitation_journal-name">The Lancet Respiratory Medicine</span><span> <strong>2017,</strong> <em>5 </em>
                                    (11)
                                     , 891-902. <a href="https://doi.org/10.1016/S2213-2600(17)30378-8" title="DOI URL">https://doi.org/10.1016/S2213-2600(17)30378-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S2213-2600(17)30378-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS2213-2600%2817%2930378-8%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Lancet%2520Respiratory%2520Medicine%26atitle%3DActivity%252Band%252Bsafety%252Bof%252BAZD3759%252Bin%252BEGFR-mutant%252Bnon-small-cell%252Blung%252Bcancer%252Bwith%252BCNS%252Bmetastases%252B%252528BLOOM%252529%25253A%252Ba%252Bphase%252B1%25252C%252Bopen-label%25252C%252Bdose-escalation%252Band%252Bdose-expansion%252Bstudy%26aulast%3DAhn%26aufirst%3DMyung-Ju%26date%3D2017%26volume%3D5%26issue%3D11%26spage%3D891%26epage%3D902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gautham  Gampa</span>, <span class="hlFld-ContribAuthor ">Shruthi  Vaidhyanathan</span>, <span class="hlFld-ContribAuthor ">Jann N.  Sarkaria</span>, <span class="hlFld-ContribAuthor ">William F.  Elmquist</span>. </span><span class="cited-content_cbyCitation_article-title">Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2017,</strong> <em>123 </em>, 10-25. <a href="https://doi.org/10.1016/j.phrs.2017.06.008" title="DOI URL">https://doi.org/10.1016/j.phrs.2017.06.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2017.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2017.06.008%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DDrug%252Bdelivery%252Bto%252Bmelanoma%252Bbrain%252Bmetastases%25253A%252BCan%252Bcurrent%252Bchallenges%252Blead%252Bto%252Bnew%252Bopportunities%25253F%26aulast%3DGampa%26aufirst%3DGautham%26date%3D2017%26volume%3D123%26spage%3D10%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gino K.  In</span>, <span class="hlFld-ContribAuthor ">Jeremy  Mason</span>, <span class="hlFld-ContribAuthor ">Sonia  Lin</span>, <span class="hlFld-ContribAuthor ">Paul K  Newton</span>, <span class="hlFld-ContribAuthor ">Peter  Kuhn</span>, <span class="hlFld-ContribAuthor ">Jorge  Nieva</span>. </span><span class="cited-content_cbyCitation_article-title">Development of metastatic brain disease involves progression through lung metastases in
              EGFR
              mutated non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Convergent Science Physical Oncology</span><span> <strong>2017,</strong> <em>3 </em>
                                    (3)
                                     , 035002. <a href="https://doi.org/10.1088/2057-1739/aa7a8d" title="DOI URL">https://doi.org/10.1088/2057-1739/aa7a8d</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1088/2057-1739/aa7a8d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1088%2F2057-1739%2Faa7a8d%26sid%3Dliteratum%253Aachs%26jtitle%3DConvergent%2520Science%2520Physical%2520Oncology%26atitle%3DDevelopment%252Bof%252Bmetastatic%252Bbrain%252Bdisease%252Binvolves%252Bprogression%252Bthrough%252Blung%252Bmetastases%252Bin%252BEGFR%252Bmutated%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DIn%26aufirst%3DGino%2BK.%26date%3D2017%26date%3D2017%26volume%3D3%26issue%3D3%26spage%3D035002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shih-Hsin  Hsiao</span>, <span class="hlFld-ContribAuthor ">Yu-Ting  Chou</span>, <span class="hlFld-ContribAuthor ">Sey-En  Lin</span>, <span class="hlFld-ContribAuthor ">Ru-Chun  Hsu</span>, <span class="hlFld-ContribAuthor ">Chi-Li  Chung</span>, <span class="hlFld-ContribAuthor ">Yu-Rung  Kao</span>, <span class="hlFld-ContribAuthor ">H. Eugene  Liu</span>, <span class="hlFld-ContribAuthor ">Cheng-Wen  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Brain metastases in patients with non-small cell lung cancer: the role of mutated-
              EGFRs
              with an exon 19 deletion or L858R point mutation in cancer cell dissemination. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (32)
                                     , 53405-53418. <a href="https://doi.org/10.18632/oncotarget.18509" title="DOI URL">https://doi.org/10.18632/oncotarget.18509</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.18509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.18509%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DBrain%252Bmetastases%252Bin%252Bpatients%252Bwith%252Bnon-small%252Bcell%252Blung%252Bcancer%25253A%252Bthe%252Brole%252Bof%252Bmutated-%252BEGFRs%252Bwith%252Ban%252Bexon%252B19%252Bdeletion%252Bor%252BL858R%252Bpoint%252Bmutation%252Bin%252Bcancer%252Bcell%252Bdissemination%26aulast%3DHsiao%26aufirst%3DShih-Hsin%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D32%26spage%3D53405%26epage%3D53418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas Lee  Collier</span>, <span class="hlFld-ContribAuthor ">Marc D.  Normandin</span>, <span class="hlFld-ContribAuthor ">Nickeisha A.  Stephenson</span>, <span class="hlFld-ContribAuthor ">Eli  Livni</span>, <span class="hlFld-ContribAuthor ">Steven H.  Liang</span>, <span class="hlFld-ContribAuthor ">Dustin W.  Wooten</span>, <span class="hlFld-ContribAuthor ">Shadi A.  Esfahani</span>, <span class="hlFld-ContribAuthor ">Michael G.  Stabin</span>, <span class="hlFld-ContribAuthor ">Umar  Mahmood</span>, <span class="hlFld-ContribAuthor ">Jianqing  Chen</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Kevin  Maresca</span>, <span class="hlFld-ContribAuthor ">Rikki N.  Waterhouse</span>, <span class="hlFld-ContribAuthor ">Georges  El Fakhri</span>, <span class="hlFld-ContribAuthor ">Paul  Richardson</span>, <span class="hlFld-ContribAuthor ">Neil  Vasdev</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2017,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/ncomms15761" title="DOI URL">https://doi.org/10.1038/ncomms15761</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/ncomms15761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fncomms15761%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DSynthesis%252Band%252Bpreliminary%252BPET%252Bimaging%252Bof%252B11C%252Band%252B18F%252Bisotopologues%252Bof%252Bthe%252BROS1%25252FALK%252Binhibitor%252Blorlatinib%26aulast%3DCollier%26aufirst%3DThomas%2BLee%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joan  How</span>, <span class="hlFld-ContribAuthor ">Janelle  Mann</span>, <span class="hlFld-ContribAuthor ">Andrew N.  Laczniak</span>, <span class="hlFld-ContribAuthor ">Maria Q.  Baggstrom</span>. </span><span class="cited-content_cbyCitation_article-title">Pulsatile Erlotinib in EGFR-Positive Non–Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature. </span><span class="cited-content_cbyCitation_journal-name">Clinical Lung Cancer</span><span> <strong>2017,</strong> <em>18 </em>
                                    (4)
                                     , 354-363. <a href="https://doi.org/10.1016/j.cllc.2017.01.013" title="DOI URL">https://doi.org/10.1016/j.cllc.2017.01.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cllc.2017.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cllc.2017.01.013%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Lung%2520Cancer%26atitle%3DPulsatile%252BErlotinib%252Bin%252BEGFR-Positive%252BNon%2525E2%252580%252593Small-Cell%252BLung%252BCancer%252BPatients%252BWith%252BLeptomeningeal%252Band%252BBrain%252BMetastases%25253A%252BReview%2525C2%2525A0of%2525C2%2525A0the%252BLiterature%26aulast%3DHow%26aufirst%3DJoan%26date%3D2017%26volume%3D18%26issue%3D4%26spage%3D354%26epage%3D363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Magnus  Schou</span>, <span class="hlFld-ContribAuthor ">Katarina  Varnäs</span>. </span><span class="cited-content_cbyCitation_article-title">PET microdosing of CNS drugs. </span><span class="cited-content_cbyCitation_journal-name">Clinical and Translational Imaging</span><span> <strong>2017,</strong> <em>5 </em>
                                    (3)
                                     , 291-298. <a href="https://doi.org/10.1007/s40336-017-0226-y" title="DOI URL">https://doi.org/10.1007/s40336-017-0226-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40336-017-0226-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40336-017-0226-y%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520and%2520Translational%2520Imaging%26atitle%3DPET%252Bmicrodosing%252Bof%252BCNS%252Bdrugs%26aulast%3DSchou%26aufirst%3DMagnus%26date%3D2017%26date%3D2017%26volume%3D5%26issue%3D3%26spage%3D291%26epage%3D298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shan  Xiong</span>, <span class="hlFld-ContribAuthor ">Mingxing  Xue</span>, <span class="hlFld-ContribAuthor ">Yanling  Mu</span>, <span class="hlFld-ContribAuthor ">Zhipeng  Deng</span>, <span class="hlFld-ContribAuthor ">Peilu  Sun</span>, <span class="hlFld-ContribAuthor ">Ruican  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Determination of AZD3759 in rat plasma and brain tissue by LC–MS/MS and its application in pharmacokinetic and brain distribution studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2017,</strong> <em>140 </em>, 362-366. <a href="https://doi.org/10.1016/j.jpba.2017.03.056" title="DOI URL">https://doi.org/10.1016/j.jpba.2017.03.056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2017.03.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2017.03.056%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DDetermination%252Bof%252BAZD3759%252Bin%252Brat%252Bplasma%252Band%252Bbrain%252Btissue%252Bby%252BLC%2525E2%252580%252593MS%25252FMS%252Band%252Bits%252Bapplication%252Bin%252Bpharmacokinetic%252Band%252Bbrain%252Bdistribution%252Bstudies%26aulast%3DXiong%26aufirst%3DShan%26date%3D2017%26volume%3D140%26spage%3D362%26epage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vineet  Talwar</span>, <span class="hlFld-ContribAuthor ">K.V.  Pradeep Babu</span>, <span class="hlFld-ContribAuthor ">Shubhra  Raina</span>. </span><span class="cited-content_cbyCitation_article-title">An overall review of targeted therapy in solid cancers. </span><span class="cited-content_cbyCitation_journal-name">Current Medicine Research and Practice</span><span> <strong>2017,</strong> <em>7 </em>
                                    (3)
                                     , 99-105. <a href="https://doi.org/10.1016/j.cmrp.2017.04.002" title="DOI URL">https://doi.org/10.1016/j.cmrp.2017.04.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cmrp.2017.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cmrp.2017.04.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicine%2520Research%2520and%2520Practice%26atitle%3DAn%252Boverall%252Breview%252Bof%252Btargeted%252Btherapy%252Bin%252Bsolid%252Bcancers%26aulast%3DTalwar%26aufirst%3DVineet%26date%3D2017%26volume%3D7%26issue%3D3%26spage%3D99%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hendra  Gunosewoyo</span>, <span class="hlFld-ContribAuthor ">Lifang  Yu</span>, <span class="hlFld-ContribAuthor ">Lenka  Munoz</span>, <span class="hlFld-ContribAuthor ">Michael  Kassiou</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase targets in CNS drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2017,</strong> <em>9 </em>
                                    (3)
                                     , 303-314. <a href="https://doi.org/10.4155/fmc-2016-0214" title="DOI URL">https://doi.org/10.4155/fmc-2016-0214</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2016-0214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2016-0214%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DKinase%252Btargets%252Bin%252BCNS%252Bdrug%252Bdiscovery%26aulast%3DGunosewoyo%26aufirst%3DHendra%26date%3D2017%26volume%3D9%26issue%3D3%26spage%3D303%26epage%3D314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Niki  Karachaliou</span>, <span class="hlFld-ContribAuthor ">Aaron E.  Sosa</span>, <span class="hlFld-ContribAuthor ">Feliciano Barron  Barron</span>, <span class="hlFld-ContribAuthor ">Maria  Gonzalez Cao</span>, <span class="hlFld-ContribAuthor ">Mariacarmela  Santarpia</span>, <span class="hlFld-ContribAuthor ">Rafael  Rosell</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological management of relapsed/refractory NSCLC with chemical drugs. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2017,</strong> <em>18 </em>
                                    (3)
                                     , 295-304. <a href="https://doi.org/10.1080/14656566.2017.1285284" title="DOI URL">https://doi.org/10.1080/14656566.2017.1285284</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2017.1285284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2017.1285284%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DPharmacological%252Bmanagement%252Bof%252Brelapsed%25252Frefractory%252BNSCLC%252Bwith%252Bchemical%252Bdrugs%26aulast%3DKarachaliou%26aufirst%3DNiki%26date%3D2017%26date%3D2017%26volume%3D18%26issue%3D3%26spage%3D295%26epage%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shi-rong  Zhang</span>, <span class="hlFld-ContribAuthor ">Lu-cheng  Zhu</span>, <span class="hlFld-ContribAuthor ">Yan-ping  Jiang</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Ru-jun  Xu</span>, <span class="hlFld-ContribAuthor ">Ya-si  Xu</span>, <span class="hlFld-ContribAuthor ">Bing  Xia</span>, <span class="hlFld-ContribAuthor ">Sheng-lin  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2017,</strong> <em>38 </em>
                                    (2)
                                     , 233-240. <a href="https://doi.org/10.1038/aps.2016.107" title="DOI URL">https://doi.org/10.1038/aps.2016.107</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/aps.2016.107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Faps.2016.107%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DEfficacy%252Bof%252Bafatinib%25252C%252Ban%252Birreversible%252BErbB%252Bfamily%252Bblocker%25252C%252Bin%252Bthe%252Btreatment%252Bof%252Bintracerebral%252Bmetastases%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bin%252Bmice%26aulast%3DZhang%26aufirst%3DShi-rong%26date%3D2017%26date%3D2016%26volume%3D38%26issue%3D2%26spage%3D233%26epage%3D240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivana  Sullivan</span>, <span class="hlFld-ContribAuthor ">David  Planchard</span>. </span><span class="cited-content_cbyCitation_article-title">Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Medicine</span><span> <strong>2017,</strong> <em>3 </em><a href="https://doi.org/10.3389/fmed.2016.00076" title="DOI URL">https://doi.org/10.3389/fmed.2016.00076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmed.2016.00076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmed.2016.00076%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Medicine%26atitle%3DNext-Generation%252BEGFR%252BTyrosine%252BKinase%252BInhibitors%252Bfor%252BTreating%252BEGFR-Mutant%252BLung%252BCancer%252Bbeyond%252BFirst%252BLine%26aulast%3DSullivan%26aufirst%3DIvana%26date%3D2017%26date%3D2017%26volume%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.A.  Mortlock</span>, <span class="hlFld-ContribAuthor ">D.M.  Wilson</span>, <span class="hlFld-ContribAuthor ">J.G.  Kettle</span>, <span class="hlFld-ContribAuthor ">F.W.  Goldberg</span>, <span class="hlFld-ContribAuthor ">K.M.  Foote</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Kinase Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 39-75. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12391-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12391-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12391-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12391-1%26sid%3Dliteratum%253Aachs%26atitle%3DSelective%252BKinase%252BInhibitors%252Bin%252BCancer%26aulast%3DMortlock%26aufirst%3DA.A.%26date%3D2017%26spage%3D39%26epage%3D75%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H.  Tsui</span>, <span class="hlFld-ContribAuthor ">Q.  Zeng</span>, <span class="hlFld-ContribAuthor ">K.  Chen</span>, <span class="hlFld-ContribAuthor ">X.  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibiting Kinases in the CNS. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 408-446. <a href="https://doi.org/10.1016/B978-0-12-409547-2.13815-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.13815-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.13815-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.13815-6%26sid%3Dliteratum%253Aachs%26atitle%3DInhibiting%252BKinases%252Bin%252Bthe%252BCNS%26aulast%3DTsui%26aufirst%3DH.%26date%3D2017%26spage%3D408%26epage%3D446%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fred R  Hirsch</span>, <span class="hlFld-ContribAuthor ">Giorgio V  Scagliotti</span>, <span class="hlFld-ContribAuthor ">James L  Mulshine</span>, <span class="hlFld-ContribAuthor ">Regina  Kwon</span>, <span class="hlFld-ContribAuthor ">Walter J  Curran</span>, <span class="hlFld-ContribAuthor ">Yi-Long  Wu</span>, <span class="hlFld-ContribAuthor ">Luis  Paz-Ares</span>. </span><span class="cited-content_cbyCitation_article-title">Lung cancer: current therapies and new targeted treatments. </span><span class="cited-content_cbyCitation_journal-name">The Lancet</span><span> <strong>2017,</strong> <em>389 </em>
                                    (10066)
                                     , 299-311. <a href="https://doi.org/10.1016/S0140-6736(16)30958-8" title="DOI URL">https://doi.org/10.1016/S0140-6736(16)30958-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/S0140-6736(16)30958-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FS0140-6736%2816%2930958-8%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Lancet%26atitle%3DLung%252Bcancer%25253A%252Bcurrent%252Btherapies%252Band%252Bnew%252Btargeted%252Btreatments%26aulast%3DHirsch%26aufirst%3DFred%2BR%26date%3D2017%26volume%3D389%26issue%3D10066%26spage%3D299%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianfei  Sheng</span>, <span class="hlFld-ContribAuthor ">Zhihong  Liu</span>, <span class="hlFld-ContribAuthor ">Ming  Yan</span>, <span class="hlFld-ContribAuthor ">Xuejing  Zhang</span>, <span class="hlFld-ContribAuthor ">Dejian  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Xu</span>, <span class="hlFld-ContribAuthor ">Ensheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Biomass-involved synthesis of N-substituted benzofuro[2,3-d]pyrimidine-4-amines and biological evaluation as novel EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2017,</strong> <em>15 </em>
                                    (23)
                                     , 4971-4977. <a href="https://doi.org/10.1039/C7OB00793K" title="DOI URL">https://doi.org/10.1039/C7OB00793K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7OB00793K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7OB00793K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DBiomass-involved%252Bsynthesis%252Bof%252BN-substituted%252Bbenzofuro%25255B2%25252C3-d%25255Dpyrimidine-4-amines%252Band%252Bbiological%252Bevaluation%252Bas%252Bnovel%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DSheng%26aufirst%3DJianfei%26date%3D2017%26date%3D2017%26volume%3D15%26issue%3D23%26spage%3D4971%26epage%3D4977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Z.  Yang</span>, <span class="hlFld-ContribAuthor ">Q.  Guo</span>, <span class="hlFld-ContribAuthor ">Y.  Wang</span>, <span class="hlFld-ContribAuthor ">K.  Chen</span>, <span class="hlFld-ContribAuthor ">L.  Zhang</span>, <span class="hlFld-ContribAuthor ">Z.  Cheng</span>, <span class="hlFld-ContribAuthor ">Y.  Xu</span>, <span class="hlFld-ContribAuthor ">X.  Yin</span>, <span class="hlFld-ContribAuthor ">Y.  Bai</span>, <span class="hlFld-ContribAuthor ">S.  Rabbie</span>, <span class="hlFld-ContribAuthor ">D.-W.  Kim</span>, <span class="hlFld-ContribAuthor ">M.-J.  Ahn</span>, <span class="hlFld-ContribAuthor ">J. C.-H.  Yang</span>, <span class="hlFld-ContribAuthor ">X.  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. </span><span class="cited-content_cbyCitation_journal-name">Science Translational Medicine</span><span> <strong>2016,</strong> <em>8 </em>
                                    (368)
                                     , 368ra172-368ra172. <a href="https://doi.org/10.1126/scitranslmed.aag0976" title="DOI URL">https://doi.org/10.1126/scitranslmed.aag0976</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/scitranslmed.aag0976&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscitranslmed.aag0976%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Translational%2520Medicine%26atitle%3DAZD3759%25252C%252Ba%252BBBB-penetrating%252BEGFR%252Binhibitor%252Bfor%252Bthe%252Btreatment%252Bof%252BEGFR%252Bmutant%252BNSCLC%252Bwith%252BCNS%252Bmetastases%26aulast%3DYang%26aufirst%3DZ.%26date%3D2016%26date%3D2016%26volume%3D8%26issue%3D368%26spage%3D368ra172%26epage%3D368ra172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ivana  Sullivan</span>, <span class="hlFld-ContribAuthor ">David  Planchard</span>. </span><span class="cited-content_cbyCitation_article-title">Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience. </span><span class="cited-content_cbyCitation_journal-name">Therapeutic Advances in Respiratory Disease</span><span> <strong>2016,</strong> <em>10 </em>
                                    (6)
                                     , 549-565. <a href="https://doi.org/10.1177/1753465816670498" title="DOI URL">https://doi.org/10.1177/1753465816670498</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1753465816670498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1753465816670498%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapeutic%2520Advances%2520in%2520Respiratory%2520Disease%26atitle%3DOsimertinib%252Bin%252Bthe%252Btreatment%252Bof%252Bpatients%252Bwith%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252BT790M%252Bmutation-positive%252Bmetastatic%252Bnon-small%252Bcell%252Blung%252Bcancer%25253A%252Bclinical%252Btrial%252Bevidence%252Band%252Bexperience%26aulast%3DSullivan%26aufirst%3DIvana%26date%3D2016%26date%3D2016%26volume%3D10%26issue%3D6%26spage%3D549%26epage%3D565" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang-Si  Li</span>, <span class="hlFld-ContribAuthor ">Ben-Yuan  Jiang</span>, <span class="hlFld-ContribAuthor ">Jin-Ji  Yang</span>, <span class="hlFld-ContribAuthor ">Hai-Yan  Tu</span>, <span class="hlFld-ContribAuthor ">Qing  Zhou</span>, <span class="hlFld-ContribAuthor ">Wei-Bang  Guo</span>, <span class="hlFld-ContribAuthor ">Hong-Hong  Yan</span>, <span class="hlFld-ContribAuthor ">Yi-Long  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thoracic Oncology</span><span> <strong>2016,</strong> <em>11 </em>
                                    (11)
                                     , 1962-1969. <a href="https://doi.org/10.1016/j.jtho.2016.06.029" title="DOI URL">https://doi.org/10.1016/j.jtho.2016.06.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtho.2016.06.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtho.2016.06.029%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thoracic%2520Oncology%26atitle%3DLeptomeningeal%252BMetastases%252Bin%252BPatients%252Bwith%252BNSCLC%252Bwith%252BEGFR%252BMutations%26aulast%3DLi%26aufirst%3DYang-Si%26date%3D2016%26volume%3D11%26issue%3D11%26spage%3D1962%26epage%3D1969" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E-->-E  -->Ke</span>, <span class="hlFld-ContribAuthor ">Yi-Long  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">EGFR as a Pharmacological Target in EGFR -Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2016,</strong> <em>37 </em>
                                    (11)
                                     , 887-903. <a href="https://doi.org/10.1016/j.tips.2016.09.003" title="DOI URL">https://doi.org/10.1016/j.tips.2016.09.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2016.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2016.09.003%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DEGFR%252Bas%252Ba%252BPharmacological%252BTarget%252Bin%252BEGFR%252B-Mutant%252BNon-Small-Cell%252BLung%252BCancer%25253A%252BWhere%252BDo%252BWe%252BStand%252BNow%25253F%26aulast%3D%252D%252D%253EKe%26aufirst%3DE%252D%252D%253E-E%26date%3D2016%26volume%3D37%26issue%3D11%26spage%3D887%26epage%3D903" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi  Zhang</span>, <span class="hlFld-ContribAuthor ">Yi-Long  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Surgery in oligometastatic NSCLC patients in the targeted therapy era. </span><span class="cited-content_cbyCitation_journal-name">Lung Cancer Management</span><span> <strong>2016,</strong> <em>5 </em>
                                    (3)
                                     , 141-153. <a href="https://doi.org/10.2217/lmt-2016-0012" title="DOI URL">https://doi.org/10.2217/lmt-2016-0012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/lmt-2016-0012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Flmt-2016-0012%26sid%3Dliteratum%253Aachs%26jtitle%3DLung%2520Cancer%2520Management%26atitle%3DSurgery%252Bin%252Boligometastatic%252BNSCLC%252Bpatients%252Bin%252Bthe%252Btargeted%252Btherapy%252Bera%26aulast%3DZhang%26aufirst%3DQi%26date%3D2016%26volume%3D5%26issue%3D3%26spage%3D141%26epage%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jason G.  Kettle</span>, <span class="hlFld-ContribAuthor ">David M.  Wilson</span>. </span><span class="cited-content_cbyCitation_article-title">Standing on the shoulders of giants: a retrospective analysis of kinase drug discovery at AstraZeneca. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2016,</strong> <em>21 </em>
                                    (10)
                                     , 1596-1608. <a href="https://doi.org/10.1016/j.drudis.2016.06.007" title="DOI URL">https://doi.org/10.1016/j.drudis.2016.06.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2016.06.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2016.06.007%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DStanding%252Bon%252Bthe%252Bshoulders%252Bof%252Bgiants%25253A%252Ba%252Bretrospective%252Banalysis%252Bof%252Bkinase%252Bdrug%252Bdiscovery%252Bat%252BAstraZeneca%26aulast%3DKettle%26aufirst%3DJason%2BG.%26date%3D2016%26volume%3D21%26issue%3D10%26spage%3D1596%26epage%3D1608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vyshak A.  Venur</span>, <span class="hlFld-ContribAuthor ">Manmeet S.  Ahluwalia</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Therapy in Brain Metastases: Ready for Primetime?. </span><span class="cited-content_cbyCitation_journal-name">American Society of Clinical Oncology Educational Book</span><span> <strong>2016,</strong> <em> </em>
                                    (36)
                                     , e123-e130. <a href="https://doi.org/10.1200/EDBK_100006" title="DOI URL">https://doi.org/10.1200/EDBK_100006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1200/EDBK_100006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1200%2FEDBK_100006%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Society%2520of%2520Clinical%2520Oncology%2520Educational%2520Book%26atitle%3DTargeted%252BTherapy%252Bin%252BBrain%252BMetastases%25253A%252BReady%252Bfor%252BPrimetime%25253F%26aulast%3DVenur%26aufirst%3DVyshak%2BA.%26date%3D2016%26issue%3D36%26spage%3De123%26epage%3De130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vadim  Bernard-Gauthier</span>, <span class="hlFld-ContribAuthor ">Justin  Bailey</span>, <span class="hlFld-ContribAuthor ">Sheldon  Berke</span>, <span class="hlFld-ContribAuthor ">Ralf  Schirrmacher</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2015,</strong> <em>20 </em>
                                    (12)
                                     , 22000-22027. <a href="https://doi.org/10.3390/molecules201219816" title="DOI URL">https://doi.org/10.3390/molecules201219816</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules201219816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules201219816%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDevelopment%252Band%252BApplication%252Bof%252BRadiolabeled%252BKinase%252BInhibitors%252Bfor%252BPET%252BImaging%26aulast%3DBernard-Gauthier%26aufirst%3DVadim%26date%3D2015%26date%3D2015%26volume%3D20%26issue%3D12%26spage%3D22000%26epage%3D22027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0017.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Approved EGFR Kinase Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Design Strategy Starting from Gefitinib as an Initial Lead</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0001.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Color-coded PET images showing the distribution of radioactivity in the monkey brain following the administration of [<sup>11</sup>C]-<b>1m</b>. Horizontal (left panel), coronal (middle panel), and sagittal (right panel) projections for monkey PET1 (A) and Monkey PET2 (B). Images created from summation images from 5 to 123 min, and image intensity is normalized for injected radioactivity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. A brain metastasis model was established by injection of luciferase transfected PC-9 cells into the brain parenchyma. Tumor growth was monitored by measuring bioluminescence signals. Approximately 2–3 weeks after cell injection, animals were treated with erlotinib at 15 mg/kg qd and <b>1m</b> at 7.5 and 15 mg/kg qd, respectively. (A) Significant tumor growth inhibition was observed by <b>1m</b> treatment in a dose-dependent manner compared with that of erlotinib. (B) Histological assessment showed a dose-dependent reduction of tumor area with <b>1m</b> treatment. (C) Modulation of pEGFR in tumor tissue was observed by a single dose of <b>1m</b> at 15 mg/kg 1 h after dosing (at 1× and 20× amplification).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Intermediates <b>6</b> and <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) acetonitrile, reflux, 4 h; (ii) potassium carbonate, methanol, 10–15 °C, 2 h; (iii) triphosgene, pyridine, dichloromethane, 0 °C to rt.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>1a</b> and <b>1c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Tf<sub>2</sub>O, pyridine, 5 °C to rt; (ii) CO, Pd(OAc)<sub>2</sub>, dppf, morpholine, 70 °C, overnight; (iii) methyl acrylate, Pd(OAc)<sub>2</sub>, Et<sub>3</sub>N, dppf, Bu<sub>4</sub>NBr, DMF, 80 °C, overnight; (iv) O<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, −78 °C then (CH<sub>3</sub>)<sub>2</sub>S, −78 °C to rt; (v) morpholine, NaBH<sub>3</sub>CN, acetic acid, rt.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>1b</b> and <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Tf<sub>2</sub>O, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 16 h; (ii) morpholine, CH<sub>3</sub>CN, reflux, overnight; (iii) Fe, NH<sub>4</sub>Cl, CH<sub>3</sub>OH, H<sub>2</sub>O, 80 °C, 4 h; (iv) formamidine acetate salt, C<sub>2</sub>H<sub>5</sub>OH, reflux, overnight; (v) oxalyl chloride, CHCl<sub>3</sub>, DMF, 60 °C, 2 h; (vi) 3-chloro-2-fluoroaniline, CH<sub>3</sub>CN, reflux, 18 h; (vii) 3-chloro-4-fluoroaniline, CH<sub>3</sub>CN, reflux, 2 days.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0008.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. General Synthesis of Compounds <b>1d</b>–<b>h</b>, <b>1k-l</b>, and <b>1n</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) (C<sub>2</sub>H<sub>5</sub>)<sub>3</sub>N or K<sub>2</sub>CO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub> or DMF, rt.</p></p></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0009.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of <b>1i</b> and <b>1j</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) K<sub>2</sub>CO<sub>3</sub>, DMF, rt, overnight; (ii) HCl, 1,4-dioxane, ethyl acetate, rt, 1 h; (iii) paraformaldehyde, NaBH<sub>3</sub>CN, CH<sub>3</sub>CO<sub>2</sub>H, methanol, rt, overnight; (iv) chiral SFC.</p></p></figure><figure data-id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/medium/jm-2015-010738_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0010.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of <b>1m</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-20/acs.jmedchem.5b01073/20151016/images/large/jm-2015-010738_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01073&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions and reagents: (i) potassium carbonate, DMF, rt; (ii) HCl in dioxane, methanol, rt; (iii) paraformaldehyde, sodium cyanoborohydride, methanol, rt.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i64">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54610" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54610" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 45 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Molina, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cassivi, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schild, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alex, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Non–small cell lung cancer: epidemiology, risk factors, treatment, and survivorship</span> <span class="citation_source-journal">Mayo Clin. Proc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">584</span><span class="NLM_x">–</span> <span class="NLM_lpage">594</span><span class="refDoi"> DOI: 10.1016/S0025-6196(11)60735-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2FS0025-6196%2811%2960735-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=18452692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BD1c3ovFyhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2008&pages=584-594&author=J.+R.+Molinaauthor=P.+Yangauthor=S.+D.+Cassiviauthor=S.+E.+Schildauthor=A.+Alexauthor=A.+A.+Adjei&title=Non%E2%80%93small+cell+lung+cancer%3A+epidemiology%2C+risk+factors%2C+treatment%2C+and+survivorship&doi=10.1016%2FS0025-6196%2811%2960735-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship</span></div><div class="casAuthors">Molina Julian R; Yang Ping; Cassivi Stephen D; Schild Steven E; Adjei Alex A</div><div class="citationInfo"><span class="NLM_cas:title">Mayo Clinic proceedings</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">584-94</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung cancer is the leading cause of cancer-related mortality not only in the United States but also around the world.  In North America, lung cancer has become more predominant among former than current smokers.  Yet in some countries, such as China, which has experienced a dramatic increase in the cigarette smoking rate during the past 2 decades, a peak in lung cancer incidence is still expected.  Approximately two-thirds of adult Chinese men are smokers, representing one-third of all smokers worldwide.  Non-small cell lung cancer accounts for 85% of all lung cancer cases in the United States.  After the initial diagnosis, accurate staging of non-small cell lung cancer using computed tomography or positron emission tomography is crucial for determining appropriate therapy.  When feasible, surgical resection remains the single most consistent and successful option for cure.  However, close to 70% of patients with lung cancer present with locally advanced or metastatic disease at the time of diagnosis.  Chemotherapy is beneficial for patients with metastatic disease, and the administration of concurrent chemotherapy and radiation is indicated for stage III lung cancer.  The introduction of angiogenesis, epidermal growth factor receptor inhibitors, and other new anti-cancer agents is changing the present and future of this disease and will certainly increase the number of lung cancer survivors.  We identified studies for this review by searching the MEDLINE and PubMed databases for English-language articles published from January 1, 1980, through January 31, 2008.  Key terms used for this search included non-small cell lung cancer, adenocarcinoma, squamous cell carcinoma, bronchioalveolar cell carcinoma, large cell carcinoma, lung cancer epidemiology, genetics, survivorship, surgery, radiation therapy, chemotherapy, targeted therapy, bevacizumab, erlotinib, and epidermal growth factor receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmyOu2OSFHeW52AMpI4GK2fW6udTcc2eaTZAzGiwTMcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c3ovFyhtQ%253D%253D&md5=7d7f1147c10a3c6b0fd344757694b4aa</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS0025-6196%2811%2960735-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0025-6196%252811%252960735-0%26sid%3Dliteratum%253Aachs%26aulast%3DMolina%26aufirst%3DJ.%2BR.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DCassivi%26aufirst%3DS.%2BD.%26aulast%3DSchild%26aufirst%3DS.%2BE.%26aulast%3DAlex%26aufirst%3DA.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DNon%25E2%2580%2593small%2520cell%2520lung%2520cancer%253A%2520epidemiology%252C%2520risk%2520factors%252C%2520treatment%252C%2520and%2520survivorship%26jtitle%3DMayo%2520Clin.%2520Proc.%26date%3D2008%26volume%3D83%26spage%3D584%26epage%3D594%26doi%3D10.1016%2FS0025-6196%2811%2960735-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Cancer Statistics, 2014</span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.3322/caac.21208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.3322%2Fcaac.21208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=24399786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BC2czjtVOlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2014&pages=9-22&author=R.+Siegelauthor=J.+Maauthor=Z.+Zouauthor=A.+Jemal&title=Cancer+Statistics%2C+2014&doi=10.3322%2Fcaac.21208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2014</span></div><div class="casAuthors">Siegel Rebecca; Ma Jiemin; Zou Zhaohui; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival.  Incidence data were collected by the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data were collected by the National Center for Health Statistics.  A total of 1,665,540 new cancer cases and 585,720 cancer deaths are projected to occur in the United States in 2014.  During the most recent 5 years for which there are data (2006-2010), delay-adjusted cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.4% per year in women.  The combined cancer death rate (deaths per 100,000 population) has been continuously declining for 2 decades, from a peak of 215.1 in 1991 to 171.8 in 2010.  This 20% decline translates to the avoidance of approximately 1,340,400 cancer deaths (952,700 among men and 387,700 among women) during this time period.  The magnitude of the decline in cancer death rates from 1991 to 2010 varies substantially by age, race, and sex, ranging from no decline among white women aged 80 years and older to a 55% decline among black men aged 40 years to 49 years.  Notably, black men experienced the largest drop within every 10-year age group.  Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-53QNNisGn5agfuraLLzSfW6udTcc2eaTZAzGiwTMcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czjtVOlsw%253D%253D&md5=2aa85d07bbfc7838e1d0e6bf94ce6c46</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21208%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DZ.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520Statistics%252C%25202014%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2014%26volume%3D64%26spage%3D9%26epage%3D22%26doi%3D10.3322%2Fcaac.21208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span><span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0li3f4CyVP6cbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Mok, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, D.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunpaweravong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margono, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishiwaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chewaskulyong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duffield, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuoka, M.</span><span> </span><span class="NLM_article-title">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">947</span><span class="NLM_x">–</span> <span class="NLM_lpage">957</span><span class="refDoi"> DOI: 10.1056/NEJMoa0810699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1056%2FNEJMoa0810699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=19692680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=947-957&author=T.+S.+Mokauthor=Y.-L.+Wuauthor=S.+Thongprasertauthor=C.-H.+Yangauthor=D.-T.+Chuauthor=N.+Saijoauthor=P.+Sunpaweravongauthor=B.+Hanauthor=B.+Margonoauthor=Y.+Ichinoseauthor=Y.+Nishiwakiauthor=Y.+Oheauthor=J.-J.+Yangauthor=B.+Chewaskulyongauthor=H.+Jiangauthor=E.+L.+Duffieldauthor=C.+L.+Watkinsauthor=A.+A.+Armourauthor=M.+Fukuoka&title=Gefitinib+or+carboplatin-paclitaxel+in+pulmonary+adenocarcinoma&doi=10.1056%2FNEJMoa0810699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</span></div><div class="casAuthors">Mok, Tony S.; Wu, Yi-Long; Thongprasert, Sumitra; Yang, Chih-Hsin; Chu, Da-Tong; Saijo, Nagahiro; Sunpaweravong, Patrapim; Han, Baohui; Margono, Benjamin; Ichinose, Yukito; Nishiwaki, Yutaka; Ohe, Yuichiro; Yang, Jin-Ji; Chewaskulyong, Busyamas; Jiang, Haiyi; Duffield, Emma L.; Watkins, Claire L.; Armour, Alison A.; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-957</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer.  METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calcd. to produce an area under the curve of 5 or 6 mg per mL per min) plus paclitaxel (200 mg per square meter of body-surface area) (608 patients).  The primary end point was progression-free survival.  RESULTS: The 12-mo rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel.  The study met its primary objective of showing the noninferiority of gefitinib and also showed its superiority, as compared with carboplatin-paclitaxel, with respect to progression-free survival in the intention-to-treat population (hazard ratio for progression or death, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P < 0.001).  In the subgroup of 261 patients who were pos. for the epidermal growth factor receptor gene (EGFR) mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin-paclitaxel (hazard ratio for progression or death, 0.48; 95% CI, 0.36 to 0.64; P < 0.001), whereas in the subgroup of 176 patients who were neg. for the mutation, progression-free survival was significantly longer among those who received carboplatin-paclitaxel (hazard ratio for progression or death with gefitinib, 2.85; 95% CI, 2.05 to 3.98; P < 0.001).  The most common adverse events were rash or acne (in 66.2% of patients) and diarrhea (46.6%) in the gefitinib group and neurotoxic effects (69.9%), neutropenia (67.1%), and alopecia (58.4%) in the carboplatin-paclitaxel group.  CONCLUSIONS: Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia.  The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwKhpFOiEQu7Vg90H21EOLACvtfcHk0li3f4CyVP6cbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVygsbfK&md5=31ce0983eedb9f248dcf0726adf18b88</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0810699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0810699%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%2BS.%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.-H.%26aulast%3DChu%26aufirst%3DD.-T.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DSunpaweravong%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DB.%26aulast%3DMargono%26aufirst%3DB.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DNishiwaki%26aufirst%3DY.%26aulast%3DOhe%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.-J.%26aulast%3DChewaskulyong%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DDuffield%26aufirst%3DE.%2BL.%26aulast%3DWatkins%26aufirst%3DC.%2BL.%26aulast%3DArmour%26aufirst%3DA.%2BA.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520or%2520carboplatin-paclitaxel%2520in%2520pulmonary%2520adenocarcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D947%26epage%3D957%26doi%3D10.1056%2FNEJMoa0810699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Shepherd, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciuleanu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maoleekoonpiroj, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smylie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kooten, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dediu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findlay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezjak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santabarbara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, L.</span><span> </span><span class="NLM_article-title">Erlotinib in previously treated non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1056/NEJMoa050753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1056%2FNEJMoa050753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=16014882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=123-132&author=F.+A.+Shepherdauthor=J.+R.+Pereiraauthor=T.+Ciuleanuauthor=E.+H.+Tanauthor=V.+Hirshauthor=S.+Thongprasertauthor=D.+Camposauthor=S.+Maoleekoonpirojauthor=M.+Smylieauthor=R.+Martinsauthor=M.+V.+Kootenauthor=M.+Dediuauthor=B.+Findlayauthor=D.+Tuauthor=D.+Johnstonauthor=A.+Bezjakauthor=G.+Clarkauthor=P.+Santabarbaraauthor=L.+Seymour&title=Erlotinib+in+previously+treated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa050753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib in previously treated non-small-cell lung cancer</span></div><div class="casAuthors">Shepherd, Frances A.; Pereira, Jose Rodrigues; Ciuleanu, Tudor; Tan, Eng Huat; Hirsh, Vera; Thongprasert, Sumitra; Campos, Daniel; Maoleekoonpiroj, Savitree; Smylie, Michael; Martins, Renato; van Kooten, Maximiliano; Dediu, Mircea; Findlay, Brian; Tu, Dongsheng; Johnston, Dianne; Bezjk, Andrea; Clark, Gary; Santabarbara, Pedro; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a randomized, placebo-controlled, double-blind trial to det. whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy.  Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens.  The patients were stratified according to center, performance status, response to prior chemotherapy, no. of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo.  The median age of the 731 patients who underwent randomization was 61.4 yeas; 49 % had received two prior chemotherapy regimens, and 93 % had received platinum-based chemotherapy.  The response rate was 8.9 % in the erlotinib group and less than 1 % in the placebo group (P < 0.001); the median duration of the response wa 7.9 mo and 3.7 mo, resp.  Progression-free survival was 2.2 mo and 1.8 mo, resp. (hazard ratio, 0.61, adjusted for stratification categories; P < 0.001).  Overall survival was 6.7 mo and 4.7 mo, resp. (hazard ratio, 0.70; P < 0.001), in favor of erlotinib.  Five percent of patients discontinued erlotinib because of toxic effects.  Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr8tjSBsYtbVg90H21EOLACvtfcHk0li3f4CyVP6cbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D&md5=1633999cf09b8387ad88f40f75a5bb93</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050753%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DPereira%26aufirst%3DJ.%2BR.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DCampos%26aufirst%3DD.%26aulast%3DMaoleekoonpiroj%26aufirst%3DS.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3DKooten%26aufirst%3DM.%2BV.%26aulast%3DDediu%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DB.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DD.%26aulast%3DBezjak%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DSantabarbara%26aufirst%3DP.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DErlotinib%2520in%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D123%26epage%3D132%26doi%3D10.1056%2FNEJMoa050753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Cataldo, V. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Soler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintás-Cardama, A.</span><span> </span><span class="NLM_article-title">Treatment of non–small-cell lung cancer with erlotinib or gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">947</span><span class="NLM_x">–</span> <span class="NLM_lpage">955</span><span class="refDoi"> DOI: 10.1056/NEJMct0807960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1056%2FNEJMct0807960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=21388312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFentbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=947-955&author=V.+D.+Cataldoauthor=D.+L.+Gibbonsauthor=R.+P%C3%A9rez-Solerauthor=A.+Quint%C3%A1s-Cardama&title=Treatment+of+non%E2%80%93small-cell+lung+cancer+with+erlotinib+or+gefitinib&doi=10.1056%2FNEJMct0807960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of non-small-cell lung cancer with erlotinib or gefitinib</span></div><div class="casAuthors">Cataldo, Vince D.; Gibbons, Don L.; Perez-Soler, Roman; Quintas-Cardama, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-955</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraDIxHbNbHr7Vg90H21EOLACvtfcHk0liv8HoYixepgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFentbg%253D&md5=5030feb97e5b6b09e3e11d6946cde577</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1056%2FNEJMct0807960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMct0807960%26sid%3Dliteratum%253Aachs%26aulast%3DCataldo%26aufirst%3DV.%2BD.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DP%25C3%25A9rez-Soler%26aufirst%3DR.%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26atitle%3DTreatment%2520of%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%2520with%2520erlotinib%2520or%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D947%26epage%3D955%26doi%3D10.1056%2FNEJMct0807960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Wu, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massey, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geater, S. L.</span><span> </span><span class="NLM_article-title">Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span><span class="refDoi"> DOI: 10.1016/S1470-2045(13)70604-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2FS1470-2045%2813%2970604-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=24439929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtF2gu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=213-222&author=Y.-L.+Wuauthor=C.+Zhouauthor=C.-P.+Huauthor=J.+Fengauthor=S.+Luauthor=Y.+Huangauthor=W.+Liauthor=M.+Houauthor=J.+H.+Shiauthor=K.-Y.+Leeauthor=C.+R.+Xuauthor=D.+Masseyauthor=M.+Kimauthor=Y.+Shiauthor=S.+L.+Geater&title=Afatinib+versus+cisplatin+plus+gemcitabine+for+first-line+treatment+of+Asian+patients+with+advanced+non-small-cell+lung+cancer+harbouring+EGFR+mutations+%28LUX-Lung+6%29%3A+an+open-label%2C+randomised+phase+3+trial&doi=10.1016%2FS1470-2045%2813%2970604-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial</span></div><div class="casAuthors">Wu, Yi-Long; Zhou, Caicun; Hu, Cheng-Ping; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Li, Wei; Hou, Mei; Shi, Jian Hua; Lee, Kye Young; Xu, Chong-Rui; Massey, Dan; Kim, Miyoung; Shi, Yang; Geater, Sarayut L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-222</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Afatinib-an oral irreversible ErbB family blocker-improves progression-free survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR mutation-pos. advanced non-small-cell lung cancer (NSCLC).  We compared afatinib with gemcitabine and cisplatin-a chemotherapy regimen widely used in Asia-for first-line treatment of Asian patients with EGFR mutation-pos. advanced NSCLC.This open-label, randomised phase 3 trial was done at 36 centers in China, Thailand, and South Korea.  After central testing for EGFR mutations, treatment-naive patients (stage IIIB or IV cancer [American Joint Committee on Cancer version 6], performance status 0-1) were randomly assigned (2:1) to receive either oral afatinib (40 mg per day) or i.v. gemcitabine 1000 mg/m2 on day 1 and day 8 plus cisplatin 75 mg/m2 on day 1 of a 3-wk schedule for up to six cycles.  Randomisation was done centrally with a random no.-generating system and an interactive internet and voice-response system.  Randomisation was stratified by EGFR mutation (Leu858Arg, exon 19 deletions, or other; block size three).  Clinicians and patients were not masked to treatment assignment, but the independent central imaging review group were.  Treatment continued until disease progression, intolerable toxic effects, or withdrawal of consent.  The primary endpoint was progression-free survival assessed by independent central review (intention-to-treat population).  This study is registered with ClinicalTrials.gov, NCT01121393.910 patients were screened and 364 were randomly assigned (242 to afatinib, 122 to gemcitabine and cisplatin).  Median progression-free survival was significantly longer in the afatinib group (11·0 mo, 95% CI 9·7-13·7) than in the gemcitabine and cisplatin group (5·6 mo, 5·1-6·7; hazard ratio 0·28, 95% CI 0·20-0·39; p<0·0001).  The most common treatment-related grade 3 or 4 adverse events in the afatinib group were rash or acne (35 [14·6%] of 239 patients), diarrhoea (13 [5·4%]), and stomatitis or mucositis (13 [5·4%]), compared with neutropenia (30 [26·5%] of 113 patients), vomiting (22 [19·5%]), and leucopenia (17 [15·0%]) in the gemcitabine and cisplatin group.  Treatment-related serious adverse events occurred in 15 (6·3%) patients in the afatinib group and nine (8·0%) patients in the gemcitabine and cisplatin group.First-line afatinib significantly improves progression-free survival with a tolerable and manageable safety profile in Asian patients with EGFR mutation-pos. advanced lung NSCLC.  Afatinib should be considered as a first-line treatment option for this patient population.Boehringer Ingelheim.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOB23gvDAjnbVg90H21EOLACvtfcHk0lirRb6--IOfmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtF2gu78%253D&md5=9c496689c6b40e1682e7d3786d9ae1b9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970604-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970604-1%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DC.-P.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DHou%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DK.-Y.%26aulast%3DXu%26aufirst%3DC.%2BR.%26aulast%3DMassey%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DGeater%26aufirst%3DS.%2BL.%26atitle%3DAfatinib%2520versus%2520cisplatin%2520plus%2520gemcitabine%2520for%2520first-line%2520treatment%2520of%2520Asian%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520harbouring%2520EGFR%2520mutations%2520%2528LUX-Lung%25206%2529%253A%2520an%2520open-label%252C%2520randomised%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D213%26epage%3D222%26doi%3D10.1016%2FS1470-2045%2813%2970604-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Barajas, R. F.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cha, S.</span><span> </span><span class="NLM_article-title">Imaging diagnosis of brain metastasis</span> <span class="citation_source-journal">Prog. Neurol. Surg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span><span class="refDoi"> DOI: 10.1159/000331174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1159%2F000331174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=22236668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BC387jslKqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=55-73&author=R.+F.+Barajasauthor=S.+Cha&title=Imaging+diagnosis+of+brain+metastasis&doi=10.1159%2F000331174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Imaging diagnosis of brain metastasis</span></div><div class="casAuthors">Barajas Ramon Francisco Jr; Cha Soonmee</div><div class="citationInfo"><span class="NLM_cas:title">Progress in neurological surgery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">55-73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Hematogeneous spread of primary neoplasm can result in central nervous system (CNS) disease burden in various anatomically distinct regions; calvarial, pachymeningeal, leptomeningeal, and intraparenchymal.  The choice of imaging modality is dependent on the individual clinical situation, but, largely depends on the patients overall clinical status and the information needed to make treatment decisions.  Contrast-enhanced magnetic resonance (MR) imaging is the preferred imaging modality of choice; however, computed tomography (CT) is often utilized as the first-pass screening modality for CNS disease.  Despite the superior soft tissue resolution, multiplanar capability, and noninvasive nature of MR imaging, T(1)- and T(2)-weighted sequences are limited to delineating morphologic anatomical deraignment of tissues by tumor.  Several physiology based MR imaging sequences have been developed which compliment anatomic MR imaging.  Proton magnetic resonance spectroscopic and dynamic susceptibility contrast-enhanced perfusion-weighted imaging are two physiologic sequences which add additional diagnostic information allowing for improved tumor characterization.  Common pitfalls in evaluating for metastatic disease burden include the misidentification of non-neoplastic hematomas, remote microvascular ischemia, and acute onset of ischemic stroke.  In the pediatric population, CNS metastases are rare; however, the onset of acute neurological symptoms in a child with known primary tumor should prompt imaging of the neuroaxis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTand0BT_8r3ynGiHuhFGv8fW6udTcc2eai8FcYcBwSZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387jslKqug%253D%253D&md5=0e6759877f00cf541284824dabe2c7e1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1159%2F000331174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000331174%26sid%3Dliteratum%253Aachs%26aulast%3DBarajas%26aufirst%3DR.%2BF.%26aulast%3DCha%26aufirst%3DS.%26atitle%3DImaging%2520diagnosis%2520of%2520brain%2520metastasis%26jtitle%3DProg.%2520Neurol.%2520Surg.%26date%3D2012%26volume%3D25%26spage%3D55%26epage%3D73%26doi%3D10.1159%2F000331174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Nguyen, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemanski, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vinh-Hung, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altdorfer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsson, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ampil, F.</span><span> </span><span class="NLM_article-title">Potential applications of imaging and image-guided radiotherapy for brain metastases and glioblastoma to improve patient quality of life</span> <span class="citation_source-journal">Front. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="refDoi"> DOI: 10.3389/fonc.2013.00284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.3389%2Ffonc.2013.00284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=24312897" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BC2cflsVamtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=284&author=N.+P.+Nguyenauthor=M.+L.+Nguyenauthor=J.+Vockauthor=C.+Lemanskiauthor=C.+Kerrauthor=V.+Vinh-Hungauthor=A.+Chiauthor=R.+Khanauthor=W.+Woodsauthor=G.+Altdorferauthor=M.+D%E2%80%99Andreaauthor=U.+Karlssonauthor=R.+Hamiltonauthor=F.+Ampil&title=Potential+applications+of+imaging+and+image-guided+radiotherapy+for+brain+metastases+and+glioblastoma+to+improve+patient+quality+of+life&doi=10.3389%2Ffonc.2013.00284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Potential applications of imaging and image-guided radiotherapy for brain metastases and glioblastoma to improve patient quality of life</span></div><div class="casAuthors">Nguyen Nam P; Nguyen Mai L; Vock Jacqueline; Lemanski Claire; Kerr Christine; Vinh-Hung Vincent; Chi Alexander; Khan Rihan; Woods William; Altdorfer Gabor; D'Andrea Mark; Karlsson Ulf; Hamilton Russ; Ampil Fred</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">284</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of glioblastoma multiforme (GBM) and brain metastasis remains a challenge because of the poor survival and the potential for brain damage following radiation.  Despite concurrent chemotherapy and radiation dose escalation, local recurrence remains the predominant pattern of failure in GBM most likely secondary to repopulation of cancer stem cells.  Even though radiotherapy is highly effective for local control of radio-resistant tumors such as melanoma and renal cell cancer, systemic disease progression is the cause of death in most patients with brain metastasis.  Preservation of quality of life (QOL) of cancer survivors is the main issue for patients with brain metastasis.  Image-guided radiotherapy (IGRT) by virtue of precise radiation dose delivery may reduce treatment time of patients with GBM without excessive toxicity and potentially improve neurocognitive function with preservation of local control in patients with brain metastasis.  Future prospective trials for primary brain tumors or brain metastasis should include IGRT to assess its efficacy to improve patient QOL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJvBOhVCPyOCEJCPKhJPuqfW6udTcc2eai8FcYcBwSZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflsVamtQ%253D%253D&md5=28575349bc8b2b0ce41ec15433ec2e86</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2013.00284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2013.00284%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DN.%2BP.%26aulast%3DNguyen%26aufirst%3DM.%2BL.%26aulast%3DVock%26aufirst%3DJ.%26aulast%3DLemanski%26aufirst%3DC.%26aulast%3DKerr%26aufirst%3DC.%26aulast%3DVinh-Hung%26aufirst%3DV.%26aulast%3DChi%26aufirst%3DA.%26aulast%3DKhan%26aufirst%3DR.%26aulast%3DWoods%26aufirst%3DW.%26aulast%3DAltdorfer%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DM.%26aulast%3DKarlsson%26aufirst%3DU.%26aulast%3DHamilton%26aufirst%3DR.%26aulast%3DAmpil%26aufirst%3DF.%26atitle%3DPotential%2520applications%2520of%2520imaging%2520and%2520image-guided%2520radiotherapy%2520for%2520brain%2520metastases%2520and%2520glioblastoma%2520to%2520improve%2520patient%2520quality%2520of%2520life%26jtitle%3DFront.%2520Oncol.%26date%3D2013%26volume%3D3%26spage%3D284%26doi%3D10.3389%2Ffonc.2013.00284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Nayak, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, P. Y.</span><span> </span><span class="NLM_article-title">Epidemiology of brain metastases</span> <span class="citation_source-journal">Curr. Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">54</span><span class="refDoi"> DOI: 10.1007/s11912-011-0203-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1007%2Fs11912-011-0203-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=22012633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BC387nsVymtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=48-54&author=L.+Nayakauthor=E.+Q.+Leeauthor=P.+Y.+Wen&title=Epidemiology+of+brain+metastases&doi=10.1007%2Fs11912-011-0203-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of brain metastases</span></div><div class="casAuthors">Nayak Lakshmi; Lee Eudocia Quant; Wen Patrick Y</div><div class="citationInfo"><span class="NLM_cas:title">Current oncology reports</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-54</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Brain metastases are one of the most common neurologic complications of cancer.  The incidence is 9%-17% based on various studies, although the exact incidence is thought to be higher.  The incidence is increasing with the availability of improved imaging techniques which aid early diagnosis, and effective systemic treatment regimens which prolong life, thus allowing cancer to disseminate to the brain.  Lung cancer, breast cancer, and melanoma are the most frequent to develop brain metastases, and account for 67%-80% of all cancers.  Most patients with brain metastases have synchronous extracerebral metastases.  Some patients present with no known primary cancer diagnosis.  In children, brain metastases are rare; germ cell tumors, sarcomas, and neuroblastoma are the common offenders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSXIJRn58ZYAfIW7hznt0zpfW6udTcc2eaB-T66-LQn_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387nsVymtw%253D%253D&md5=441177f538efd8fb60f13df12602117e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs11912-011-0203-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-011-0203-y%26sid%3Dliteratum%253Aachs%26aulast%3DNayak%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DE.%2BQ.%26aulast%3DWen%26aufirst%3DP.%2BY.%26atitle%3DEpidemiology%2520of%2520brain%2520metastases%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2012%26volume%3D14%26spage%3D48%26epage%3D54%26doi%3D10.1007%2Fs11912-011-0203-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Gril, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeg, P. S.</span><span> </span><span class="NLM_article-title">Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1204</span><span class="NLM_x">–</span> <span class="NLM_lpage">1210</span><span class="refDoi"> DOI: 10.1016/j.ejca.2010.02.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2Fj.ejca.2010.02.033" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2010&pages=1204-1210&author=B.+Grilauthor=L.+Evansauthor=D.+Palmieriauthor=P.+S.+Steeg&title=Translational+research+in+brain+metastasis+is+identifying+molecular+pathways+that+may+lead+to+the+development+of+new+therapeutic+strategies&doi=10.1016%2Fj.ejca.2010.02.033"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2010.02.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2010.02.033%26sid%3Dliteratum%253Aachs%26aulast%3DGril%26aufirst%3DB.%26aulast%3DEvans%26aufirst%3DL.%26aulast%3DPalmieri%26aufirst%3DD.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26atitle%3DTranslational%2520research%2520in%2520brain%2520metastasis%2520is%2520identifying%2520molecular%2520pathways%2520that%2520may%2520lead%2520to%2520the%2520development%2520of%2520new%2520therapeutic%2520strategies%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2010%26volume%3D46%26spage%3D1204%26epage%3D1210%26doi%3D10.1016%2Fj.ejca.2010.02.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Grommes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holodny, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassman, A. B.</span><span> </span><span class="NLM_article-title">Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer</span> <span class="citation_source-journal">Neuro-Oncology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1364</span><span class="NLM_x">–</span> <span class="NLM_lpage">1369</span><span class="refDoi"> DOI: 10.1093/neuonc/nor121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1093%2Fneuonc%2Fnor121" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=1364-1369&author=C.+Grommesauthor=G.+R.+Oxnardauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=W.+Paoauthor=A.+I.+Holodnyauthor=J.+L.+Clarkeauthor=A.+B.+Lassman&title=Pulsatile%E2%80%9D+high-dose+weekly+erlotinib+for+CNS+metastases+from+EGFR+mutant+non-small+cell+lung+cancer&doi=10.1093%2Fneuonc%2Fnor121"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnor121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnor121%26sid%3Dliteratum%253Aachs%26aulast%3DGrommes%26aufirst%3DC.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DHolodny%26aufirst%3DA.%2BI.%26aulast%3DClarke%26aufirst%3DJ.%2BL.%26aulast%3DLassman%26aufirst%3DA.%2BB.%26atitle%3DPulsatile%25E2%2580%259D%2520high-dose%2520weekly%2520erlotinib%2520for%2520CNS%2520metastases%2520from%2520EGFR%2520mutant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DNeuro-Oncology%26date%3D2011%26volume%3D13%26spage%3D1364%26epage%3D1369%26doi%3D10.1093%2Fneuonc%2Fnor121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Jackman, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindeman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesari, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borras, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bailey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jong, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span> </span><span class="NLM_article-title">Response and resistance in a non–small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4517</span><span class="NLM_x">–</span> <span class="NLM_lpage">4520</span><span class="refDoi"> DOI: 10.1200/JCO.2006.06.6126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1200%2FJCO.2006.06.6126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=16983123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BD28rlslemtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=4517-4520&author=D.+M.+Jackmanauthor=A.+J.+Holmesauthor=N.+Lindemanauthor=P.+Y.+Wenauthor=S.+Kesariauthor=A.+M.+Borrasauthor=C.+Baileyauthor=F.+D.+Jongauthor=P.+A.+J%C3%A4nneauthor=B.+E.+Johnson&title=Response+and+resistance+in+a+non%E2%80%93small-cell+lung+cancer+patient+with+an+epidermal+growth+factor+receptor+mutation+and+leptomeningeal+metastases+treated+with+high-dose+gefitinib&doi=10.1200%2FJCO.2006.06.6126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib</span></div><div class="casAuthors">Jackman David M; Holmes Alison J; Lindeman Neal; Wen Patrick Y; Kesari Santosh; Borras Ana M; Bailey Christopher; de Jong Francisca; Janne Pasi A; Johnson Bruce E</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">4517-20</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQqXLAoggZ9OCO2kE7krGOBfW6udTcc2eaB-T66-LQn_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28rlslemtA%253D%253D&md5=391e78d72a39626276f7ffcbee76d1a1</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2006.06.6126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2006.06.6126%26sid%3Dliteratum%253Aachs%26aulast%3DJackman%26aufirst%3DD.%2BM.%26aulast%3DHolmes%26aufirst%3DA.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DKesari%26aufirst%3DS.%26aulast%3DBorras%26aufirst%3DA.%2BM.%26aulast%3DBailey%26aufirst%3DC.%26aulast%3DJong%26aufirst%3DF.%2BD.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26atitle%3DResponse%2520and%2520resistance%2520in%2520a%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%2520patient%2520with%2520an%2520epidermal%2520growth%2520factor%2520receptor%2520mutation%2520and%2520leptomeningeal%2520metastases%2520treated%2520with%2520high-dose%2520gefitinib%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D4517%26epage%3D4520%26doi%3D10.1200%2FJCO.2006.06.6126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Owonikoko, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbiser, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zelnak, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shu, H.-K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalkanis, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitsett, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salhia, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryken, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, J. J.</span><span> </span><span class="NLM_article-title">Current approaches to the treatment of metastatic brain tumours</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">222</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2014.25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1038%2Fnrclinonc.2014.25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=24569448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjsVChsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=203-222&author=T.+K.+Owonikokoauthor=J.+Arbiserauthor=A.+Zelnakauthor=H.-K.+G.+Shuauthor=H.+Shimauthor=A.+M.+Robinauthor=S.+N.+Kalkanisauthor=T.+G.+Whitsettauthor=B.+Salhiaauthor=N.+L.+Tranauthor=T.+Rykenauthor=M.+K.+Mooreauthor=K.+M.+Eganauthor=J.+Jeffreyauthor=J.+J.+Olson&title=Current+approaches+to+the+treatment+of+metastatic+brain+tumours&doi=10.1038%2Fnrclinonc.2014.25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Current approaches to the treatment of metastatic brain tumours</span></div><div class="casAuthors">Owonikoko, Taofeek K.; Arbiser, Jack; Zelnak, Amelia; Shu, Hui-Kuo G.; Shim, Hyunsuk; Robin, Adam M.; Kalkanis, Steven N.; Whitsett, Timothy G.; Salhia, Bodour; Tran, Nhan L.; Ryken, Timothy; Moore, Michael K.; Egan, Kathleen M.; Olson, Jeffrey J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">203-222</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Metastatic tumors involving the brain overshadow primary brain neoplasms in frequency and are an important complication in the overall management of many cancers.  Importantly, advances are being made in understanding the mol. biol. underlying the initial development and eventual proliferation of brain metastases.  Surgery and radiation remain the cornerstones of the therapy for symptomatic lesions; however, image-based guidance is improving surgical technique to maximize the preservation of normal tissue, while more sophisticated approaches to radiation therapy are being used to minimize the long-standing concerns over the toxicity of whole-brain radiation protocols used in the past.  Furthermore, the burgeoning knowledge of tumor biol. has facilitated the entry of systemically administered therapies into the clinic.  Responses to these targeted interventions have ranged from substantial toxicity with no control of disease to periods of useful tumor control with no decrement in performance status of the treated individual.  This experience enables recognition of the limits of targeted therapy, but has also informed methods to optimize this approach.  This Review focuses on the clin. relevant mol. biol. of brain metastases, and summarizes the current applications of these data to imaging, surgery, radiation therapy, cytotoxic chemotherapy and targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMkDee2-upYrVg90H21EOLACvtfcHk0likaGiqjvkQ7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjsVChsrY%253D&md5=499d772b17c0f7a323ddbdb7cfd88341</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2014.25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2014.25%26sid%3Dliteratum%253Aachs%26aulast%3DOwonikoko%26aufirst%3DT.%2BK.%26aulast%3DArbiser%26aufirst%3DJ.%26aulast%3DZelnak%26aufirst%3DA.%26aulast%3DShu%26aufirst%3DH.-K.%2BG.%26aulast%3DShim%26aufirst%3DH.%26aulast%3DRobin%26aufirst%3DA.%2BM.%26aulast%3DKalkanis%26aufirst%3DS.%2BN.%26aulast%3DWhitsett%26aufirst%3DT.%2BG.%26aulast%3DSalhia%26aufirst%3DB.%26aulast%3DTran%26aufirst%3DN.%2BL.%26aulast%3DRyken%26aufirst%3DT.%26aulast%3DMoore%26aufirst%3DM.%2BK.%26aulast%3DEgan%26aufirst%3DK.%2BM.%26aulast%3DJeffrey%26aufirst%3DJ.%26aulast%3DOlson%26aufirst%3DJ.%2BJ.%26atitle%3DCurrent%2520approaches%2520to%2520the%2520treatment%2520of%2520metastatic%2520brain%2520tumours%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D11%26spage%3D203%26epage%3D222%26doi%3D10.1038%2Fnrclinonc.2014.25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Gow, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, C.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiu, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, Y.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, P.-C.</span><span> </span><span class="NLM_article-title">Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">162</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-1468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1158%2F1078-0432.CCR-07-1468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=18172267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslGj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=162-168&author=C.-H.+Gowauthor=C.-R.+Chienauthor=Y.-L.+Changauthor=Y.-H.+Chiuauthor=S.-H.+Kuoauthor=J.-Y.+Shihauthor=Y.-C.+Changauthor=C.-J.+Yuauthor=C.-H.+Yangauthor=P.-C.+Yang&title=Radiotherapy+in+lung+adenocarcinoma+with+brain+metastases%3A+effects+of+activating+epidermal+growth+factor+receptor+mutations+on+clinical+response&doi=10.1158%2F1078-0432.CCR-07-1468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response</span></div><div class="casAuthors">Gow, Chien-Hung; Chien, Chun-Ru; Chang, Yih-Leong; Chiu, Yueh-Hsia; Kuo, Sung-Hsin; Shih, Jin-Yuan; Chang, Yeun-Chung; Yu, Chong-Jen; Yang, Chih-Hsin; Yang, Pan-Chyr</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">162-168</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Whole-brain radiation therapy (WBRT) has been applied to inoperable brain metastases in lung adenocarcinoma.  Recently, an in vitro study showed reduced clonogenic survival of mutant epidermal growth factor receptor (EGFR) lung cancer cell lines in response to ionizing radiation compared with that of the wild type.  To elucidate the role of EGFR mutations in radiation treatment, we evaluated the clin. response to WBRT and survival of lung adenocarcinoma patients with brain metastases.  Exptl. Design: This was a retrospective anal. of 63 patients with brain metastases from lung adenocarcinoma who were treated with WBRT.  Demog. data, EGFR mutation status, response to WBRT, and survival data were collected.  Clin. response was assessed 1 mo after the start of WBRT.  Univariate and logistic regression models were used to test potential predictive factors assocd. with clin. response.  Log-rank test and Cox regression were analyzed to identify factors that affected survival.  RESULTS: Clin. response to WBRT was obsd. in 29 patients (46%), with 34 nonresponder patients (54%).  Patients with EGFR mutations had higher response rates to WBRT compared with those with the wild-type (54% vs. 24%; P = 0.045).  Both the administration of EGFR tyrosine kinase inhibitor (P = 0.034) and EGFR mutation (P = 0.029) were independently assocd. with response to WBRT.  In Cox regression anal., WBRT responder (P = 0.010) and absence of extracranial metastases (P = 0.002) were assocd. with better survival.  CONCLUSIONS: Both the EGFR mutations and the administration of EGFR TKI during WBRT were independent predictors of response to WBRT in brain metastases of lung adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriObBEhxHr1rVg90H21EOLACvtfcHk0likaGiqjvkQ7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslGj&md5=b2228545dd1001b614a66817770ca85b</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-1468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-1468%26sid%3Dliteratum%253Aachs%26aulast%3DGow%26aufirst%3DC.-H.%26aulast%3DChien%26aufirst%3DC.-R.%26aulast%3DChang%26aufirst%3DY.-L.%26aulast%3DChiu%26aufirst%3DY.-H.%26aulast%3DKuo%26aufirst%3DS.-H.%26aulast%3DShih%26aufirst%3DJ.-Y.%26aulast%3DChang%26aufirst%3DY.-C.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DYang%26aufirst%3DC.-H.%26aulast%3DYang%26aufirst%3DP.-C.%26atitle%3DRadiotherapy%2520in%2520lung%2520adenocarcinoma%2520with%2520brain%2520metastases%253A%2520effects%2520of%2520activating%2520epidermal%2520growth%2520factor%2520receptor%2520mutations%2520on%2520clinical%2520response%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D162%26epage%3D168%26doi%3D10.1158%2F1078-0432.CCR-07-1468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Pardridge, W. M.</span><span> </span><span class="NLM_article-title">The blood-brain barrier: bottleneck in brain drug development</span> <span class="citation_source-journal">NeuroRx</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1602/neurorx.2.1.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1602%2Fneurorx.2.1.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=15717053" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BD2MzntVaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=3-14&author=W.+M.+Pardridge&title=The+blood-brain+barrier%3A+bottleneck+in+brain+drug+development&doi=10.1602%2Fneurorx.2.1.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The blood-brain barrier: bottleneck in brain drug development</span></div><div class="casAuthors">Pardridge William M</div><div class="citationInfo"><span class="NLM_cas:title">NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-14</span>
        ISSN:<span class="NLM_cas:issn">1545-5343</span>.
    </div><div class="casAbstract">The blood-brain barrier (BBB) is formed by the brain capillary endothelium and excludes from the brain approximately 100% of large-molecule neurotherapeutics and more than 98% of all small-molecule drugs.  Despite the importance of the BBB to the neurotherapeutics mission, the BBB receives insufficient attention in either academic neuroscience or industry programs.  The combination of so little effort in developing solutions to the BBB problem, and the minimal BBB transport of the majority of all potential CNS drugs, leads predictably to the present situation in neurotherapeutics, which is that there are few effective treatments for the majority of CNS disorders.  This situation can be reversed by an accelerated effort to develop a knowledge base in the fundamental transport properties of the BBB, and the molecular and cellular biology of the brain capillary endothelium.  This provides the platform for CNS drug delivery programs, which should be developed in parallel with traditional CNS drug discovery efforts in the molecular neurosciences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8zmuJRBq_D9y3lHz94U-GfW6udTcc2eZkTq5uwR1VCbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzntVaqtw%253D%253D&md5=88e326d840c4ab0f4e55da8a2ffd513c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1602%2Fneurorx.2.1.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1602%252Fneurorx.2.1.3%26sid%3Dliteratum%253Aachs%26aulast%3DPardridge%26aufirst%3DW.%2BM.%26atitle%3DThe%2520blood-brain%2520barrier%253A%2520bottleneck%2520in%2520brain%2520drug%2520development%26jtitle%3DNeuroRx%26date%3D2005%26volume%3D2%26spage%3D3%26epage%3D14%26doi%3D10.1602%2Fneurorx.2.1.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Löscher, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potschka, H.</span><span> </span><span class="NLM_article-title">Blood-brain barrier active efflux transporters: ATP-binding cassette gene family</span> <span class="citation_source-journal">NeuroRx</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">86</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span><span class="refDoi"> DOI: 10.1602/neurorx.2.1.86</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1602%2Fneurorx.2.1.86" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=15717060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BD2MzntVejsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=86-98&author=W.+L%C3%B6scherauthor=H.+Potschka&title=Blood-brain+barrier+active+efflux+transporters%3A+ATP-binding+cassette+gene+family&doi=10.1602%2Fneurorx.2.1.86"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Blood-brain barrier active efflux transporters: ATP-binding cassette gene family</span></div><div class="casAuthors">Loscher Wolfgang; Potschka Heidrun</div><div class="citationInfo"><span class="NLM_cas:title">NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">86-98</span>
        ISSN:<span class="NLM_cas:issn">1545-5343</span>.
    </div><div class="casAbstract">The blood-brain barrier (BBB) contributes to brain homeostasis by protecting the brain from potentially harmful endogenous and exogenous substances.  BBB active drug efflux transporters of the ATP-binding cassette (ABC) gene family are increasingly recognized as important determinants of drug distribution to, and elimination from, the CNS.  The ABC efflux transporter P-glycoprotein (Pgp) has been demonstrated as a key element of the BBB that can actively transport a huge variety of lipophilic drugs out of the brain capillary endothelial cells that form the BBB.  In addition to Pgp, other ABC efflux transporters such as members of the multidrug resistance protein (MRP) family and breast cancer resistance protein (BCRP) seem to contribute to BBB function.  Consequences of ABC efflux transporters in the BBB include minimizing or avoiding neurotoxic adverse effects of drugs that otherwise would penetrate into the brain.  However, ABC efflux transporters may also limit the central distribution of drugs that are beneficial to treat CNS diseases.  Furthermore, neurological disorders such as epilepsy may be associated with overexpression of ABC efflux transporters at the BBB, resulting in pharmacoresistance to therapeutic medication.  Therefore, modulation of ABC efflux transporters at the BBB forms a novel strategy to enhance the penetration of drugs into the brain and may yield new therapeutic options for drug-resistant CNS diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR8zmuJRBq_DwvupmecNw_lfW6udTcc2eZ0YQtQ8KF_b7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzntVejsA%253D%253D&md5=4de8b6e417fdc59a41aef2629475da8d</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1602%2Fneurorx.2.1.86&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1602%252Fneurorx.2.1.86%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26aulast%3DPotschka%26aufirst%3DH.%26atitle%3DBlood-brain%2520barrier%2520active%2520efflux%2520transporters%253A%2520ATP-binding%2520cassette%2520gene%2520family%26jtitle%3DNeuroRx%26date%3D2005%26volume%3D2%26spage%3D86%26epage%3D98%26doi%3D10.1602%2Fneurorx.2.1.86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Mahringer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reimold, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fricker, G.</span><span> </span><span class="NLM_article-title">The ABC of the blood-brain barrier-regulation of drug efflux pumps</span> <span class="citation_source-journal">Curr. Pharm. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2762</span><span class="NLM_x">–</span> <span class="NLM_lpage">2770</span><span class="refDoi"> DOI: 10.2174/138161211797440221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.2174%2F138161211797440221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=21827407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSis7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2762-2770&author=A.+Mahringerauthor=M.+Ottauthor=I.+Reimoldauthor=V.+Reichelauthor=G.+Fricker&title=The+ABC+of+the+blood-brain+barrier-regulation+of+drug+efflux+pumps&doi=10.2174%2F138161211797440221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The ABC of the blood-brain barrier - regulation of drug efflux pumps</span></div><div class="casAuthors">Mahringer, Anne; Ott, Melanie; Reimold, Isolde; Reichel, Valeska; Fricker, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2762-2770</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  According to the World Health Organization Central nervous system disorders are the major medical challenge of the 21st Century, yet treatments for many CNS disorders are either inadequate or absent.  One reason is the existence of the blood-brain barrier, which strictly limits the access of substances to the brain.  A key element of the barrier function is the expression of ABC export proteins in the luminal membrane of brain microvessel endothelial cells.  Understanding the signaling cascades, which lead to altered expression or function of the transporters, and the response to endogenous and exogenous stimuli as well as subsequent modulation of the transporters may offer novel strategies to overcome the barrier and to improve drug delivery to the brain.  This review gives a short overview about structure of the key elements of the blood-brain barrier with emphasis on ABC transporters.  An insight into regulation of function and expression of these transport proteins is given and the involvement of these transporters in CNS diseases is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOs9iG4klPaLVg90H21EOLACvtfcHk0lh0xWEfd3pMSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSis7vL&md5=bb59f862120c3812d19088d30103d57b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F138161211797440221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161211797440221%26sid%3Dliteratum%253Aachs%26aulast%3DMahringer%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DReimold%26aufirst%3DI.%26aulast%3DReichel%26aufirst%3DV.%26aulast%3DFricker%26aufirst%3DG.%26atitle%3DThe%2520ABC%2520of%2520the%2520blood-brain%2520barrier-regulation%2520of%2520drug%2520efflux%2520pumps%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2011%26volume%3D17%26spage%3D2762%26epage%3D2770%26doi%3D10.2174%2F138161211797440221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Mahar Doan, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphreys, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wring, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shampine, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serabjit-Singh, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adkison, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, J. W.</span><span> </span><span class="NLM_article-title">Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">303</span><span class="NLM_x">, </span> <span class="NLM_fpage">1029</span><span class="NLM_x">–</span> <span class="NLM_lpage">1037</span><span class="refDoi"> DOI: 10.1124/jpet.102.039255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1124%2Fjpet.102.039255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=12438524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BD38nptVKmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=303&publication_year=2002&pages=1029-1037&author=K.+M.+Mahar+Doanauthor=J.+E.+Humphreysauthor=L.+O.+Websterauthor=S.+A.+Wringauthor=L.+J.+Shampineauthor=C.+J.+Serabjit-Singhauthor=K.+K.+Adkisonauthor=J.+W.+Polli&title=Passive+permeability+and+P-glycoprotein-mediated+efflux+differentiate+central+nervous+system+%28CNS%29+and+non-CNS+marketed+drugs&doi=10.1124%2Fjpet.102.039255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs</span></div><div class="casAuthors">Mahar Doan Kelly M; Humphreys Joan E; Webster Lindsey O; Wring Stephen A; Shampine Larry J; Serabjit-Singh Cosette J; Adkison Kimberly K; Polli Joseph W</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">303</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1029-37</span>
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Membrane permeability and P-glycoprotein (Pgp) can be limiting factors for blood-brain barrier penetration.  The objectives of this study were to determine whether there are differences in the in vitro permeability, Pgp substrate profiles, and physicochemical properties of drugs for central nervous system (CNS) and non-CNS indications, and whether these differences are useful criteria in selecting compounds for drug development.  Apparent permeability (P(app)) and Pgp substrate profiles for 93 CNS (n = 48) and non-CNS (n = 45) drugs were determined by monolayer efflux.  Calcein-AM inhibition assays were used to supplement the efflux results.  The CNS set (2 of 48, 4.2%) had a 7-fold lower incidence of passive permeability values <150 nm/s compared with the non-CNS set (13 of 45, 28.9%).  The majority of drugs (72.0%, 67 of 93) were not Pgp substrates; however, 49.5% (46 of 93) were positive in the calcein-AM assay when tested at 100 microM.  The CNS drug set (n = 7 of 48, 14.6%) had a 3-fold lower incidence of Pgp-mediated efflux than the non-CNS drug set (n = 19 of 45, 42.2%).  Analysis of 18 physicochemical properties revealed that the CNS drug set had fewer hydrogen bond donors, fewer positive charges, greater lipophilicity, lower polar surface area, and reduced flexibility compared with the non-CNS group (p < 0.05), properties that enhance membrane permeability.  This study on a large, diverse set of marketed compounds clearly demonstrates that permeability, Pgp-mediated efflux, and certain physicochemical properties are factors that differentiate CNS and non-CNS drugs.  For CNS delivery, a drug should ideally have an in vitro passive permeability >150 nm/s and not be a good (B --> A/A --> B ratio <2.5) Pgp substrate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_HiV1Xqt18Vf1XRtfYM0dfW6udTcc2eZ0YQtQ8KF_b7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38nptVKmsw%253D%253D&md5=b841902aa8502de47c1e1603c80e09fb</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.039255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.039255%26sid%3Dliteratum%253Aachs%26aulast%3DMahar%2BDoan%26aufirst%3DK.%2BM.%26aulast%3DHumphreys%26aufirst%3DJ.%2BE.%26aulast%3DWebster%26aufirst%3DL.%2BO.%26aulast%3DWring%26aufirst%3DS.%2BA.%26aulast%3DShampine%26aufirst%3DL.%2BJ.%26aulast%3DSerabjit-Singh%26aufirst%3DC.%2BJ.%26aulast%3DAdkison%26aufirst%3DK.%2BK.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26atitle%3DPassive%2520permeability%2520and%2520P-glycoprotein-mediated%2520efflux%2520differentiate%2520central%2520nervous%2520system%2520%2528CNS%2529%2520and%2520non-CNS%2520marketed%2520drugs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D303%26spage%3D1029%26epage%3D1037%26doi%3D10.1124%2Fjpet.102.039255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Wager, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villalobos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span> </span><span class="NLM_article-title">Strategies to optimize the brain availability of central nervous system drug candidates</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">371</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span><span class="refDoi"> DOI: 10.1517/17460441.2011.564158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1517%2F17460441.2011.564158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=22646015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVKmsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=371-381&author=T.+T.+Wagerauthor=A.+Villalobosauthor=P.+R.+Verhoestauthor=X.+Houauthor=C.+L.+Shaffer&title=Strategies+to+optimize+the+brain+availability+of+central+nervous+system+drug+candidates&doi=10.1517%2F17460441.2011.564158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to optimize the brain availability of central nervous system drug candidates</span></div><div class="casAuthors">Wager, Travis T.; Villalobos, Anabella; Verhoest, Patrick R.; Hou, Xinjun; Shaffer, Christopher L.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">371-381</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Access to the CNS is essential for most neurotherapeutics to elicit their effects.  Leveraging design strategies incorporating physicochem. properties, in vitro and in vivo assays to predict and measure brain penetration, and brain delivery approaches may enable the drug discovery community to improve access of drug candidates into the CNS compartment.Areas covered: This article reviews aspects of the most recent mol. design, in vitro and in vivo strategies, and delivery technologies to optimize the unbound brain concns. (C b,u) of CNS mols.  Through this, the article provides insight into recent ideas and concepts in CNS drug mol. design, methods for evaluating CNS drug exposures and alternative approaches to maximize drug access to neurocompartments.Expert opinion: The most pharmacol. relevant measure in assessing a compd.'s pharmacodynamic response in the CNS is its C b,u.  The utilization of emerging design strategies, together with in vitro and in vivo assays, may enable the design of mols. with optimal C b,u:C p,u (C p,u, unbound plasma concn.) and appropriate C b,u, to elicit a biol. response from the neurotherapeutic target.  Where drug properties intrinsically render a compd. CNS impaired, using novel CNS delivery approaches may result in sufficient C b,u to furnish a biol. response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs2ijS8dIydLVg90H21EOLACvtfcHk0lgfRBU8g9FXFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVKmsbw%253D&md5=09a2b8b06bdbdc63db728416cb01081f</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1517%2F17460441.2011.564158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2011.564158%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DVillalobos%26aufirst%3DA.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26atitle%3DStrategies%2520to%2520optimize%2520the%2520brain%2520availability%2520of%2520central%2520nervous%2520system%2520drug%2520candidates%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2011%26volume%3D6%26spage%3D371%26epage%3D381%26doi%3D10.1517%2F17460441.2011.564158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Hitchcock, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennington, L. D.</span><span> </span><span class="NLM_article-title">Structure-brain exposure relationships</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">7559</span><span class="NLM_x">–</span> <span class="NLM_lpage">7583</span><span class="refDoi"> DOI: 10.1021/jm060642i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060642i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yrtrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7559-7583&author=S.+A.+Hitchcockauthor=L.+D.+Pennington&title=Structure-brain+exposure+relationships&doi=10.1021%2Fjm060642i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-brain exposure relationships</span></div><div class="casAuthors">Hitchcock, Stephen A.; Pennington, Lewis D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7559-7583</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the use of structure modification to influence blood-brain barrier penetration by modulating either passive diffusion or active transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3V-TERRGy07Vg90H21EOLACvtfcHk0lgfRBU8g9FXFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yrtrnK&md5=97dff583ffae6d0ef66512ffbee38c34</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm060642i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060642i%26sid%3Dliteratum%253Aachs%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26atitle%3DStructure-brain%2520exposure%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7559%26epage%3D7583%26doi%3D10.1021%2Fjm060642i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbertz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">50</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1021/cn200100h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn200100h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=50-68&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=R.+L.+Hudkinsauthor=B.+D.+Dorseyauthor=J.+P.+Mallamo&title=Knowledge-based%2C+central+nervous+system+%28CNS%29+lead+selection+and+lead+optimization+for+CNS+drug+discovery&doi=10.1021%2Fcn200100h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery</span></div><div class="casAuthors">Ghose, Arup K.; Herbertz, Torsten; Hudkins, Robert L.; Dorsey, Bruce D.; Mallamo, John P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-68</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The central nervous system (CNS) is the major area that is affected by aging.  Alzheimer's disease (AD), Parkinson's disease (PD), brain cancer, and stroke are the CNS diseases that will cost trillions of dollars for their treatment.  Achievement of appropriate blood-brain barrier (BBB) penetration is often considered a significant hurdle in the CNS drug discovery process.  On the other hand, BBB penetration may be a liability for many of the non-CNS drug targets, and a clear understanding of the physicochem. and structural differences between CNS and non-CNS drugs may assist both research areas.  Because of the numerous and challenging issues in CNS drug discovery and the low success rates, pharmaceutical companies are beginning to deprioritize their drug discovery efforts in the CNS arena.  Prompted by these challenges and to aid in the design of high-quality, efficacious CNS compds., we analyzed the physicochem. property and the chem. structural profiles of 317 CNS and 626 non-CNS oral drugs.  The conclusions derived provide an ideal property profile for lead selection and the property modification strategy during the lead optimization process.  A list of substructural units that may be useful for CNS drug design was also provided here.  A classification tree was also developed to differentiate between CNS drugs and non-CNS oral drugs.  The combined anal. provided the following guidelines for designing high-quality CNS drugs: (i) topol. mol. polar surface area of <76 Å2 (25-60 Å2), (ii) at least one (one or two, including one aliph. amine) nitrogen, (iii) fewer than seven (two to four) linear chains outside of rings, (iv) fewer than three (zero or one) polar hydrogen atoms, (v) vol. of 740-970 Å3, (vi) solvent accessible surface area of 460-580 Å2, and (vii) pos. QikProp parameter CNS.  The ranges within parentheses may be used during lead optimization.  One violation to this proposed profile may be acceptable.  The chemoinformatics approaches for graphically analyzing multiple properties efficiently are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozqfO0vq2i5bVg90H21EOLACvtfcHk0lgfRBU8g9FXFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSit7rO&md5=4c20ba34c3d5397170b50242975ce25d</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fcn200100h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn200100h%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge-based%252C%2520central%2520nervous%2520system%2520%2528CNS%2529%2520lead%2520selection%2520and%2520lead%2520optimization%2520for%2520CNS%2520drug%2520discovery%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D50%26epage%3D68%26doi%3D10.1021%2Fcn200100h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">CNS drug design: balancing physicochemical properties for optimal brain exposure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2584</span><span class="NLM_x">–</span> <span class="NLM_lpage">2608</span><span class="refDoi"> DOI: 10.1021/jm501535r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501535r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2584-2608&author=Z.+Rankovic&title=CNS+drug+design%3A+balancing+physicochemical+properties+for+optimal+brain+exposure&doi=10.1021%2Fjm501535r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure</span></div><div class="casAuthors">Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2584-2608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to prevent injury from external insults and toxins.  Designing mols. that can overcome this protection system and achieve optimal concn. at the desired therapeutic target in the brain is a specific and major challenge for medicinal chemists working in CNS drug discovery.  Analogous to the now widely accepted rule of 5 in the design of oral drugs, the physicochem. properties required for optimal brain exposure have been extensively studied in an attempt to similarly define the attributes of successful CNS drugs and drug candidates.  This body of work is systematically reviewed here, with a particular emphasis on the interplay between the most crit. physicochem. and pharmacokinetic parameters of CNS drugs as well as their impact on medicinal chem. strategies toward mols. with optimal brain exposure.  A summary of modern CNS pharmacokinetic concepts and methods is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8V0N1j49uuLVg90H21EOLACvtfcHk0ljEZ9WfjO3cWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP&md5=f01e3f2dc4e2eff7b0618124277a5cf8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm501535r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501535r%26sid%3Dliteratum%253Aachs%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DCNS%2520drug%2520design%253A%2520balancing%2520physicochemical%2520properties%2520for%2520optimal%2520brain%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2584%26epage%3D2608%26doi%3D10.1021%2Fjm501535r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span><span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.-H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0ljEZ9WfjO3cWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennequin, L. F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kettle, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendrew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogilvie, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, I.</span><span> </span><span class="NLM_article-title">Inhibitors of epidermal growth factor receptor tyrosine kinase: optimization of potency and in vivo pharmacokinetics</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4908</span><span class="NLM_x">–</span> <span class="NLM_lpage">4912</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.06.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2Fj.bmcl.2006.06.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=16806916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD28XotlSgsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4908-4912&author=P.+Ballardauthor=R.+H.+Bradburyauthor=C.+S.+Harrisauthor=L.+F.+A.+Hennequinauthor=M.+Hickinsonauthor=J.+G.+Kettleauthor=J.+Kendrewauthor=T.+Klinowskaauthor=D.+J.+Ogilvieauthor=S.+E.+Pearsonauthor=E.+J.+Williamsauthor=I.+Wilson&title=Inhibitors+of+epidermal+growth+factor+receptor+tyrosine+kinase%3A+optimization+of+potency+and+in+vivo+pharmacokinetics&doi=10.1016%2Fj.bmcl.2006.06.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of epidermal growth factor receptor tyrosine kinase: Optimization of potency and in vivo pharmacokinetics</span></div><div class="casAuthors">Ballard, Peter; Bradbury, Robert H.; Harris, Craig S.; Hennequin, Laurent F. A.; Hickinson, Mark; Kettle, Jason G.; Kendrew, Jane; Klinowska, Teresa; Ogilvie, Donald J.; Pearson, Stuart E.; Williams, Emma J.; Wilson, Ingrid</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4908-4912</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure-activity and structure-property relationships of anilinoquinazoline inhibitors of EGFR were investigated.  Strategies to lower vol. of distribution and shorten half-life through structure and pKa modulation are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG_WeMAluLubVg90H21EOLACvtfcHk0ljEZ9WfjO3cWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotlSgsbg%253D&md5=1e126a9191432d33cd0bec15e155fec5</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.06.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.06.054%26sid%3Dliteratum%253Aachs%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DHarris%26aufirst%3DC.%2BS.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%2BA.%26aulast%3DHickinson%26aufirst%3DM.%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DKendrew%26aufirst%3DJ.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DOgilvie%26aufirst%3DD.%2BJ.%26aulast%3DPearson%26aufirst%3DS.%2BE.%26aulast%3DWilliams%26aufirst%3DE.%2BJ.%26aulast%3DWilson%26aufirst%3DI.%26atitle%3DInhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%253A%2520optimization%2520of%2520potency%2520and%2520in%2520vivo%2520pharmacokinetics%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4908%26epage%3D4912%26doi%3D10.1016%2Fj.bmcl.2006.06.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Pankratov, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shalabay, A. V.</span><span> </span><span class="NLM_article-title">Effect of the intramolecular hydrogen bond on the electronic structure of the organic molecules with a planar quasicycle</span> <span class="citation_source-journal">J. Struct. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span><span class="refDoi"> DOI: 10.1007/s10947-007-0064-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1007%2Fs10947-007-0064-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVSktb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=427-432&author=A.+N.+Pankratovauthor=A.+V.+Shalabay&title=Effect+of+the+intramolecular+hydrogen+bond+on+the+electronic+structure+of+the+organic+molecules+with+a+planar+quasicycle&doi=10.1007%2Fs10947-007-0064-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of the intramolecular hydrogen bond on the electronic structure of organic molecules with a planar quasicycle</span></div><div class="casAuthors">Pankratov, A. N.; Shalabay, A. V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Structural Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-432</span>CODEN:
                <span class="NLM_cas:coden">JSTCAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-4766</span>.
    
            (<span class="NLM_cas:orgname">Pleiades Publishing, Ltd.</span>)
        </div><div class="casAbstract">The electronic structure of the following org. mols. is studied using the HF/6-311G(d,p) method: malonic dialdehyde, acetylacetone, thiomalonic aldehyde, 2-XC6H4NH2 aniline derivs., 2-XC6H4OH phenol derivs., 2-XC6H4SH thiophenol derivs. (X = CHO, COOH, COO-, NO, NO2, OH, OCH3, SH, SCH3, F, Cl, Br), 8-hydroxyquinoline, 8-mercaptoquinoline, tropolone.  It is found that the intramol. hydrogen bond (IHB) leads to a local electronic redistribution in the quasi-cycle, and above all to the electron d. transfer among the immediate participants of IHB - from the hydrogen atom to the proton-acceptor atom.  When the IHB of the S-H···O type forms, the electron d. mainly decreases on sulfhydryl hydrogen atom and increases on sulfur atom.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeEyyfjJACFLVg90H21EOLACvtfcHk0liARslfOhVxPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVSktb7J&md5=59f81fb4b1ad0a45465da865723bfb38</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2Fs10947-007-0064-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10947-007-0064-2%26sid%3Dliteratum%253Aachs%26aulast%3DPankratov%26aufirst%3DA.%2BN.%26aulast%3DShalabay%26aufirst%3DA.%2BV.%26atitle%3DEffect%2520of%2520the%2520intramolecular%2520hydrogen%2520bond%2520on%2520the%2520electronic%2520structure%2520of%2520the%2520organic%2520molecules%2520with%2520a%2520planar%2520quasicycle%26jtitle%3DJ.%2520Struct.%2520Chem.%26date%3D2007%26volume%3D48%26spage%3D427%26epage%3D432%26doi%3D10.1007%2Fs10947-007-0064-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Galan, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wildin, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pophristic, V.</span><span> </span><span class="NLM_article-title">Intramolecular hydrogen bonding in <i>ortho</i>-substituted arylamide oligomers: a computational and experimental study of <i>ortho</i>-fluoro- and ortho-chloro-N-methylbenzamide</span> <span class="citation_source-journal">J. Phys. Chem. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">12809</span><span class="NLM_x">–</span> <span class="NLM_lpage">12815</span><span class="refDoi"> DOI: 10.1021/jp905261p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp905261p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=12809-12815&author=J.+F.+Galanauthor=J.+Brownauthor=J.+L.+Wildinauthor=Z.+Liuauthor=D.+Liuauthor=G.+Moynaauthor=V.+Pophristic&title=Intramolecular+hydrogen+bonding+in+ortho-substituted+arylamide+oligomers%3A+a+computational+and+experimental+study+of+ortho-fluoro-+and+ortho-chloro-N-methylbenzamide&doi=10.1021%2Fjp905261p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjp905261p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp905261p%26sid%3Dliteratum%253Aachs%26aulast%3DGalan%26aufirst%3DJ.%2BF.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DWildin%26aufirst%3DJ.%2BL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMoyna%26aufirst%3DG.%26aulast%3DPophristic%26aufirst%3DV.%26atitle%3DIntramolecular%2520hydrogen%2520bonding%2520in%2520ortho-substituted%2520arylamide%2520oligomers%253A%2520a%2520computational%2520and%2520experimental%2520study%2520of%2520ortho-fluoro-%2520and%2520ortho-chloro-N-methylbenzamide%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2009%26volume%3D113%26spage%3D12809%26epage%3D12815%26doi%3D10.1021%2Fjp905261p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Weiss, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williamson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babu-Khan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartberger, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Citron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croghan, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dineen, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Esmay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graceffa, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harried, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horne, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imbeah-Ampiah, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judd, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaller, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreiman, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monenschein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennington, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rattan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">San Miguel, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sickmier, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, W.</span><span> </span><span class="NLM_article-title">Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">9009</span><span class="NLM_x">–</span> <span class="NLM_lpage">9024</span><span class="refDoi"> DOI: 10.1021/jm300119p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300119p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9009-9024&author=M.+M.+Weissauthor=T.+Williamsonauthor=S.+Babu-Khanauthor=M.+D.+Bartbergerauthor=J.+Brownauthor=K.+Chenauthor=Y.+Chengauthor=M.+Citronauthor=M.+D.+Croghanauthor=T.+A.+Dineenauthor=J.+Esmayauthor=R.+F.+Graceffaauthor=S.+S.+Harriedauthor=D.+Hickmanauthor=S.+A.+Hitchcockauthor=D.+B.+Horneauthor=H.+Huangauthor=R.+Imbeah-Ampiahauthor=T.+Juddauthor=M.+R.+Kallerauthor=C.+R.+Kreimanauthor=D.+S.+Laauthor=V.+Liauthor=P.+Lopezauthor=S.+Louieauthor=H.+Monenscheinauthor=T.+T.+Nguyenauthor=L.+D.+Penningtonauthor=C.+Rattanauthor=T.+San+Miguelauthor=E.+A.+Sickmierauthor=R.+C.+Wahlauthor=P.+H.+Wenauthor=S.+Woodauthor=Q.+Xueauthor=B.+H.+Yangauthor=V.+F.+Patelauthor=W.+Zhong&title=Design+and+preparation+of+a+potent+series+of+hydroxyethylamine+containing+%CE%B2-secretase+inhibitors+that+demonstrate+robust+reduction+of+central+%CE%B2-amyloid&doi=10.1021%2Fjm300119p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm300119p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300119p%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DWilliamson%26aufirst%3DT.%26aulast%3DBabu-Khan%26aufirst%3DS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCitron%26aufirst%3DM.%26aulast%3DCroghan%26aufirst%3DM.%2BD.%26aulast%3DDineen%26aufirst%3DT.%2BA.%26aulast%3DEsmay%26aufirst%3DJ.%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DHarried%26aufirst%3DS.%2BS.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DHorne%26aufirst%3DD.%2BB.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DImbeah-Ampiah%26aufirst%3DR.%26aulast%3DJudd%26aufirst%3DT.%26aulast%3DKaller%26aufirst%3DM.%2BR.%26aulast%3DKreiman%26aufirst%3DC.%2BR.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLi%26aufirst%3DV.%26aulast%3DLopez%26aufirst%3DP.%26aulast%3DLouie%26aufirst%3DS.%26aulast%3DMonenschein%26aufirst%3DH.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DRattan%26aufirst%3DC.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DSickmier%26aufirst%3DE.%2BA.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWen%26aufirst%3DP.%2BH.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DXue%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DB.%2BH.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DZhong%26aufirst%3DW.%26atitle%3DDesign%2520and%2520preparation%2520of%2520a%2520potent%2520series%2520of%2520hydroxyethylamine%2520containing%2520%25CE%25B2-secretase%2520inhibitors%2520that%2520demonstrate%2520robust%2520reduction%2520of%2520central%2520%25CE%25B2-amyloid%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9009%26epage%3D9024%26doi%3D10.1021%2Fjm300119p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callegari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianfrogna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doran, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doran, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosea, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewc, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deusen, J. V.</span><span> </span><span class="NLM_article-title">Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1443</span><span class="NLM_x">–</span> <span class="NLM_lpage">1447</span><span class="refDoi"> DOI: 10.1124/dmd.105.008201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1124%2Fdmd.105.008201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=16760229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1Sksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=1443-1447&author=X.+Liuauthor=B.+J.+Smithauthor=C.+Chenauthor=E.+Callegariauthor=S.+I.+Beckerauthor=X.+Chenauthor=J.+Cianfrognaauthor=A.+C.+Doranauthor=S.+D.+Doranauthor=J.+P.+Gibbsauthor=N.+Hoseaauthor=J.+Liuauthor=F.+R.+Nelsonauthor=M.+A.+Szewcauthor=J.+V.+Deusen&title=Evaluation+of+cerebrospinal+fluid+concentration+and+plasma+free+concentration+as+a+surrogate+measurement+for+brain+free+concentration&doi=10.1124%2Fdmd.105.008201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration</span></div><div class="casAuthors">Liu, Xingrong; Smith, Bill J.; Chen, Cuiping; Callegari, Ernesto; Becker, Stacey L.; Chen, Xi; Cianfrogna, Julie; Doran, Angela C.; Doran, Shawn D.; Gibbs, John P.; Hosea, Natilie; Liu, Jianhua; Nelson, Frederick R.; Szewc, Mark A.; Van Deusen, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1443-1447</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study was designed to evaluate the use of cerebrospinal fluid (CSF) drug concn. and plasma unbound concn. (Cu,plasma) to predict brain unbound concn. (Cu,brain).  The concn.-time profiles in CSF, plasma, and brain of seven model compds. were detd. after s.c. administration in rats.  The Cu,brain was estd. from the product of total brain concns. and unbound fractions, which were detd. using brain tissue slice and brain homogenate methods.  For theobromine, theophylline, caffeine, fluoxetine, and propranolol, which represent rapid brain penetration compds. with a simple diffusion mechanism, the ratios of the area under the curve of Cu,brain/CCSF and Cu,brain/Cu,plasma were 0.27 to 1.5 and 0.29 to 2.1, resp., using the brain slice method, and were 0.27 to 2.9 and 0.36 to 3.9, resp., using the brain homogenate method.  A P-glycoprotein substrate, CP-141938 (methoxy-3-[(2-phenyl-piperidinyl-3-amino)-methyl]-phenyl-N-methyl-methane-sulfonamide), had Cu,brain/CCSF and Cu,brain/Cu,plasma ratios of 0.57 and 0.066, using the brain slice method, and 1.1 and 0.13, using the brain homogenate method, resp.  The slow brain-penetrating compd., N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine, had Cu,brain/CCSF and Cu,brain/Cu,plasma ratios of 0.94 and 0.12 using the brain slice method and 0.15 and 0.018 using the brain homogenate method, resp.  Therefore, for quick brain penetration with simple diffusion mechanism compds., CCSF and Cu,plasma represent Cu,brain equally well; for efflux substrates or slow brain penetration compds., CCSF appears to be equiv. to or more accurate than Cu,plasma to represent Cu,brain.  Thus, we hypothesize that CCSF is equiv. to or better than Cu,plasma to predict Cu,brain.  This hypothesis is supported by the literature data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw43dRkq9lx7Vg90H21EOLACvtfcHk0liARslfOhVxPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1Sksrc%253D&md5=cef079e1a667dbddf9d5a2f7d01889e8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.008201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.008201%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DBecker%26aufirst%3DS.%2BI.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCianfrogna%26aufirst%3DJ.%26aulast%3DDoran%26aufirst%3DA.%2BC.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DGibbs%26aufirst%3DJ.%2BP.%26aulast%3DHosea%26aufirst%3DN.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DF.%2BR.%26aulast%3DSzewc%26aufirst%3DM.%2BA.%26aulast%3DDeusen%26aufirst%3DJ.%2BV.%26atitle%3DEvaluation%2520of%2520cerebrospinal%2520fluid%2520concentration%2520and%2520plasma%2520free%2520concentration%2520as%2520a%2520surrogate%2520measurement%2520for%2520brain%2520free%2520concentration%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D1443%26epage%3D1447%26doi%3D10.1124%2Fdmd.105.008201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span> </span><span class="NLM_article-title">Demystifying brain penetration in central nervous system drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1021/jm301297f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301297f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2-12&author=L.+Diauthor=H.+Rongauthor=B.+Feng&title=Demystifying+brain+penetration+in+central+nervous+system+drug+discovery&doi=10.1021%2Fjm301297f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Demystifying Brain Penetration in Central Nervous System Drug Discovery</span></div><div class="casAuthors">Di, Li; Rong, Haojing; Feng, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-12</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This Perspective provides important concepts about the blood-brain barrier (BBB) in drug discovery and how they should be applied effectively in designing successful CNS drugs.  Key parameters for brain penetration are discussed, including unbound brain concn., unbound brain-to-plasma ratio, BBB permeability, fraction unbound in brain and plasma, and transporters.  Results from a retrospective anal. of 32 Pfizer CNS clin. drug candidates are described.  Frequently encountered misconceptions about brain penetration in drug discovery programs are clarified.  Strategies and guidance are provided to enhance or minimize brain exposure for CNS or peripheral targets, resp.  Recommendations for screening methodologies and a cascade in assessing brain penetration potential are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmurs7cfju37Vg90H21EOLACvtfcHk0ljd8X0pFbe5YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ&md5=8b88e2044bf41898ab40c45e18f2a20d</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm301297f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301297f%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DB.%26atitle%3DDemystifying%2520brain%2520penetration%2520in%2520central%2520nervous%2520system%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2%26epage%3D12%26doi%3D10.1021%2Fjm301297f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Riley, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnity, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, R. P.</span><span> </span><span class="NLM_article-title">A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1304</span><span class="NLM_x">–</span> <span class="NLM_lpage">1311</span><span class="refDoi"> DOI: 10.1124/dmd.105.004259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1124%2Fdmd.105.004259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=15932954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFamt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=1304-1311&author=R.+J.+Rileyauthor=D.+F.+McGinnityauthor=R.+P.+Austin&title=A+unified+model+for+predicting+human+hepatic%2C+metabolic+clearance+from+in+vitro+intrinsic+clearance+data+in+hepatocytes+and+microsomes&doi=10.1124%2Fdmd.105.004259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes</span></div><div class="casAuthors">Riley, Robert J.; McGinnity, D. F.; Austin, R. P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1304-1311</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate a unified method for predicting human in vivo intrinsic clearance (CLint, in vivo) and hepatic clearance (CLh) from in vitro data in hepatocytes and microsomes by applying the unbound fraction in blood (fub) and in vitro incubations (fuinc).  Human CLint, in vivo was projected using in vitro data together with biol. scaling factors and compared with the unbound intrinsic clearance (CLint, ub, in vivo) estd. from clin. data using liver models with and without the various fu terms.  For incubations conducted with fetal calf serum (n = 14), the obsd. CLint, in vivo was modeled well assuming fuinc and fub were equiv.  CLint, ub, in vivo was predicted best using both fub and fuinc for other hepatocyte data (n = 56; r2 = 0.78, p = 3.3×10-19, av. fold error = 5.2).  A similar model for CLint, ub, in vivo was established for microsomal data (n = 37; r2 = 0.77, p = 1.2×10-12, av. fold error = 6.1).  Using the model for CLint, ub, in vivo (including a further empirical scaling factor), the CLh in humans was also calcd. according to the well stirred liver model for the most extensive dataset.  CLint, in vivo and CLh were both predicted well using in vitro human data from several labs. for acidic, basic, and neutral drugs.  The direct use of this model using only in vitro human data to predict the metabolic component of CLh is attractive, as it does not require extra information from preclin. studies in animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnrU05rRTm6LVg90H21EOLACvtfcHk0ljd8X0pFbe5YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFamt74%253D&md5=79b80848977739267e4dd0ae82e5cbab</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.004259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.004259%26sid%3Dliteratum%253Aachs%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26aulast%3DAustin%26aufirst%3DR.%2BP.%26atitle%3DA%2520unified%2520model%2520for%2520predicting%2520human%2520hepatic%252C%2520metabolic%2520clearance%2520from%2520in%2520vitro%2520intrinsic%2520clearance%2520data%2520in%2520hepatocytes%2520and%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D1304%26epage%3D1311%26doi%3D10.1124%2Fdmd.105.004259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Sohlenius-Sternbeck, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Projean, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floby, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bylund, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afzelius, L.</span><span> </span><span class="NLM_article-title">Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">841</span><span class="NLM_x">–</span> <span class="NLM_lpage">853</span><span class="refDoi"> DOI: 10.3109/00498254.2012.669080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.3109%2F00498254.2012.669080" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2012&pages=841-853&author=A.+K.+Sohlenius-Sternbeckauthor=C.+Jonesauthor=D.+Fergusonauthor=B.+J.+Middletonauthor=D.+Projeanauthor=E.+Flobyauthor=J.+Bylundauthor=L.+Afzelius&title=Practical+use+of+the+regression+offset+approach+for+the+prediction+of+in+vivo+intrinsic+clearance+from+hepatocytes&doi=10.3109%2F00498254.2012.669080"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.3109%2F00498254.2012.669080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2012.669080%26sid%3Dliteratum%253Aachs%26aulast%3DSohlenius-Sternbeck%26aufirst%3DA.%2BK.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DFerguson%26aufirst%3DD.%26aulast%3DMiddleton%26aufirst%3DB.%2BJ.%26aulast%3DProjean%26aufirst%3DD.%26aulast%3DFloby%26aufirst%3DE.%26aulast%3DBylund%26aufirst%3DJ.%26aulast%3DAfzelius%26aufirst%3DL.%26atitle%3DPractical%2520use%2520of%2520the%2520regression%2520offset%2520approach%2520for%2520the%2520prediction%2520of%2520in%2520vivo%2520intrinsic%2520clearance%2520from%2520hepatocytes%26jtitle%3DXenobiotica%26date%3D2012%26volume%3D42%26spage%3D841%26epage%3D853%26doi%3D10.3109%2F00498254.2012.669080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Mahmood, I.</span><span> </span><span class="NLM_article-title">Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches</span> <span class="citation_source-journal">Drug Metab. Drug Interact.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">64</span><span class="refDoi"> DOI: 10.1515/DMDI.2002.19.1.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1515%2FDMDI.2002.19.1.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=12222754" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BD38XmvFWhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=49-64&author=I.+Mahmood&title=Prediction+of+clearance+in+humans+from+in+vitro+human+liver+microsomes+and+allometric+scaling.+A+comparative+study+of+the+two+approaches&doi=10.1515%2FDMDI.2002.19.1.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches</span></div><div class="casAuthors">Mahmood, Iftekhar</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Drug Interactions</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-64</span>CODEN:
                <span class="NLM_cas:coden">DMDIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0792-5077</span>.
    
            (<span class="NLM_cas:orgname">Freund Publishing House Ltd.</span>)
        </div><div class="casAbstract">The objective of this study was to evaluate whether the predicted clearance of a drug in humans from in vitro human liver microsomes was comparable with the predicted clearance in humans obtained by allometric scaling.  Sixteen drugs were randomly selected from the literature and their hepatic clearances were predicted using human liver microsomes.  For allometric scaling at least three animal species were used and three methods were utilized to generate allometric equations to predict the clearance in humans: (i) clearance vs. body wt. (simple allometry); (ii) product of the clearance and max. life-span potential (MLP) vs. body wt.; and (iii) the product of clearance and brain wt. vs. body wt.  The choice of one of the methods was based on the "rule of exponents" as described by Mahmood and Balian.  The results of this study indicated that the use of human liver microsomes to predict hepatic clearance in humans may not provide reliable predictions.  The prediction of clearance in humans using allometric scaling combined with the "rule of exponents" can provide comparatively better prediction of clearance in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAEtC7Bfrx_rVg90H21EOLACvtfcHk0lhr10g6Tf8MAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmvFWhu7k%253D&md5=ec50ac9cc77f3db2a020cda9245ae705</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1515%2FDMDI.2002.19.1.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FDMDI.2002.19.1.49%26sid%3Dliteratum%253Aachs%26aulast%3DMahmood%26aufirst%3DI.%26atitle%3DPrediction%2520of%2520clearance%2520in%2520humans%2520from%2520in%2520vitro%2520human%2520liver%2520microsomes%2520and%2520allometric%2520scaling.%2520A%2520comparative%2520study%2520of%2520the%2520two%2520approaches%26jtitle%3DDrug%2520Metab.%2520Drug%2520Interact.%26date%3D2002%26volume%3D19%26spage%3D49%26epage%3D64%26doi%3D10.1515%2FDMDI.2002.19.1.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Mahmood, I.</span><span> </span><span class="NLM_article-title">Prediction of human drug clearance from animal data: Application of the rule of exponent and fu corrected intercept method (FCIM)</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">1810</span><span class="NLM_x">–</span> <span class="NLM_lpage">1821</span><span class="refDoi"> DOI: 10.1002/jps.20650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1002%2Fjps.20650" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2006&pages=1810-1821&author=I.+Mahmood&title=Prediction+of+human+drug+clearance+from+animal+data%3A+Application+of+the+rule+of+exponent+and+fu+corrected+intercept+method+%28FCIM%29&doi=10.1002%2Fjps.20650"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fjps.20650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20650%26sid%3Dliteratum%253Aachs%26aulast%3DMahmood%26aufirst%3DI.%26atitle%3DPrediction%2520of%2520human%2520drug%2520clearance%2520from%2520animal%2520data%253A%2520Application%2520of%2520the%2520rule%2520of%2520exponent%2520and%2520fu%2520corrected%2520intercept%2520method%2520%2528FCIM%2529%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2006%26volume%3D95%26spage%3D1810%26epage%3D1821%26doi%3D10.1002%2Fjps.20650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Ward, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. R.</span><span> </span><span class="NLM_article-title">A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog and monkey to humans. I. Clearance</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">603</span><span class="NLM_x">–</span> <span class="NLM_lpage">611</span><span class="refDoi"> DOI: 10.1124/dmd.32.6.603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1124%2Fdmd.32.6.603" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2004&pages=603-611&author=K.+W.+Wardauthor=B.+R.+Smith&title=A+comprehensive+quantitative+and+qualitative+evaluation+of+extrapolation+of+intravenous+pharmacokinetic+parameters+from+rat%2C+dog+and+monkey+to+humans.+I.+Clearance&doi=10.1124%2Fdmd.32.6.603"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fdmd.32.6.603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.32.6.603%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26atitle%3DA%2520comprehensive%2520quantitative%2520and%2520qualitative%2520evaluation%2520of%2520extrapolation%2520of%2520intravenous%2520pharmacokinetic%2520parameters%2520from%2520rat%252C%2520dog%2520and%2520monkey%2520to%2520humans.%2520I.%2520Clearance%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2004%26volume%3D32%26spage%3D603%26epage%3D611%26doi%3D10.1124%2Fdmd.32.6.603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">FDA</span><span class="NLM_x"> guidance for industry (</span><span class="NLM_x"> (</span><span class="NLM_year">2012</span><span class="NLM_x">) </span>on drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. <a href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf" class="extLink">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+guidance+for+industry+%28+%282012%29+on+drug+interaction+studies-study+design%2C+data+analysis%2C+implications+for+dosing%2C+and+labeling+recommendations.+http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FGuidanceComplianceRegulatoryInformation%2FGuidances%2Fucm292362.pdf."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Fahmi, O. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boldt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug metabolizing enzymes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1605</span><span class="NLM_x">–</span> <span class="NLM_lpage">1611</span><span class="refDoi"> DOI: 10.1124/dmd.110.033126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1124%2Fdmd.110.033126" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2010&pages=1605-1611&author=O.+A.+Fahmiauthor=M.+Kishauthor=S.+Boldtauthor=R.+S.+Obach&title=Cytochrome+P450+3A4+mRNA+is+a+more+reliable+marker+than+CYP3A4+activity+for+detecting+pregnane+X+receptor-activated+induction+of+drug+metabolizing+enzymes&doi=10.1124%2Fdmd.110.033126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.033126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.033126%26sid%3Dliteratum%253Aachs%26aulast%3DFahmi%26aufirst%3DO.%2BA.%26aulast%3DKish%26aufirst%3DM.%26aulast%3DBoldt%26aufirst%3DS.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DCytochrome%2520P450%25203A4%2520mRNA%2520is%2520a%2520more%2520reliable%2520marker%2520than%2520CYP3A4%2520activity%2520for%2520detecting%2520pregnane%2520X%2520receptor-activated%2520induction%2520of%2520drug%2520metabolizing%2520enzymes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2010%26volume%3D38%26spage%3D1605%26epage%3D1611%26doi%3D10.1124%2Fdmd.110.033126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Varnäs, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varrone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farde, L.</span><span> </span><span class="NLM_article-title">Modeling of PET data in CNS drug discovery and development</span> <span class="citation_source-journal">J. Pharmacokinet. Pharmacodyn.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span><span class="refDoi"> DOI: 10.1007/s10928-013-9320-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1007%2Fs10928-013-9320-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=23660778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BC3snisVajtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2013&pages=267-279&author=K.+Varn%C3%A4sauthor=A.+Varroneauthor=L.+Farde&title=Modeling+of+PET+data+in+CNS+drug+discovery+and+development&doi=10.1007%2Fs10928-013-9320-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling of PET data in CNS drug discovery and development</span></div><div class="casAuthors">Varnas Katarina; Varrone Andrea; Farde Lars</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacokinetics and pharmacodynamics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">267-79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Positron emission tomography (PET) is increasingly used in drug discovery and development for evaluation of CNS drug disposition and for studies of disease biomarkers to monitor drug effects on brain pathology.  The quantitative analysis of PET data is based on kinetic modeling of radioactivity concentrations in plasma and brain tissue compartments.  A number of quantitative methods of analysis have been developed that allow the determination of parameters describing drug pharmacokinetics and interaction with target binding sites in the brain.  The optimal method of quantification depends on the properties of the radiolabeled drug or radioligand and the binding site studied.  We here review the most frequently used methods for quantification of PET data in relation to CNS drug discovery and development.  The utility of PET kinetic modeling in the development of novel CNS drugs is illustrated by examples from studies of the brain kinetic properties of radiolabeled drug molecules.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQLO3rZf95a5PEeosoOnpOLfW6udTcc2eb9_CEky_mjsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3snisVajtQ%253D%253D&md5=8afb967eb7584f68ed62fa08f7907a74</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10928-013-9320-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10928-013-9320-6%26sid%3Dliteratum%253Aachs%26aulast%3DVarn%25C3%25A4s%26aufirst%3DK.%26aulast%3DVarrone%26aufirst%3DA.%26aulast%3DFarde%26aufirst%3DL.%26atitle%3DModeling%2520of%2520PET%2520data%2520in%2520CNS%2520drug%2520discovery%2520and%2520development%26jtitle%3DJ.%2520Pharmacokinet.%2520Pharmacodyn.%26date%3D2013%26volume%3D40%26spage%3D267%26epage%3D279%26doi%3D10.1007%2Fs10928-013-9320-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umland, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span> </span><span class="NLM_article-title">Species independence in brain tissue binding using brain homogenates</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1270</span><span class="NLM_x">–</span> <span class="NLM_lpage">1277</span><span class="refDoi"> DOI: 10.1124/dmd.111.038778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1124%2Fdmd.111.038778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=21474681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFWktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1270-1277&author=L.+Diauthor=J.+P.+Umlandauthor=G.+Changauthor=Y.+Huangauthor=Z.+Linauthor=D.+O.+Scottauthor=M.+D.+Troutmanauthor=T.+E.+Liston&title=Species+independence+in+brain+tissue+binding+using+brain+homogenates&doi=10.1124%2Fdmd.111.038778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Species independence in brain tissue binding using brain homogenates</span></div><div class="casAuthors">Di, Li; Umland, John P.; Chang, George; Huang, Youping; Lin, Zhen; Scott, Dennis O.; Troutman, Matthew D.; Liston, Theodore E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1270-1277</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Species independence of brain tissue binding was assessed with a large no. of structurally diverse compds. using equil. dialysis with brain homogenates of seven species and strains (Wistar Han rat, Sprague-Dawley rat, CD-1 mouse, Hartley guinea pig, beagle dog, cynomolgus monkey, and human).  The results showed that the fractions unbound of the seven species and strains were strongly correlated with correlation coeffs. ranging from 0.93 to 0.99.  The cross-species/strain correlations were not significantly different from the interassay correlation with the same species.  The linear correlation between Wistar Han and other species had a slope close to 1 and an intercept near 0.  Based on orthogonal statistical anal., no correction is needed for extrapolation of fraction unbound from Wistar Han rat to the other species or strains.  Hence, brain tissue binding of Wistar Han rat can be used to obtain binding of other species and strains in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoub4FiLWkAFrVg90H21EOLACvtfcHk0ljx32eBcbngMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFWktrg%253D&md5=93a51addedb22de4648e6e5ee39c6c81</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.038778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.038778%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DChang%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DScott%26aufirst%3DD.%2BO.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3DListon%26aufirst%3DT.%2BE.%26atitle%3DSpecies%2520independence%2520in%2520brain%2520tissue%2520binding%2520using%2520brain%2520homogenates%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1270%26epage%3D1277%26doi%3D10.1124%2Fdmd.111.038778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Helal, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandit, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chappie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Humphrey, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marr, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenard, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapin, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siuciak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebel, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menniti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cianfrogna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonseca, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacDougall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDowell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, S.</span><span> </span><span class="NLM_article-title">Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10a inhibitor lead series for the treatment of schizophrenia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4536</span><span class="NLM_x">–</span> <span class="NLM_lpage">4547</span><span class="refDoi"> DOI: 10.1021/jm2001508</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2001508" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnt1ahtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4536-4547&author=C.+J.+Helalauthor=Z.+Kangauthor=X.+Houauthor=J.+Panditauthor=T.+A.+Chappieauthor=J.+M.+Humphreyauthor=E.+S.+Marrauthor=K.+F.+Fennellauthor=L.+K.+Chenardauthor=C.+Foxauthor=C.+J.+Schmidtauthor=R.+D.+Williamsauthor=D.+S.+Chapinauthor=J.+Siuciakauthor=L.+Lebelauthor=F.+Mennitiauthor=J.+Cianfrognaauthor=K.+R.+Fonsecaauthor=F.+R.+Nelsonauthor=R.+O%E2%80%99Connorauthor=M.+MacDougallauthor=L.+McDowellauthor=S.+Liras&title=Use+of+structure-based+design+to+discover+a+potent%2C+selective%2C+in+vivo+active+phosphodiesterase+10a+inhibitor+lead+series+for+the+treatment+of+schizophrenia&doi=10.1021%2Fjm2001508"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia</span></div><div class="casAuthors">Helal, Christopher J.; Kang, Zhijun; Hou, Xinjun; Pandit, Jayvardhan; Chappie, Thomas A.; Humphrey, John M.; Marr, Eric S.; Fennell, Kimberly F.; Chenard, Lois K.; Fox, Carol; Schmidt, Christopher J.; Williams, Robert D.; Chapin, Douglas S.; Siuciak, Judith; Lebel, Lorraine; Menniti, Frank; Cianfrogna, Julia; Fonseca, Kari R.; Nelson, Frederick R.; O'Connor, Rebecca; MacDougall, Mary; McDowell, Laura; Liras, Spiros</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4536-4547</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Utilizing structure-based virtual library design and scoring, a novel chimeric series of phosphodiesterase 10A (PDE10A) inhibitors was discovered by synergizing binding site interactions and ADME properties of two chemotypes.  Virtual libraries were docked and scored for potential binding ability, followed by visual inspection to prioritize analogs for parallel and directed synthesis.  The process yielded highly potent and selective compds. such as 16.  New X-ray cocrystal structures enabled rational design of substituents that resulted in the successful optimization of phys. properties to produce in vivo activity and to modulate microsomal clearance and permeability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqicmqMcqmW6rVg90H21EOLACvtfcHk0ljx32eBcbngMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnt1ahtb8%253D&md5=8df1d09717074a5c468ca017031fed65</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm2001508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2001508%26sid%3Dliteratum%253Aachs%26aulast%3DHelal%26aufirst%3DC.%2BJ.%26aulast%3DKang%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DPandit%26aufirst%3DJ.%26aulast%3DChappie%26aufirst%3DT.%2BA.%26aulast%3DHumphrey%26aufirst%3DJ.%2BM.%26aulast%3DMarr%26aufirst%3DE.%2BS.%26aulast%3DFennell%26aufirst%3DK.%2BF.%26aulast%3DChenard%26aufirst%3DL.%2BK.%26aulast%3DFox%26aufirst%3DC.%26aulast%3DSchmidt%26aufirst%3DC.%2BJ.%26aulast%3DWilliams%26aufirst%3DR.%2BD.%26aulast%3DChapin%26aufirst%3DD.%2BS.%26aulast%3DSiuciak%26aufirst%3DJ.%26aulast%3DLebel%26aufirst%3DL.%26aulast%3DMenniti%26aufirst%3DF.%26aulast%3DCianfrogna%26aufirst%3DJ.%26aulast%3DFonseca%26aufirst%3DK.%2BR.%26aulast%3DNelson%26aufirst%3DF.%2BR.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%26aulast%3DMacDougall%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DL.%26aulast%3DLiras%26aufirst%3DS.%26atitle%3DUse%2520of%2520structure-based%2520design%2520to%2520discover%2520a%2520potent%252C%2520selective%252C%2520in%2520vivo%2520active%2520phosphodiesterase%252010a%2520inhibitor%2520lead%2520series%2520for%2520the%2520treatment%2520of%2520schizophrenia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4536%26epage%3D4547%26doi%3D10.1021%2Fjm2001508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, C.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of novel F-18 labeled 4-aminoquinazoline derivatives: Potential PET imaging agents for tumor detection</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4745</span><span class="NLM_x">–</span> <span class="NLM_lpage">4749</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.05.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2Fj.bmcl.2012.05.069" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4745-4749&author=Y.+Chenauthor=M.+Fengauthor=S.+Liauthor=J.+Xuauthor=H.+Ningauthor=Y.+Heauthor=X.+Wangauthor=R.+Dingauthor=C.+Qi&title=Synthesis+and+evaluation+of+novel+F-18+labeled+4-aminoquinazoline+derivatives%3A+Potential+PET+imaging+agents+for+tumor+detection&doi=10.1016%2Fj.bmcl.2012.05.069"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.05.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.05.069%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DNing%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DR.%26aulast%3DQi%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novel%2520F-18%2520labeled%25204-aminoquinazoline%2520derivatives%253A%2520Potential%2520PET%2520imaging%2520agents%2520for%2520tumor%2520detection%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4745%26epage%3D4749%26doi%3D10.1016%2Fj.bmcl.2012.05.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Rice, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangloff, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuo, E. Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dener, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newcomb, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Putnam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cregar, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warne, R. L.</span><span> </span><span class="NLM_article-title">Dibasic inhibitors of human mast cell tryptase. part 1: synthesis and optimization of a novel class of inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2357</span><span class="NLM_x">–</span> <span class="NLM_lpage">2360</span><span class="refDoi"> DOI: 10.1016/S0960-894X(00)00484-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2FS0960-894X%2800%2900484-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2000&pages=2357-2360&author=K.+D.+Riceauthor=A.+R.+Gangloffauthor=E.+Y.-L.+Kuoauthor=J.+M.+Denerauthor=V.+R.+Wangauthor=R.+Lumauthor=W.+S.+Newcombauthor=C.+Havelauthor=D.+Putnamauthor=L.+Cregarauthor=M.+Wongauthor=R.+L.+Warne&title=Dibasic+inhibitors+of+human+mast+cell+tryptase.+part+1%3A+synthesis+and+optimization+of+a+novel+class+of+inhibitors&doi=10.1016%2FS0960-894X%2800%2900484-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2800%2900484-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252800%252900484-4%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DK.%2BD.%26aulast%3DGangloff%26aufirst%3DA.%2BR.%26aulast%3DKuo%26aufirst%3DE.%2BY.-L.%26aulast%3DDener%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DV.%2BR.%26aulast%3DLum%26aufirst%3DR.%26aulast%3DNewcomb%26aufirst%3DW.%2BS.%26aulast%3DHavel%26aufirst%3DC.%26aulast%3DPutnam%26aufirst%3DD.%26aulast%3DCregar%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DWarne%26aufirst%3DR.%2BL.%26atitle%3DDibasic%2520inhibitors%2520of%2520human%2520mast%2520cell%2520tryptase.%2520part%25201%253A%2520synthesis%2520and%2520optimization%2520of%2520a%2520novel%2520class%2520of%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2000%26volume%3D10%26spage%3D2357%26epage%3D2360%26doi%3D10.1016%2FS0960-894X%2800%2900484-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tilley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trilles, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwinge, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R.</span><span> </span><span class="NLM_article-title">N-Acyl-L-phenylalanine derivatives as potent VLA-4 antagonists that mimic a cyclic peptide conformation</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00711-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2FS0960-894X%2801%2900711-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2002&pages=137-140&author=L.+Chenauthor=J.+Tilleyauthor=R.+V.+Trillesauthor=W.+Yunauthor=D.+Fryauthor=C.+Cookauthor=K.+Rowanauthor=V.+Schwingeauthor=R.+Campbell&title=N-Acyl-L-phenylalanine+derivatives+as+potent+VLA-4+antagonists+that+mimic+a+cyclic+peptide+conformation&doi=10.1016%2FS0960-894X%2801%2900711-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900711-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900711-9%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DTilley%26aufirst%3DJ.%26aulast%3DTrilles%26aufirst%3DR.%2BV.%26aulast%3DYun%26aufirst%3DW.%26aulast%3DFry%26aufirst%3DD.%26aulast%3DCook%26aufirst%3DC.%26aulast%3DRowan%26aufirst%3DK.%26aulast%3DSchwinge%26aufirst%3DV.%26aulast%3DCampbell%26aufirst%3DR.%26atitle%3DN-Acyl-L-phenylalanine%2520derivatives%2520as%2520potent%2520VLA-4%2520antagonists%2520that%2520mimic%2520a%2520cyclic%2520peptide%2520conformation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2002%26volume%3D12%26spage%3D137%26epage%3D140%26doi%3D10.1016%2FS0960-894X%2801%2900711-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Kemper, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leenders, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Küsters, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heerschap, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boogerd, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Tellingen, O.</span><span> </span><span class="NLM_article-title">Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">3294</span><span class="NLM_x">–</span> <span class="NLM_lpage">3303</span><span class="refDoi"> DOI: 10.1016/j.ejca.2006.07.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.1016%2Fj.ejca.2006.07.013" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=3294-3303&author=E.+M.+Kemperauthor=W.+Leendersauthor=B.+K%C3%BCstersauthor=S.+Lyonsauthor=T.+Buckleauthor=A.+Heerschapauthor=W.+Boogerdauthor=J.+H.+Beijnenauthor=O.+van+Tellingen&title=Development+of+luciferase+tagged+brain+tumour+models+in+mice+for+chemotherapy+intervention+studies&doi=10.1016%2Fj.ejca.2006.07.013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2006.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2006.07.013%26sid%3Dliteratum%253Aachs%26aulast%3DKemper%26aufirst%3DE.%2BM.%26aulast%3DLeenders%26aufirst%3DW.%26aulast%3DK%25C3%25BCsters%26aufirst%3DB.%26aulast%3DLyons%26aufirst%3DS.%26aulast%3DBuckle%26aufirst%3DT.%26aulast%3DHeerschap%26aufirst%3DA.%26aulast%3DBoogerd%26aufirst%3DW.%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3Dvan%2BTellingen%26aufirst%3DO.%26atitle%3DDevelopment%2520of%2520luciferase%2520tagged%2520brain%2520tumour%2520models%2520in%2520mice%2520for%2520chemotherapy%2520intervention%2520studies%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26spage%3D3294%26epage%3D3303%26doi%3D10.1016%2Fj.ejca.2006.07.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Lal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacroix, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tofilon, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuller, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawaya, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, F. F.</span><span> </span><span class="NLM_article-title">An implantable guide-screw system for brain tumor studies in small animals</span> <span class="citation_source-journal">J. Neurosurg.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">326</span><span class="NLM_x">–</span> <span class="NLM_lpage">333</span><span class="refDoi"> DOI: 10.3171/jns.2000.92.2.0326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10.3171%2Fjns.2000.92.2.0326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=10659021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;key=1%3ACAS%3A280%3ADC%252BD3c7it1Wgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2000&pages=326-333&author=S.+Lalauthor=M.+Lacroixauthor=P.+Tofilonauthor=G.+N.+Fullerauthor=R.+Sawayaauthor=F.+F.+Lang&title=An+implantable+guide-screw+system+for+brain+tumor+studies+in+small+animals&doi=10.3171%2Fjns.2000.92.2.0326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">An implantable guide-screw system for brain tumor studies in small animals</span></div><div class="casAuthors">Lal S; Lacroix M; Tofilon P; Fuller G N; Sawaya R; Lang F F</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurosurgery</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">326-33</span>
        ISSN:<span class="NLM_cas:issn">0022-3085</span>.
    </div><div class="casAbstract">OBJECT:  To overcome the problems associated with using stereotactic techniques to establish intracranial xenografts in nude mice and to treat engrafted tumors with intratumoral therapies (such as gene or viral therapies), the authors developed an implantable guide-screw system.  In this study, they describe the guide-screw system, its method of implantation, and their experience with establishing xenografts and delivering intratumoral therapy.  METHODS:  The system consists of a 2.6-mm guide screw with a central 0.5-mm diameter hole that accepts the 26-gauge needle of a Hamilton syringe.  The screw is implanted into a small drill hole made 2.5 mm lateral and 1 mm anterior to the bregma.  A stylet is used to cap the screw between treatments.  Tumor cells or therapeutic agents are injected in a freehand fashion by using a Hamilton syringe and a 26-gauge needle fitted with a cuff to determine the depth of injection.  To test this system, guide screws were successfully implanted in 44 (98%) of 45 nude mice.  After 1 to 2 weeks of recovery, 38 mice were inoculated with U87MG cells and killed 5 days later.  On histological studies in 37 (97%) of these animals, xenografts were evident within the caudate nucleus (mean diameter 2.5 mm).  To determine whether injections into the center of an established xenograft could be reproducibly achieved with the guide-screw system, an adenovirus vector containing the beta-galactosidase gene was injected 3 days after cell implantation in 15 of the mice.  All of these animals demonstrated transduced cells within the tumor.  To demonstrate that engrafted animals have a uniform survival time that is indicative of reproducible tumor growth, the survival of six mice was assessed after engraftment with U87MG cells.  All six animals died within 28 to 35 days.  CONCLUSIONS:  The guide-screw system allows a large number of animals to be rapidly and reproducibly engrafted and for intratumoral treatments to be accurately delivered into established xenografts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRCBLvcGyXMxL7NkxioyDXTfW6udTcc2eZqo_K1qo7n6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7it1Wgsw%253D%253D&md5=b382d2e29677f71b8e9672951f4b2e33</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.3171%2Fjns.2000.92.2.0326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3171%252Fjns.2000.92.2.0326%26sid%3Dliteratum%253Aachs%26aulast%3DLal%26aufirst%3DS.%26aulast%3DLacroix%26aufirst%3DM.%26aulast%3DTofilon%26aufirst%3DP.%26aulast%3DFuller%26aufirst%3DG.%2BN.%26aulast%3DSawaya%26aufirst%3DR.%26aulast%3DLang%26aufirst%3DF.%2BF.%26atitle%3DAn%2520implantable%2520guide-screw%2520system%2520for%2520brain%2520tumor%2520studies%2520in%2520small%2520animals%26jtitle%3DJ.%2520Neurosurg.%26date%3D2000%26volume%3D92%26spage%3D326%26epage%3D333%26doi%3D10.3171%2Fjns.2000.92.2.0326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i60"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01073">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_46136"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01073">10.1021/acs.jmedchem.5b01073</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">EGFR inhibition activity of compounds <b>1a</b>–<b>n</b> and <b>2</b> in biochemical assay; cellular assay data of compounds <b>1a</b>–<b>n</b> and <b>2</b>; biochemical assay protocols; cellular phosphorylation and proliferation assay procedures; permeability and efflux transport in MDCKII-MDR1 and MDCKII-BCRP cell lines; unbound brain to unbound blood (<i>K</i><sub>puu,brain</sub>) and CSF to unbound blood (<i>K</i><sub>puu,CSF</sub>) ratios; compound <b>1e</b> hepatocyte metabolite ID; Millipore kinase panel screening results; secondary pharmacology panel screening results; PET microdosing study; summary of in vitro DMPK of <b>1m</b>; metabolites identified in rat, dog, monkey, and human hepatocytes; physical properties of <b>1m</b>; procedures for assessing pEGFR expression in tumor tissue by using immunohistochemistry; tumor growth curve of individual animals (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01073/suppl_file/jm5b01073_si_001.pdf">PDF</a>)</p></li><li><p class="inline">L858R pEGFR IC<sub>50</sub> values for gefitinib, compounds <b>1a</b>−<b>n</b>, and <b>2</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01073/suppl_file/jm5b01073_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01073/suppl_file/jm5b01073_si_001.pdf">jm5b01073_si_001.pdf (752.19 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01073/suppl_file/jm5b01073_si_002.csv">jm5b01073_si_002.csv (1.0 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01073&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-20%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01073%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01073" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a6c41df493cf4","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
